Skip to content
Triangle logo TriangleGet started
← Back to this collection

LABELS · 5826517b-d2d2-4636-ad9c-0dc676abad9e

IMFINZI

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date
2026-08-31
Captured
2026-09-09T23:37:47.659725+00:00
Current indication reconciliation
Not reconciled

Indications and usage: exact source text

  1. 1 INDICATIONS AND USAGE IMFINZI is a programmed death-ligand 1 (PD-L1) blocking antibody indicated: • in combination with platinum-containing chemotherapy as neoadjuvant treatment, followed by IMFINZI continued as a single agent as adjuvant treatment after surgery, for the treatment of adult patients with resectable (tumors ≥ 4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. ( 1.1 ) • as a single agent, for the treatment of adult patients with unresectable, Stage III NSCLC whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. ( 1.1 ) • in combination with tremelimumab-actl and platinum-based chemotherapy, for the treatment of adult patients with metastatic NSCLC with no sensitizing EGFR mutations or ALK genomic tumor aberrations. ( 1.1 ) • as a single agent, for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. ( 1.2 ) • in combination with etoposide and either carboplatin or cisplatin, as first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). ( 1.2 ) • in combination with gemcitabine and cisplatin, as treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC). ( 1.3 ) • in combination with tremelimumab-actl, for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC). ( 1.4 ) • in combination with carboplatin and paclitaxel followed by IMFINZI as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR) as determined by an FDA-authorized test. ( 1.5 , 2.1 ) • in combination with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-naive, high-risk non-muscle-invasive bladder cancer (NMIBC). ( 1.6 ) • in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent IMFINZI as adjuvant treatment following radical cystectomy, for the treatment of adult patients with muscle invasive bladder cancer (MIBC). ( 1.6 ) • in combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy as neoadjuvant and adjuvant treatment, followed by single agent IMFINZI, for the treatment of adult patients with resectable gastric or gastroesophageal junction adenocarcinoma (GC/GEJC). ( 1.7 ) 1.1 Non-Small Cell Lung Cancer • IMFINZI in combination with platinum-containing chemotherapy as neoadjuvant treatment, followed by IMFINZI continued as a single agent as adjuvant treatment after surgery, is indicated for the treatment of adult patients with resectable (tumors ≥ 4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. • IMFINZI, as a single agent, is indicated for the treatment of adult patients with unresectable Stage III NSCLC whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy (cCRT). • IMFINZI, in combination with tremelimumab-actl and platinum-based chemotherapy, is indicated for the treatment of adult patients with metastatic NSCLC with no sensitizing EGFR mutations or ALK genomic tumor aberrations. 1.2 Small Cell Lung Cancer • IMFINZI, as a single agent, is indicated for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy (cCRT). • IMFINZI, in combination with etoposide and either carboplatin or cisplatin, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). 1.3 Biliary Tract Cancers IMFINZI, in combination with gemcitabine and cisplatin, is indicated for the treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC). 1.4 Hepatocellular Carcinoma IMFINZI, in combination with tremelimumab-actl, is indicated for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC). 1.5 Endometrial Cancer IMFINZI, in combination with carboplatin and paclitaxel followed by IMFINZI as a single agent, is indicated for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] . 1.6 Bladder Cancer • IMFINZI in combination with Bacillus Calmette-Guérin (BCG) is indicated for the treatment of adult patients with BCG-naive, high-risk non-muscle-invasive bladder cancer (NMIBC). • IMFINZI in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent IMFINZI as adjuvant treatment following radical cystectomy, is indicated for the treatment of adult patients with muscle invasive bladder cancer (MIBC). 1. 7 Gastric or gastroesophageal junction adeno carcinoma IMFINZI in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) as neoadjuvant and adjuvant treatment, followed by single-agent IMFINZI, is indicated for the treatment of adult patients with resectable gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).
Full extracted label fields
application numbers
  1. BLA761069
boxed warning exact
    brand names
    1. IMFINZI
    current indication status
    not_reconciled
    dailymed set url
    https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8baba4ea-2855-42fa-9bd9-5a7548d4cec3
    generic names
    1. DURVALUMAB
    id
    5826517b-d2d2-4636-ad9c-0dc676abad9e
    indications and usage exact
    1. 1 INDICATIONS AND USAGE IMFINZI is a programmed death-ligand 1 (PD-L1) blocking antibody indicated: • in combination with platinum-containing chemotherapy as neoadjuvant treatment, followed by IMFINZI continued as a single agent as adjuvant treatment after surgery, for the treatment of adult patients with resectable (tumors ≥ 4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. ( 1.1 ) • as a single agent, for the treatment of adult patients with unresectable, Stage III NSCLC whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. ( 1.1 ) • in combination with tremelimumab-actl and platinum-based chemotherapy, for the treatment of adult patients with metastatic NSCLC with no sensitizing EGFR mutations or ALK genomic tumor aberrations. ( 1.1 ) • as a single agent, for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. ( 1.2 ) • in combination with etoposide and either carboplatin or cisplatin, as first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). ( 1.2 ) • in combination with gemcitabine and cisplatin, as treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC). ( 1.3 ) • in combination with tremelimumab-actl, for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC). ( 1.4 ) • in combination with carboplatin and paclitaxel followed by IMFINZI as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR) as determined by an FDA-authorized test. ( 1.5 , 2.1 ) • in combination with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-naive, high-risk non-muscle-invasive bladder cancer (NMIBC). ( 1.6 ) • in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent IMFINZI as adjuvant treatment following radical cystectomy, for the treatment of adult patients with muscle invasive bladder cancer (MIBC). ( 1.6 ) • in combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy as neoadjuvant and adjuvant treatment, followed by single agent IMFINZI, for the treatment of adult patients with resectable gastric or gastroesophageal junction adenocarcinoma (GC/GEJC). ( 1.7 ) 1.1 Non-Small Cell Lung Cancer • IMFINZI in combination with platinum-containing chemotherapy as neoadjuvant treatment, followed by IMFINZI continued as a single agent as adjuvant treatment after surgery, is indicated for the treatment of adult patients with resectable (tumors ≥ 4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. • IMFINZI, as a single agent, is indicated for the treatment of adult patients with unresectable Stage III NSCLC whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy (cCRT). • IMFINZI, in combination with tremelimumab-actl and platinum-based chemotherapy, is indicated for the treatment of adult patients with metastatic NSCLC with no sensitizing EGFR mutations or ALK genomic tumor aberrations. 1.2 Small Cell Lung Cancer • IMFINZI, as a single agent, is indicated for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy (cCRT). • IMFINZI, in combination with etoposide and either carboplatin or cisplatin, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). 1.3 Biliary Tract Cancers IMFINZI, in combination with gemcitabine and cisplatin, is indicated for the treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC). 1.4 Hepatocellular Carcinoma IMFINZI, in combination with tremelimumab-actl, is indicated for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC). 1.5 Endometrial Cancer IMFINZI, in combination with carboplatin and paclitaxel followed by IMFINZI as a single agent, is indicated for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] . 1.6 Bladder Cancer • IMFINZI in combination with Bacillus Calmette-Guérin (BCG) is indicated for the treatment of adult patients with BCG-naive, high-risk non-muscle-invasive bladder cancer (NMIBC). • IMFINZI in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent IMFINZI as adjuvant treatment following radical cystectomy, is indicated for the treatment of adult patients with muscle invasive bladder cancer (MIBC). 1. 7 Gastric or gastroesophageal junction adeno carcinoma IMFINZI in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) as neoadjuvant and adjuvant treatment, followed by single-agent IMFINZI, is indicated for the treatment of adult patients with resectable gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).
    indications and usage tables exact
      is original packager
      1. true
      manufacturer names
      1. AstraZeneca Pharmaceuticals LP
      matched search terms
      1. cancer
      2. carcinoma
      3. lymphoma
      4. tumor
      5. tumors
      package ndcs
      1. 0310-4500-12
      2. 0310-4611-50
      product ndcs
      1. 0310-4500
      2. 0310-4611
      product types
      1. HUMAN PRESCRIPTION DRUG
      recent major changes exact
      1. Indications and Usage ( 1.6 ) 05/2026 Indications and Usage ( 1.7 ) 11/2025 Dosage and Administration ( 2.2 ) 05/2026 Warnings and Precautions ( 5.1 ) 08/2026
      record type
      complete_spl_indications_section_candidate
      routes
      1. INTRAVENOUS
      rxcuis
        source batch
        file
        /private/tmp/cancer-full-research/indications/raw/labels-00300.json
        meta
        disclaimer
        Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
        last updated
        2026-09-09
        results
        limit
        100
        skip
        300
        total
        830
        sha256
        bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
        url
        https://api.fda.gov/drug/label.json?search=%28indications_and_usage%3Acancer+OR+indications_and_usage%3Acarcinoma+OR+indications_and_usage%3Acarcinomas+OR+indications_and_usage%3Alymphoma+OR+indications_and_usage%3Alymphomas+OR+indications_and_usage%3Aleukemia+OR+indications_and_usage%3Aleukaemia+OR+indications_and_usage%3Asarcoma+OR+indications_and_usage%3Asarcomas+OR+indications_and_usage%3Amelanoma+OR+indications_and_usage%3Amyeloma+OR+indications_and_usage%3Atumor+OR+indications_and_usage%3Atumors+OR+indications_and_usage%3Atumour+OR+indications_and_usage%3Atumours+OR+indications_and_usage%3Aneoplasm+OR+indications_and_usage%3Aneoplasms+OR+indications_and_usage%3Amalignant+OR+indications_and_usage%3Amalignancy+OR+indications_and_usage%3Amyelodysplastic+OR+indications_and_usage%3Amyelofibrosis+OR+indications_and_usage%3Amastocytosis+OR+indications_and_usage%3Aglioma+OR+indications_and_usage%3Aglioblastoma+OR+indications_and_usage%3Aneuroblastoma+OR+indications_and_usage%3Aretinoblastoma+OR+indications_and_usage%3Apheochromocytoma+OR+indications_and_usage%3Aparaganglioma+OR+indications_and_usage%3Amyeloproliferative+OR+indications_and_usage%3Awaldenstrom+OR+indications_and_usage%3Apolycythemia+OR+indications_and_usage%3Athrombocythemia+OR+indications_and_usage%3Adesmoid+OR+indications_and_usage%3Aneurofibromatosis+OR+indications_and_usage%3Ahistiocytosis%29+AND+%28openfda.application_number%3ANDA%2A+OR+openfda.application_number%3ABLA%2A%29&limit=100&skip=300&sort=id%3Aasc
        source url
        https://api.fda.gov/drug/label.json?search=id%3A%225826517b-d2d2-4636-ad9c-0dc676abad9e%22
        spl effective date
        2026-08-31
        spl effective time
        20260831
        spl set id
        8baba4ea-2855-42fa-9bd9-5a7548d4cec3
        spl version
        34
        substance names
        1. DURVALUMAB
        uniis
        1. 28X28X9OKV
        verification flags
        1. oncology_keyword_candidate_not_clinically_classified
        2. spl_text_not_verified_identical_to_latest_approved_label
        3. individual_indications_not_split_or_reconciled
        4. fda_label_posted_after_spl_effective_date_requires_version_review
        Drugs@FDA application source records
        1. application number
          BLA761069
          payload
          all indexed label documents
          1. Appl No
            761069
            Application Docs Date
            2017-05-01 00:00:00
            Application Docs ID
            48172
            Application Docs Title
            0
            Application Docs Type ID
            2
            Submission No
            1
            Submission Type
            ORIG
          2. Appl No
            761069
            Application Docs Date
            2018-02-16 00:00:00
            Application Docs ID
            52668
            Application Docs Title
            0
            Application Docs Type ID
            2
            Submission No
            2
            Submission Type
            SUPPL
          3. Appl No
            761069
            Application Docs Date
            2019-07-22 00:00:00
            Application Docs ID
            59388
            Application Docs Title
            0
            Application Docs Type ID
            2
            Submission No
            13
            Submission Type
            SUPPL
          4. Appl No
            761069
            Application Docs Date
            2020-03-30 00:00:00
            Application Docs ID
            62355
            Application Docs Title
            0
            Application Docs Type ID
            2
            Submission No
            18
            Submission Type
            SUPPL
          5. Appl No
            761069
            Application Docs Date
            2020-06-08 00:00:00
            Application Docs ID
            63451
            Application Docs Title
            0
            Application Docs Type ID
            2
            Submission No
            20
            Submission Type
            SUPPL
          6. Appl No
            761069
            Application Docs Date
            2020-11-13 00:00:00
            Application Docs ID
            65210
            Application Docs Title
            0
            Application Docs Type ID
            2
            Submission No
            12
            Submission Type
            SUPPL
          7. Appl No
            761069
            Application Docs Date
            2020-11-19 00:00:00
            Application Docs ID
            65270
            Application Docs Title
            0
            Application Docs Type ID
            2
            Submission No
            23
            Submission Type
            SUPPL
          8. Appl No
            761069
            Application Docs Date
            2020-11-19 00:00:00
            Application Docs ID
            65271
            Application Docs Title
            0
            Application Docs Type ID
            2
            Submission No
            24
            Submission Type
            SUPPL
          9. Appl No
            761069
            Application Docs Date
            2020-11-19 00:00:00
            Application Docs ID
            65272
            Application Docs Title
            0
            Application Docs Type ID
            2
            Submission No
            25
            Submission Type
            SUPPL
          10. Appl No
            761069
            Application Docs Date
            2021-02-24 00:00:00
            Application Docs ID
            66354
            Application Docs Title
            0
            Application Docs Type ID
            2
            Submission No
            29
            Submission Type
            SUPPL
          11. Appl No
            761069
            Application Docs Date
            2021-07-19 00:00:00
            Application Docs ID
            68123
            Application Docs Title
            0
            Application Docs Type ID
            2
            Submission No
            28
            Submission Type
            SUPPL
          12. Appl No
            761069
            Application Docs Date
            2022-05-12 00:00:00
            Application Docs ID
            71050
            Application Docs Title
            0
            Application Docs Type ID
            2
            Submission No
            32
            Submission Type
            SUPPL
          all submission records
          1. Appl No
            761069
            Review Priority
            STANDARD
            Submission Class Code ID
            3
            Submission No
            60
            Submission Status
            AP
            Submission Status Date
            2026-08-31 00:00:00
            Submission Type
            SUPPL
            Submissions Public Notes
          2. Appl No
            761069
            Review Priority
            STANDARD
            Submission Class Code ID
            2
            Submission No
            53
            Submission Status
            AP
            Submission Status Date
            2026-05-28 00:00:00
            Submission Type
            SUPPL
            Submissions Public Notes
          3. Appl No
            761069
            Review Priority
            PRIORITY
            Submission Class Code ID
            2
            Submission No
            52
            Submission Status
            AP
            Submission Status Date
            2025-11-25 00:00:00
            Submission Type
            SUPPL
            Submissions Public Notes
          4. Appl No
            761069
            Review Priority
            STANDARD
            Submission Class Code ID
            2
            Submission No
            51
            Submission Status
            AP
            Submission Status Date
            2025-02-28 00:00:00
            Submission Type
            SUPPL
            Submissions Public Notes
          5. Appl No
            761069
            Review Priority
            PRIORITY
            Submission Class Code ID
            2
            Submission No
            50
            Submission Status
            AP
            Submission Status Date
            2025-03-28 00:00:00
            Submission Type
            SUPPL
            Submissions Public Notes
          6. Appl No
            761069
            Review Priority
            PRIORITY
            Submission Class Code ID
            2
            Submission No
            49
            Submission Status
            AP
            Submission Status Date
            2024-12-04 00:00:00
            Submission Type
            SUPPL
            Submissions Public Notes
          7. Appl No
            761069
            Review Priority
            STANDARD
            Submission Class Code ID
            3
            Submission No
            48
            Submission Status
            AP
            Submission Status Date
            2024-04-22 00:00:00
            Submission Type
            SUPPL
            Submissions Public Notes
          8. Appl No
            761069
            Review Priority
            STANDARD
            Submission Class Code ID
            3
            Submission No
            47
            Submission Status
            AP
            Submission Status Date
            2024-07-24 00:00:00
            Submission Type
            SUPPL
            Submissions Public Notes
          9. Appl No
            761069
            Review Priority
            STANDARD
            Submission Class Code ID
            2
            Submission No
            45
            Submission Status
            AP
            Submission Status Date
            2024-06-14 00:00:00
            Submission Type
            SUPPL
            Submissions Public Notes
          10. Appl No
            761069
            Review Priority
            STANDARD
            Submission Class Code ID
            3
            Submission No
            44
            Submission Status
            AP
            Submission Status Date
            2023-12-20 00:00:00
            Submission Type
            SUPPL
            Submissions Public Notes
          11. Appl No
            761069
            Review Priority
            STANDARD
            Submission Class Code ID
            2
            Submission No
            43
            Submission Status
            AP
            Submission Status Date
            2024-08-15 00:00:00
            Submission Type
            SUPPL
            Submissions Public Notes
          12. Appl No
            761069
            Review Priority
            STANDARD
            Submission Class Code ID
            3
            Submission No
            42
            Submission Status
            AP
            Submission Status Date
            2023-06-16 00:00:00
            Submission Type
            SUPPL
            Submissions Public Notes
          application number
          BLA761069
          approval interpretation
          Application linkage and approved submission are not indication-level current approval verification
          current indication status
          not_reconciled
          has approved submission record
          true
          latest approved submission date
          2026-08-31
          latest label selection rule
          max FDA ApplicationDocsDate, including all ties; posting date is not approval date and latest indexed document may be incomplete
          latest posted label documents
          1. Appl No
            761069
            Application Docs Date
            2026-09-01 00:00:00
            Application Docs ID
            87109
            Application Docs Title
            0
            Application Docs Type ID
            2
            Submission No
            60
            Submission Type
            SUPPL
          official application record
          Appl No
          761069
          Appl Public Notes
          Appl Type
          BLA
          Sponsor Name
          ASTRAZENECA UK LTD
          openfda application present
          true
          products
          1. Active Ingredient
            DURVALUMAB
            Appl No
            761069
            Drug Name
            IMFINZI
            Form
            INJECTABLE;INJECTION
            Product No
            001
            Reference Drug
            2
            Reference Standard
            0
            Strength
            50MG/ML
            marketing status
            1. Prescription

        Source passages and status connections

        Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

        Passage 1 · indication intro context
        application numbers
        1. BLA761069
        brand names
        1. IMFINZI
        classification reasons
        1. explicit_positive_indication_predicate
        2. no_tumor_directed_keyword_in_positive_statement
        3. incomplete_colon_led_indication_intro
        clinical review status
        pending
        content role
        indication_intro_context
        context span
        end
        299
        end exclusive
        true
        exact text
        1 INDICATIONS AND USAGE IMFINZI is a programmed death-ligand 1 (PD-L1) blocking antibody indicated: • in combination with platinum-containing chemotherapy as neoadjuvant treatment, followed by IMFINZI continued as a single agent as adjuvant treatment after surgery, for the treatment of adult patien
        label id
        5826517b-d2d2-4636-ad9c-0dc676abad9e
        offset unit
        unicode_code_points
        source array index
        0
        source field
        indications_and_usage_exact
        source text sha256
        f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
        start
        0
        current approval status
        not_reconciled
        duplicate text group
        dup-2b762e44ea0f255d0c10
        extraction review status
        automated_candidate_pending_source_review
        generic names
        1. DURVALUMAB
        id
        ind-span-1f495432b312e900203b
        label id
        5826517b-d2d2-4636-ad9c-0dc676abad9e
        positive predicate support span
        end
        98
        end exclusive
        true
        exact text
        is a programmed death-ligand 1 (PD-L1) blocking antibody indicated
        label id
        5826517b-d2d2-4636-ad9c-0dc676abad9e
        offset unit
        unicode_code_points
        source array index
        0
        source field
        indications_and_usage_exact
        source text sha256
        f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
        start
        32
        qualifier mentions
        1. context exact
          DICATIONS AND USAGE IMFINZI is a programmed death-ligand 1 (PD-L1) blocking antibody indicated:
          kind
          biomarker
          polarity
          not_inferred
          span
          end
          99
          end exclusive
          true
          exact text
          PD-L1) blocking antibody indicated:
          label id
          5826517b-d2d2-4636-ad9c-0dc676abad9e
          offset unit
          unicode_code_points
          source array index
          0
          source field
          indications_and_usage_exact
          source text sha256
          f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
          start
          64
        regulatory links
          schema version
          0.1.0
          source batch sha256
          bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
          source defined aliases
          1. abbreviation
            NSCLC
            definition exact
            non-small cell lung cancer
            definition span
            end
            389
            end exclusive
            true
            exact text
            non-small cell lung cancer (NSCLC)
            label id
            5826517b-d2d2-4636-ad9c-0dc676abad9e
            offset unit
            unicode_code_points
            source array index
            0
            source field
            indications_and_usage_exact
            source text sha256
            f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
            start
            355
          source span
          end
          99
          end exclusive
          true
          exact text
          1 INDICATIONS AND USAGE IMFINZI is a programmed death-ligand 1 (PD-L1) blocking antibody indicated:
          label id
          5826517b-d2d2-4636-ad9c-0dc676abad9e
          offset unit
          unicode_code_points
          source array index
          0
          source field
          indications_and_usage_exact
          source text sha256
          f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
          start
          0
          source url
          https://api.fda.gov/drug/label.json?search=id%3A%225826517b-d2d2-4636-ad9c-0dc676abad9e%22
          spl effective date
          2026-08-31
          spl set id
          8baba4ea-2855-42fa-9bd9-5a7548d4cec3
          spl version
          34
          structured fields status
          not_extracted_no_values_inferred_from_mentions
          structured indication
          age
          Source null
          approval pathway
          Source null
          biomarker and test
          Source null
          disease stage
          Source null
          limitations
          Source null
          line
          Source null
          prior therapy
          Source null
          regimen
          Source null
          tumor histology
          Source null
          use intent
          not_applicable
          Passage 2 · positive indication candidate
          application numbers
          1. BLA761069
          brand names
          1. IMFINZI
          classification reasons
          1. inherited_predicate_from_same_label_section_requires_review
          2. tumor_or_malignant_hematology_words_in_positive_statement
          clinical review status
          pending
          content role
          positive_indication_candidate
          context span
          end
          704
          end exclusive
          true
          exact text
          1 INDICATIONS AND USAGE IMFINZI is a programmed death-ligand 1 (PD-L1) blocking antibody indicated: • in combination with platinum-containing chemotherapy as neoadjuvant treatment, followed by IMFINZI continued as a single agent as adjuvant treatment after surgery, for the treatment of adult patients with resectable (tumors ≥ 4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. ( 1.1 ) • as a single agent, for the treatment of adult patients with unresectable, Stage III NSCLC whose disease has not progressed following concurrent platinum-based chemotherapy and radiation the
          label id
          5826517b-d2d2-4636-ad9c-0dc676abad9e
          offset unit
          unicode_code_points
          source array index
          0
          source field
          indications_and_usage_exact
          source text sha256
          f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
          start
          0
          current approval status
          not_reconciled
          duplicate text group
          dup-96a309d6ca93a245bef5
          extraction review status
          automated_candidate_pending_source_review
          generic names
          1. DURVALUMAB
          id
          ind-span-07894d26cdd9b2e01e19
          label id
          5826517b-d2d2-4636-ad9c-0dc676abad9e
          positive predicate support span
          end
          98
          end exclusive
          true
          exact text
          is a programmed death-ligand 1 (PD-L1) blocking antibody indicated
          label id
          5826517b-d2d2-4636-ad9c-0dc676abad9e
          offset unit
          unicode_code_points
          source array index
          0
          source field
          indications_and_usage_exact
          source text sha256
          f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
          start
          32
          qualifier mentions
          1. context exact
            t as adjuvant treatment after surgery, for the treatment of adult patients with resectable (tumors ≥ 4 cm and/or node positive) non-sm
            kind
            age
            polarity
            not_inferred
            span
            end
            301
            end exclusive
            true
            exact text
            adult patients
            label id
            5826517b-d2d2-4636-ad9c-0dc676abad9e
            offset unit
            unicode_code_points
            source array index
            0
            source field
            indications_and_usage_exact
            source text sha256
            f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
            start
            287
          2. context exact
            ncer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements.
            kind
            biomarker
            polarity
            not_inferred
            span
            end
            481
            end exclusive
            true
            exact text
            EGFR) mutations or anaplastic lymphoma kinas
            label id
            5826517b-d2d2-4636-ad9c-0dc676abad9e
            offset unit
            unicode_code_points
            source array index
            0
            source field
            indications_and_usage_exact
            source text sha256
            f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
            start
            437
          3. context exact
            or receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements.
            kind
            biomarker
            polarity
            not_inferred
            span
            end
            503
            end exclusive
            true
            exact text
            ALK) rearrangements
            label id
            5826517b-d2d2-4636-ad9c-0dc676abad9e
            offset unit
            unicode_code_points
            source array index
            0
            source field
            indications_and_usage_exact
            source text sha256
            f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
            start
            484
          4. context exact
            • in combination with platinum-containing chemotherapy as neoadjuvant treatment, followed by IMFINZI continued as a single agent as adjuvan
            kind
            stage_or_setting
            polarity
            not_inferred
            span
            end
            179
            end exclusive
            true
            exact text
            neoadjuvant treatment
            label id
            5826517b-d2d2-4636-ad9c-0dc676abad9e
            offset unit
            unicode_code_points
            source array index
            0
            source field
            indications_and_usage_exact
            source text sha256
            f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
            start
            158
          5. context exact
            eatment, followed by IMFINZI continued as a single agent as adjuvant treatment after surgery, for the treatment of adult patients with resectable (tumor
            kind
            stage_or_setting
            polarity
            not_inferred
            span
            end
            264
            end exclusive
            true
            exact text
            adjuvant treatment after surgery
            label id
            5826517b-d2d2-4636-ad9c-0dc676abad9e
            offset unit
            unicode_code_points
            source array index
            0
            source field
            indications_and_usage_exact
            source text sha256
            f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
            start
            232
          6. context exact
            ent after surgery, for the treatment of adult patients with resectable (tumors ≥ 4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal
            kind
            stage_or_setting
            polarity
            not_inferred
            span
            end
            352
            end exclusive
            true
            exact text
            resectable (tumors ≥ 4 cm and/or node positiv
            label id
            5826517b-d2d2-4636-ad9c-0dc676abad9e
            offset unit
            unicode_code_points
            source array index
            0
            source field
            indications_and_usage_exact
            source text sha256
            f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
            start
            307
          7. context exact
            • in combination with platinum-containing chemotherapy as neoadjuvant treatment, followed by IMFINZI continued as a single agent as adjuvant treatment after surgery, for the treatment of adult patients with resectable (tumors ≥ 4 cm and/or n
            kind
            regimen
            polarity
            not_inferred
            span
            end
            281
            end exclusive
            true
            exact text
            in combination with platinum-containing chemotherapy as neoadjuvant treatment, followed by IMFINZI continued as a single agent as adjuvant treatment after surgery, for the treatme
            label id
            5826517b-d2d2-4636-ad9c-0dc676abad9e
            offset unit
            unicode_code_points
            source array index
            0
            source field
            indications_and_usage_exact
            source text sha256
            f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
            start
            102
          regulatory links
            schema version
            0.1.0
            source batch sha256
            bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
            source defined aliases
            1. abbreviation
              NSCLC
              definition exact
              non-small cell lung cancer
              definition span
              end
              389
              end exclusive
              true
              exact text
              non-small cell lung cancer (NSCLC)
              label id
              5826517b-d2d2-4636-ad9c-0dc676abad9e
              offset unit
              unicode_code_points
              source array index
              0
              source field
              indications_and_usage_exact
              source text sha256
              f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
              start
              355
            source span
            end
            504
            end exclusive
            true
            exact text
            • in combination with platinum-containing chemotherapy as neoadjuvant treatment, followed by IMFINZI continued as a single agent as adjuvant treatment after surgery, for the treatment of adult patients with resectable (tumors ≥ 4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements.
            label id
            5826517b-d2d2-4636-ad9c-0dc676abad9e
            offset unit
            unicode_code_points
            source array index
            0
            source field
            indications_and_usage_exact
            source text sha256
            f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
            start
            100
            source url
            https://api.fda.gov/drug/label.json?search=id%3A%225826517b-d2d2-4636-ad9c-0dc676abad9e%22
            spl effective date
            2026-08-31
            spl set id
            8baba4ea-2855-42fa-9bd9-5a7548d4cec3
            spl version
            34
            structured fields status
            not_extracted_no_values_inferred_from_mentions
            structured indication
            age
            Source null
            approval pathway
            Source null
            biomarker and test
            Source null
            disease stage
            Source null
            limitations
            Source null
            line
            Source null
            prior therapy
            Source null
            regimen
            Source null
            tumor histology
            Source null
            use intent
            tumor_directed_candidate
            Passage 3 · unclassified context
            application numbers
            1. BLA761069
            brand names
            1. IMFINZI
            classification reasons
            1. no_unambiguous_positive_indication_predicate
            clinical review status
            pending
            content role
            unclassified_context
            context span
            end
            712
            end exclusive
            true
            exact text
            h resectable (tumors ≥ 4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. ( 1.1 ) • as a single agent, for the treatment of adult patients with unresectable, Stage III NSCLC whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. (
            label id
            5826517b-d2d2-4636-ad9c-0dc676abad9e
            offset unit
            unicode_code_points
            source array index
            0
            source field
            indications_and_usage_exact
            source text sha256
            f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
            start
            305
            current approval status
            not_reconciled
            duplicate text group
            dup-32ca03139198699d179b
            extraction review status
            automated_candidate_pending_source_review
            generic names
            1. DURVALUMAB
            id
            ind-span-a01b6b9ab344e43bb235
            label id
            5826517b-d2d2-4636-ad9c-0dc676abad9e
            positive predicate support span
            Source null
            qualifier mentions
              regulatory links
                schema version
                0.1.0
                source batch sha256
                bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
                source defined aliases
                1. abbreviation
                  NSCLC
                  definition exact
                  non-small cell lung cancer
                  definition span
                  end
                  389
                  end exclusive
                  true
                  exact text
                  non-small cell lung cancer (NSCLC)
                  label id
                  5826517b-d2d2-4636-ad9c-0dc676abad9e
                  offset unit
                  unicode_code_points
                  source array index
                  0
                  source field
                  indications_and_usage_exact
                  source text sha256
                  f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                  start
                  355
                source span
                end
                512
                end exclusive
                true
                exact text
                ( 1.1 )
                label id
                5826517b-d2d2-4636-ad9c-0dc676abad9e
                offset unit
                unicode_code_points
                source array index
                0
                source field
                indications_and_usage_exact
                source text sha256
                f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                start
                505
                source url
                https://api.fda.gov/drug/label.json?search=id%3A%225826517b-d2d2-4636-ad9c-0dc676abad9e%22
                spl effective date
                2026-08-31
                spl set id
                8baba4ea-2855-42fa-9bd9-5a7548d4cec3
                spl version
                34
                structured fields status
                not_extracted_no_values_inferred_from_mentions
                structured indication
                age
                Source null
                approval pathway
                Source null
                biomarker and test
                Source null
                disease stage
                Source null
                limitations
                Source null
                line
                Source null
                prior therapy
                Source null
                regimen
                Source null
                tumor histology
                Source null
                use intent
                unclear
                Passage 4 · positive indication candidate
                application numbers
                1. BLA761069
                brand names
                1. IMFINZI
                classification reasons
                1. inherited_predicate_from_same_label_section_requires_review
                2. tumor_or_malignant_hematology_words_in_positive_statement
                clinical review status
                pending
                content role
                positive_indication_candidate
                context span
                end
                909
                end exclusive
                true
                exact text
                able (tumors ≥ 4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. ( 1.1 ) • as a single agent, for the treatment of adult patients with unresectable, Stage III NSCLC whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. ( 1.1 ) • in combination with tremelimumab-actl and platinum-based chemotherapy, for the treatment of adult patients with metastatic NSCLC with no sensitizing EGFR mutations or ALK genomic tumor aber
                label id
                5826517b-d2d2-4636-ad9c-0dc676abad9e
                offset unit
                unicode_code_points
                source array index
                0
                source field
                indications_and_usage_exact
                source text sha256
                f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                start
                313
                current approval status
                not_reconciled
                duplicate text group
                dup-8ba6de9638e9cb70330e
                extraction review status
                automated_candidate_pending_source_review
                generic names
                1. DURVALUMAB
                id
                ind-span-096724a9086516ba920f
                label id
                5826517b-d2d2-4636-ad9c-0dc676abad9e
                positive predicate support span
                end
                98
                end exclusive
                true
                exact text
                is a programmed death-ligand 1 (PD-L1) blocking antibody indicated
                label id
                5826517b-d2d2-4636-ad9c-0dc676abad9e
                offset unit
                unicode_code_points
                source array index
                0
                source field
                indications_and_usage_exact
                source text sha256
                f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                start
                32
                qualifier mentions
                1. context exact
                  • as a single agent, for the treatment of adult patients with unresectable, Stage III NSCLC whose disease has not pr
                  kind
                  age
                  polarity
                  not_inferred
                  span
                  end
                  569
                  end exclusive
                  true
                  exact text
                  adult patients
                  label id
                  5826517b-d2d2-4636-ad9c-0dc676abad9e
                  offset unit
                  unicode_code_points
                  source array index
                  0
                  source field
                  indications_and_usage_exact
                  source text sha256
                  f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                  start
                  555
                2. context exact
                  as a single agent, for the treatment of adult patients with unresectable, Stage III NSCLC whose disease has not progressed following
                  kind
                  stage_or_setting
                  polarity
                  not_inferred
                  span
                  end
                  587
                  end exclusive
                  true
                  exact text
                  unresectable
                  label id
                  5826517b-d2d2-4636-ad9c-0dc676abad9e
                  offset unit
                  unicode_code_points
                  source array index
                  0
                  source field
                  indications_and_usage_exact
                  source text sha256
                  f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                  start
                  575
                3. context exact
                  • as a single agent, for the treatment of adult patients with unresectable, Stage III NSCLC whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.
                  kind
                  regimen
                  polarity
                  not_inferred
                  span
                  end
                  692
                  end exclusive
                  true
                  exact text
                  as a single agent, for the treatment of adult patients with unresectable, Stage III NSCLC whose disease has not progressed following concurrent platinum-based chemotherapy and r
                  label id
                  5826517b-d2d2-4636-ad9c-0dc676abad9e
                  offset unit
                  unicode_code_points
                  source array index
                  0
                  source field
                  indications_and_usage_exact
                  source text sha256
                  f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                  start
                  515
                regulatory links
                  schema version
                  0.1.0
                  source batch sha256
                  bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
                  source defined aliases
                  1. abbreviation
                    NSCLC
                    definition exact
                    non-small cell lung cancer
                    definition span
                    end
                    389
                    end exclusive
                    true
                    exact text
                    non-small cell lung cancer (NSCLC)
                    label id
                    5826517b-d2d2-4636-ad9c-0dc676abad9e
                    offset unit
                    unicode_code_points
                    source array index
                    0
                    source field
                    indications_and_usage_exact
                    source text sha256
                    f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                    start
                    355
                  source span
                  end
                  709
                  end exclusive
                  true
                  exact text
                  • as a single agent, for the treatment of adult patients with unresectable, Stage III NSCLC whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.
                  label id
                  5826517b-d2d2-4636-ad9c-0dc676abad9e
                  offset unit
                  unicode_code_points
                  source array index
                  0
                  source field
                  indications_and_usage_exact
                  source text sha256
                  f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                  start
                  513
                  source url
                  https://api.fda.gov/drug/label.json?search=id%3A%225826517b-d2d2-4636-ad9c-0dc676abad9e%22
                  spl effective date
                  2026-08-31
                  spl set id
                  8baba4ea-2855-42fa-9bd9-5a7548d4cec3
                  spl version
                  34
                  structured fields status
                  not_extracted_no_values_inferred_from_mentions
                  structured indication
                  age
                  Source null
                  approval pathway
                  Source null
                  biomarker and test
                  Source null
                  disease stage
                  Source null
                  limitations
                  Source null
                  line
                  Source null
                  prior therapy
                  Source null
                  regimen
                  Source null
                  tumor histology
                  Source null
                  use intent
                  tumor_directed_candidate
                  Passage 5 · unclassified context
                  application numbers
                  1. BLA761069
                  brand names
                  1. IMFINZI
                  classification reasons
                  1. no_unambiguous_positive_indication_predicate
                  clinical review status
                  pending
                  content role
                  unclassified_context
                  context span
                  end
                  917
                  end exclusive
                  true
                  exact text
                  ) • as a single agent, for the treatment of adult patients with unresectable, Stage III NSCLC whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. ( 1.1 ) • in combination with tremelimumab-actl and platinum-based chemotherapy, for the treatment of adult patients with metastatic NSCLC with no sensitizing EGFR mutations or ALK genomic tumor aberrations.
                  label id
                  5826517b-d2d2-4636-ad9c-0dc676abad9e
                  offset unit
                  unicode_code_points
                  source array index
                  0
                  source field
                  indications_and_usage_exact
                  source text sha256
                  f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                  start
                  510
                  current approval status
                  not_reconciled
                  duplicate text group
                  dup-32ca03139198699d179b
                  extraction review status
                  automated_candidate_pending_source_review
                  generic names
                  1. DURVALUMAB
                  id
                  ind-span-40d8df3878d6772b212e
                  label id
                  5826517b-d2d2-4636-ad9c-0dc676abad9e
                  positive predicate support span
                  Source null
                  qualifier mentions
                    regulatory links
                      schema version
                      0.1.0
                      source batch sha256
                      bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
                      source defined aliases
                      1. abbreviation
                        NSCLC
                        definition exact
                        non-small cell lung cancer
                        definition span
                        end
                        389
                        end exclusive
                        true
                        exact text
                        non-small cell lung cancer (NSCLC)
                        label id
                        5826517b-d2d2-4636-ad9c-0dc676abad9e
                        offset unit
                        unicode_code_points
                        source array index
                        0
                        source field
                        indications_and_usage_exact
                        source text sha256
                        f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                        start
                        355
                      source span
                      end
                      717
                      end exclusive
                      true
                      exact text
                      ( 1.1 )
                      label id
                      5826517b-d2d2-4636-ad9c-0dc676abad9e
                      offset unit
                      unicode_code_points
                      source array index
                      0
                      source field
                      indications_and_usage_exact
                      source text sha256
                      f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                      start
                      710
                      source url
                      https://api.fda.gov/drug/label.json?search=id%3A%225826517b-d2d2-4636-ad9c-0dc676abad9e%22
                      spl effective date
                      2026-08-31
                      spl set id
                      8baba4ea-2855-42fa-9bd9-5a7548d4cec3
                      spl version
                      34
                      structured fields status
                      not_extracted_no_values_inferred_from_mentions
                      structured indication
                      age
                      Source null
                      approval pathway
                      Source null
                      biomarker and test
                      Source null
                      disease stage
                      Source null
                      limitations
                      Source null
                      line
                      Source null
                      prior therapy
                      Source null
                      regimen
                      Source null
                      tumor histology
                      Source null
                      use intent
                      unclear
                      Passage 6 · positive indication candidate
                      application numbers
                      1. BLA761069
                      brand names
                      1. IMFINZI
                      classification reasons
                      1. inherited_predicate_from_same_label_section_requires_review
                      2. tumor_or_malignant_hematology_words_in_positive_statement
                      clinical review status
                      pending
                      content role
                      positive_indication_candidate
                      context span
                      end
                      1117
                      end exclusive
                      true
                      exact text
                      a single agent, for the treatment of adult patients with unresectable, Stage III NSCLC whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. ( 1.1 ) • in combination with tremelimumab-actl and platinum-based chemotherapy, for the treatment of adult patients with metastatic NSCLC with no sensitizing EGFR mutations or ALK genomic tumor aberrations. ( 1.1 ) • as a single agent, for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy
                      label id
                      5826517b-d2d2-4636-ad9c-0dc676abad9e
                      offset unit
                      unicode_code_points
                      source array index
                      0
                      source field
                      indications_and_usage_exact
                      source text sha256
                      f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                      start
                      518
                      current approval status
                      not_reconciled
                      duplicate text group
                      dup-facf2a542e48de2575d5
                      extraction review status
                      automated_candidate_pending_source_review
                      generic names
                      1. DURVALUMAB
                      id
                      ind-span-74af7f80b248c98d12d8
                      label id
                      5826517b-d2d2-4636-ad9c-0dc676abad9e
                      positive predicate support span
                      end
                      98
                      end exclusive
                      true
                      exact text
                      is a programmed death-ligand 1 (PD-L1) blocking antibody indicated
                      label id
                      5826517b-d2d2-4636-ad9c-0dc676abad9e
                      offset unit
                      unicode_code_points
                      source array index
                      0
                      source field
                      indications_and_usage_exact
                      source text sha256
                      f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                      start
                      32
                      qualifier mentions
                      1. context exact
                        -actl and platinum-based chemotherapy, for the treatment of adult patients with metastatic NSCLC with no sensitizing EGFR mutations or
                        kind
                        age
                        polarity
                        not_inferred
                        span
                        end
                        826
                        end exclusive
                        true
                        exact text
                        adult patients
                        label id
                        5826517b-d2d2-4636-ad9c-0dc676abad9e
                        offset unit
                        unicode_code_points
                        source array index
                        0
                        source field
                        indications_and_usage_exact
                        source text sha256
                        f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                        start
                        812
                      2. context exact
                        ased chemotherapy, for the treatment of adult patients with metastatic NSCLC with no sensitizing EGFR mutations or ALK genomic tumor aberrations.
                        kind
                        biomarker
                        polarity
                        not_inferred
                        span
                        end
                        875
                        end exclusive
                        true
                        exact text
                        metastatic NSCLC with no sensitizing EGFR m
                        label id
                        5826517b-d2d2-4636-ad9c-0dc676abad9e
                        offset unit
                        unicode_code_points
                        source array index
                        0
                        source field
                        indications_and_usage_exact
                        source text sha256
                        f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                        start
                        832
                      3. context exact
                        with metastatic NSCLC with no sensitizing EGFR mutations or ALK genomic tumor aberrations.
                        kind
                        biomarker
                        polarity
                        not_inferred
                        span
                        end
                        916
                        end exclusive
                        true
                        exact text
                        ALK genomic tumor aberrations
                        label id
                        5826517b-d2d2-4636-ad9c-0dc676abad9e
                        offset unit
                        unicode_code_points
                        source array index
                        0
                        source field
                        indications_and_usage_exact
                        source text sha256
                        f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                        start
                        887
                      4. context exact
                        ased chemotherapy, for the treatment of adult patients with metastatic NSCLC with no sensitizing EGFR mutations or ALK genomic tumor aberrations.
                        kind
                        stage_or_setting
                        polarity
                        not_inferred
                        span
                        end
                        877
                        end exclusive
                        true
                        exact text
                        metastatic NSCLC with no sensitizing EGFR mut
                        label id
                        5826517b-d2d2-4636-ad9c-0dc676abad9e
                        offset unit
                        unicode_code_points
                        source array index
                        0
                        source field
                        indications_and_usage_exact
                        source text sha256
                        f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                        start
                        832
                      5. context exact
                        • in combination with tremelimumab-actl and platinum-based chemotherapy, for the treatment of adult patients with metastatic NSCLC with no sensitizing EGFR mutations or ALK genomic tumor aberrations.
                        kind
                        regimen
                        polarity
                        not_inferred
                        span
                        end
                        899
                        end exclusive
                        true
                        exact text
                        in combination with tremelimumab-actl and platinum-based chemotherapy, for the treatment of adult patients with metastatic NSCLC with no sensitizing EGFR mutations or ALK genomic
                        label id
                        5826517b-d2d2-4636-ad9c-0dc676abad9e
                        offset unit
                        unicode_code_points
                        source array index
                        0
                        source field
                        indications_and_usage_exact
                        source text sha256
                        f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                        start
                        720
                      regulatory links
                        schema version
                        0.1.0
                        source batch sha256
                        bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
                        source defined aliases
                        1. abbreviation
                          NSCLC
                          definition exact
                          non-small cell lung cancer
                          definition span
                          end
                          389
                          end exclusive
                          true
                          exact text
                          non-small cell lung cancer (NSCLC)
                          label id
                          5826517b-d2d2-4636-ad9c-0dc676abad9e
                          offset unit
                          unicode_code_points
                          source array index
                          0
                          source field
                          indications_and_usage_exact
                          source text sha256
                          f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                          start
                          355
                        source span
                        end
                        917
                        end exclusive
                        true
                        exact text
                        • in combination with tremelimumab-actl and platinum-based chemotherapy, for the treatment of adult patients with metastatic NSCLC with no sensitizing EGFR mutations or ALK genomic tumor aberrations.
                        label id
                        5826517b-d2d2-4636-ad9c-0dc676abad9e
                        offset unit
                        unicode_code_points
                        source array index
                        0
                        source field
                        indications_and_usage_exact
                        source text sha256
                        f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                        start
                        718
                        source url
                        https://api.fda.gov/drug/label.json?search=id%3A%225826517b-d2d2-4636-ad9c-0dc676abad9e%22
                        spl effective date
                        2026-08-31
                        spl set id
                        8baba4ea-2855-42fa-9bd9-5a7548d4cec3
                        spl version
                        34
                        structured fields status
                        not_extracted_no_values_inferred_from_mentions
                        structured indication
                        age
                        Source null
                        approval pathway
                        Source null
                        biomarker and test
                        Source null
                        disease stage
                        Source null
                        limitations
                        Source null
                        line
                        Source null
                        prior therapy
                        Source null
                        regimen
                        Source null
                        tumor histology
                        Source null
                        use intent
                        tumor_directed_candidate
                        Passage 7 · unclassified context
                        application numbers
                        1. BLA761069
                        brand names
                        1. IMFINZI
                        classification reasons
                        1. no_unambiguous_positive_indication_predicate
                        clinical review status
                        pending
                        content role
                        unclassified_context
                        context span
                        end
                        1125
                        end exclusive
                        true
                        exact text
                        • in combination with tremelimumab-actl and platinum-based chemotherapy, for the treatment of adult patients with metastatic NSCLC with no sensitizing EGFR mutations or ALK genomic tumor aberrations. ( 1.1 ) • as a single agent, for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radi
                        label id
                        5826517b-d2d2-4636-ad9c-0dc676abad9e
                        offset unit
                        unicode_code_points
                        source array index
                        0
                        source field
                        indications_and_usage_exact
                        source text sha256
                        f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                        start
                        718
                        current approval status
                        not_reconciled
                        duplicate text group
                        dup-32ca03139198699d179b
                        extraction review status
                        automated_candidate_pending_source_review
                        generic names
                        1. DURVALUMAB
                        id
                        ind-span-939920fcda0e4e517792
                        label id
                        5826517b-d2d2-4636-ad9c-0dc676abad9e
                        positive predicate support span
                        Source null
                        qualifier mentions
                          regulatory links
                            schema version
                            0.1.0
                            source batch sha256
                            bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
                            source defined aliases
                            1. abbreviation
                              NSCLC
                              definition exact
                              non-small cell lung cancer
                              definition span
                              end
                              389
                              end exclusive
                              true
                              exact text
                              non-small cell lung cancer (NSCLC)
                              label id
                              5826517b-d2d2-4636-ad9c-0dc676abad9e
                              offset unit
                              unicode_code_points
                              source array index
                              0
                              source field
                              indications_and_usage_exact
                              source text sha256
                              f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                              start
                              355
                            source span
                            end
                            925
                            end exclusive
                            true
                            exact text
                            ( 1.1 )
                            label id
                            5826517b-d2d2-4636-ad9c-0dc676abad9e
                            offset unit
                            unicode_code_points
                            source array index
                            0
                            source field
                            indications_and_usage_exact
                            source text sha256
                            f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                            start
                            918
                            source url
                            https://api.fda.gov/drug/label.json?search=id%3A%225826517b-d2d2-4636-ad9c-0dc676abad9e%22
                            spl effective date
                            2026-08-31
                            spl set id
                            8baba4ea-2855-42fa-9bd9-5a7548d4cec3
                            spl version
                            34
                            structured fields status
                            not_extracted_no_values_inferred_from_mentions
                            structured indication
                            age
                            Source null
                            approval pathway
                            Source null
                            biomarker and test
                            Source null
                            disease stage
                            Source null
                            limitations
                            Source null
                            line
                            Source null
                            prior therapy
                            Source null
                            regimen
                            Source null
                            tumor histology
                            Source null
                            use intent
                            unclear
                            Passage 8 · unclassified context
                            application numbers
                            1. BLA761069
                            brand names
                            1. IMFINZI
                            classification reasons
                            1. no_unambiguous_positive_indication_predicate
                            clinical review status
                            pending
                            content role
                            unclassified_context
                            context span
                            end
                            1339
                            end exclusive
                            true
                            exact text
                            bination with tremelimumab-actl and platinum-based chemotherapy, for the treatment of adult patients with metastatic NSCLC with no sensitizing EGFR mutations or ALK genomic tumor aberrations. ( 1.1 ) • as a single agent, for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. ( 1.2 ) • in combination with etoposide and either carboplatin or cisplatin, as first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). ( 1.2 ) • in combination
                            label id
                            5826517b-d2d2-4636-ad9c-0dc676abad9e
                            offset unit
                            unicode_code_points
                            source array index
                            0
                            source field
                            indications_and_usage_exact
                            source text sha256
                            f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                            start
                            726
                            current approval status
                            not_reconciled
                            duplicate text group
                            dup-eeb99ce598d1a0052d55
                            extraction review status
                            automated_candidate_pending_source_review
                            generic names
                            1. DURVALUMAB
                            id
                            ind-span-be958b0c0c04fbd42c17
                            label id
                            5826517b-d2d2-4636-ad9c-0dc676abad9e
                            positive predicate support span
                            Source null
                            qualifier mentions
                            1. context exact
                              • as a single agent, for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose d
                              kind
                              age
                              polarity
                              not_inferred
                              span
                              end
                              982
                              end exclusive
                              true
                              exact text
                              adult patients
                              label id
                              5826517b-d2d2-4636-ad9c-0dc676abad9e
                              offset unit
                              unicode_code_points
                              source array index
                              0
                              source field
                              indications_and_usage_exact
                              source text sha256
                              f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                              start
                              968
                            2. context exact
                              • as a single agent, for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.
                              kind
                              regimen
                              polarity
                              not_inferred
                              span
                              end
                              1105
                              end exclusive
                              true
                              exact text
                              as a single agent, for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based c
                              label id
                              5826517b-d2d2-4636-ad9c-0dc676abad9e
                              offset unit
                              unicode_code_points
                              source array index
                              0
                              source field
                              indications_and_usage_exact
                              source text sha256
                              f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                              start
                              928
                            regulatory links
                              schema version
                              0.1.0
                              source batch sha256
                              bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
                              source defined aliases
                              1. abbreviation
                                NSCLC
                                definition exact
                                non-small cell lung cancer
                                definition span
                                end
                                389
                                end exclusive
                                true
                                exact text
                                non-small cell lung cancer (NSCLC)
                                label id
                                5826517b-d2d2-4636-ad9c-0dc676abad9e
                                offset unit
                                unicode_code_points
                                source array index
                                0
                                source field
                                indications_and_usage_exact
                                source text sha256
                                f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                start
                                355
                              source span
                              end
                              1139
                              end exclusive
                              true
                              exact text
                              • as a single agent, for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.
                              label id
                              5826517b-d2d2-4636-ad9c-0dc676abad9e
                              offset unit
                              unicode_code_points
                              source array index
                              0
                              source field
                              indications_and_usage_exact
                              source text sha256
                              f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                              start
                              926
                              source url
                              https://api.fda.gov/drug/label.json?search=id%3A%225826517b-d2d2-4636-ad9c-0dc676abad9e%22
                              spl effective date
                              2026-08-31
                              spl set id
                              8baba4ea-2855-42fa-9bd9-5a7548d4cec3
                              spl version
                              34
                              structured fields status
                              not_extracted_no_values_inferred_from_mentions
                              structured indication
                              age
                              Source null
                              approval pathway
                              Source null
                              biomarker and test
                              Source null
                              disease stage
                              Source null
                              limitations
                              Source null
                              line
                              Source null
                              prior therapy
                              Source null
                              regimen
                              Source null
                              tumor histology
                              Source null
                              use intent
                              unclear
                              Passage 9 · unclassified context
                              application numbers
                              1. BLA761069
                              brand names
                              1. IMFINZI
                              classification reasons
                              1. no_unambiguous_positive_indication_predicate
                              clinical review status
                              pending
                              content role
                              unclassified_context
                              context span
                              end
                              1347
                              end exclusive
                              true
                              exact text
                              agent, for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. ( 1.2 ) • in combination with etoposide and either carboplatin or cisplatin, as first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). ( 1.2 ) • in combination with gem
                              label id
                              5826517b-d2d2-4636-ad9c-0dc676abad9e
                              offset unit
                              unicode_code_points
                              source array index
                              0
                              source field
                              indications_and_usage_exact
                              source text sha256
                              f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                              start
                              940
                              current approval status
                              not_reconciled
                              duplicate text group
                              dup-781aec186884004da174
                              extraction review status
                              automated_candidate_pending_source_review
                              generic names
                              1. DURVALUMAB
                              id
                              ind-span-615992e90853da6ef5d0
                              label id
                              5826517b-d2d2-4636-ad9c-0dc676abad9e
                              positive predicate support span
                              Source null
                              qualifier mentions
                                regulatory links
                                  schema version
                                  0.1.0
                                  source batch sha256
                                  bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
                                  source defined aliases
                                  1. abbreviation
                                    NSCLC
                                    definition exact
                                    non-small cell lung cancer
                                    definition span
                                    end
                                    389
                                    end exclusive
                                    true
                                    exact text
                                    non-small cell lung cancer (NSCLC)
                                    label id
                                    5826517b-d2d2-4636-ad9c-0dc676abad9e
                                    offset unit
                                    unicode_code_points
                                    source array index
                                    0
                                    source field
                                    indications_and_usage_exact
                                    source text sha256
                                    f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                    start
                                    355
                                  source span
                                  end
                                  1147
                                  end exclusive
                                  true
                                  exact text
                                  ( 1.2 )
                                  label id
                                  5826517b-d2d2-4636-ad9c-0dc676abad9e
                                  offset unit
                                  unicode_code_points
                                  source array index
                                  0
                                  source field
                                  indications_and_usage_exact
                                  source text sha256
                                  f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                  start
                                  1140
                                  source url
                                  https://api.fda.gov/drug/label.json?search=id%3A%225826517b-d2d2-4636-ad9c-0dc676abad9e%22
                                  spl effective date
                                  2026-08-31
                                  spl set id
                                  8baba4ea-2855-42fa-9bd9-5a7548d4cec3
                                  spl version
                                  34
                                  structured fields status
                                  not_extracted_no_values_inferred_from_mentions
                                  structured indication
                                  age
                                  Source null
                                  approval pathway
                                  Source null
                                  biomarker and test
                                  Source null
                                  disease stage
                                  Source null
                                  limitations
                                  Source null
                                  line
                                  Source null
                                  prior therapy
                                  Source null
                                  regimen
                                  Source null
                                  tumor histology
                                  Source null
                                  use intent
                                  unclear
                                  Passage 10 · unclassified context
                                  application numbers
                                  1. BLA761069
                                  brand names
                                  1. IMFINZI
                                  classification reasons
                                  1. no_unambiguous_positive_indication_predicate
                                  clinical review status
                                  pending
                                  content role
                                  unclassified_context
                                  context span
                                  end
                                  1513
                                  end exclusive
                                  true
                                  exact text
                                  or the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. ( 1.2 ) • in combination with etoposide and either carboplatin or cisplatin, as first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). ( 1.2 ) • in combination with gemcitabine and cisplatin, as treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC). ( 1.3 ) • in combination with tremelimumab-actl
                                  label id
                                  5826517b-d2d2-4636-ad9c-0dc676abad9e
                                  offset unit
                                  unicode_code_points
                                  source array index
                                  0
                                  source field
                                  indications_and_usage_exact
                                  source text sha256
                                  f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                  start
                                  948
                                  current approval status
                                  not_reconciled
                                  duplicate text group
                                  dup-92e1368adb9c49bd2ea3
                                  extraction review status
                                  automated_candidate_pending_source_review
                                  generic names
                                  1. DURVALUMAB
                                  id
                                  ind-span-e4e1ab78830461333605
                                  label id
                                  5826517b-d2d2-4636-ad9c-0dc676abad9e
                                  positive predicate support span
                                  Source null
                                  qualifier mentions
                                  1. context exact
                                    either carboplatin or cisplatin, as first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).
                                    kind
                                    age
                                    polarity
                                    not_inferred
                                    span
                                    end
                                    1258
                                    end exclusive
                                    true
                                    exact text
                                    adult patients
                                    label id
                                    5826517b-d2d2-4636-ad9c-0dc676abad9e
                                    offset unit
                                    unicode_code_points
                                    source array index
                                    0
                                    source field
                                    indications_and_usage_exact
                                    source text sha256
                                    f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                    start
                                    1244
                                  2. context exact
                                    tion with etoposide and either carboplatin or cisplatin, as first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).
                                    kind
                                    prior_therapy_or_line
                                    polarity
                                    not_inferred
                                    span
                                    end
                                    1312
                                    end exclusive
                                    true
                                    exact text
                                    first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC)
                                    label id
                                    5826517b-d2d2-4636-ad9c-0dc676abad9e
                                    offset unit
                                    unicode_code_points
                                    source array index
                                    0
                                    source field
                                    indications_and_usage_exact
                                    source text sha256
                                    f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                    start
                                    1220
                                  3. context exact
                                    • in combination with etoposide and either carboplatin or cisplatin, as first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).
                                    kind
                                    regimen
                                    polarity
                                    not_inferred
                                    span
                                    end
                                    1312
                                    end exclusive
                                    true
                                    exact text
                                    in combination with etoposide and either carboplatin or cisplatin, as first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC)
                                    label id
                                    5826517b-d2d2-4636-ad9c-0dc676abad9e
                                    offset unit
                                    unicode_code_points
                                    source array index
                                    0
                                    source field
                                    indications_and_usage_exact
                                    source text sha256
                                    f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                    start
                                    1150
                                  regulatory links
                                    schema version
                                    0.1.0
                                    source batch sha256
                                    bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
                                    source defined aliases
                                    1. abbreviation
                                      NSCLC
                                      definition exact
                                      non-small cell lung cancer
                                      definition span
                                      end
                                      389
                                      end exclusive
                                      true
                                      exact text
                                      non-small cell lung cancer (NSCLC)
                                      label id
                                      5826517b-d2d2-4636-ad9c-0dc676abad9e
                                      offset unit
                                      unicode_code_points
                                      source array index
                                      0
                                      source field
                                      indications_and_usage_exact
                                      source text sha256
                                      f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                      start
                                      355
                                    source span
                                    end
                                    1313
                                    end exclusive
                                    true
                                    exact text
                                    • in combination with etoposide and either carboplatin or cisplatin, as first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).
                                    label id
                                    5826517b-d2d2-4636-ad9c-0dc676abad9e
                                    offset unit
                                    unicode_code_points
                                    source array index
                                    0
                                    source field
                                    indications_and_usage_exact
                                    source text sha256
                                    f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                    start
                                    1148
                                    source url
                                    https://api.fda.gov/drug/label.json?search=id%3A%225826517b-d2d2-4636-ad9c-0dc676abad9e%22
                                    spl effective date
                                    2026-08-31
                                    spl set id
                                    8baba4ea-2855-42fa-9bd9-5a7548d4cec3
                                    spl version
                                    34
                                    structured fields status
                                    not_extracted_no_values_inferred_from_mentions
                                    structured indication
                                    age
                                    Source null
                                    approval pathway
                                    Source null
                                    biomarker and test
                                    Source null
                                    disease stage
                                    Source null
                                    limitations
                                    Source null
                                    line
                                    Source null
                                    prior therapy
                                    Source null
                                    regimen
                                    Source null
                                    tumor histology
                                    Source null
                                    use intent
                                    unclear
                                    Passage 11 · unclassified context
                                    application numbers
                                    1. BLA761069
                                    brand names
                                    1. IMFINZI
                                    classification reasons
                                    1. no_unambiguous_positive_indication_predicate
                                    clinical review status
                                    pending
                                    content role
                                    unclassified_context
                                    context span
                                    end
                                    1521
                                    end exclusive
                                    true
                                    exact text
                                    py and radiation therapy. ( 1.2 ) • in combination with etoposide and either carboplatin or cisplatin, as first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). ( 1.2 ) • in combination with gemcitabine and cisplatin, as treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC). ( 1.3 ) • in combination with tremelimumab-actl, for th
                                    label id
                                    5826517b-d2d2-4636-ad9c-0dc676abad9e
                                    offset unit
                                    unicode_code_points
                                    source array index
                                    0
                                    source field
                                    indications_and_usage_exact
                                    source text sha256
                                    f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                    start
                                    1114
                                    current approval status
                                    not_reconciled
                                    duplicate text group
                                    dup-781aec186884004da174
                                    extraction review status
                                    automated_candidate_pending_source_review
                                    generic names
                                    1. DURVALUMAB
                                    id
                                    ind-span-b18561bc4d5d42119a39
                                    label id
                                    5826517b-d2d2-4636-ad9c-0dc676abad9e
                                    positive predicate support span
                                    Source null
                                    qualifier mentions
                                      regulatory links
                                        schema version
                                        0.1.0
                                        source batch sha256
                                        bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
                                        source defined aliases
                                        1. abbreviation
                                          NSCLC
                                          definition exact
                                          non-small cell lung cancer
                                          definition span
                                          end
                                          389
                                          end exclusive
                                          true
                                          exact text
                                          non-small cell lung cancer (NSCLC)
                                          label id
                                          5826517b-d2d2-4636-ad9c-0dc676abad9e
                                          offset unit
                                          unicode_code_points
                                          source array index
                                          0
                                          source field
                                          indications_and_usage_exact
                                          source text sha256
                                          f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                          start
                                          355
                                        source span
                                        end
                                        1321
                                        end exclusive
                                        true
                                        exact text
                                        ( 1.2 )
                                        label id
                                        5826517b-d2d2-4636-ad9c-0dc676abad9e
                                        offset unit
                                        unicode_code_points
                                        source array index
                                        0
                                        source field
                                        indications_and_usage_exact
                                        source text sha256
                                        f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                        start
                                        1314
                                        source url
                                        https://api.fda.gov/drug/label.json?search=id%3A%225826517b-d2d2-4636-ad9c-0dc676abad9e%22
                                        spl effective date
                                        2026-08-31
                                        spl set id
                                        8baba4ea-2855-42fa-9bd9-5a7548d4cec3
                                        spl version
                                        34
                                        structured fields status
                                        not_extracted_no_values_inferred_from_mentions
                                        structured indication
                                        age
                                        Source null
                                        approval pathway
                                        Source null
                                        biomarker and test
                                        Source null
                                        disease stage
                                        Source null
                                        limitations
                                        Source null
                                        line
                                        Source null
                                        prior therapy
                                        Source null
                                        regimen
                                        Source null
                                        tumor histology
                                        Source null
                                        use intent
                                        unclear
                                        Passage 12 · unclassified context
                                        application numbers
                                        1. BLA761069
                                        brand names
                                        1. IMFINZI
                                        classification reasons
                                        1. no_unambiguous_positive_indication_predicate
                                        clinical review status
                                        pending
                                        content role
                                        unclassified_context
                                        context span
                                        end
                                        1665
                                        end exclusive
                                        true
                                        exact text
                                        adiation therapy. ( 1.2 ) • in combination with etoposide and either carboplatin or cisplatin, as first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). ( 1.2 ) • in combination with gemcitabine and cisplatin, as treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC). ( 1.3 ) • in combination with tremelimumab-actl, for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC). ( 1.4 ) • in combination with carboplatin and paclitaxel follow
                                        label id
                                        5826517b-d2d2-4636-ad9c-0dc676abad9e
                                        offset unit
                                        unicode_code_points
                                        source array index
                                        0
                                        source field
                                        indications_and_usage_exact
                                        source text sha256
                                        f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                        start
                                        1122
                                        current approval status
                                        not_reconciled
                                        duplicate text group
                                        dup-9514c301edaafe3a05ff
                                        extraction review status
                                        automated_candidate_pending_source_review
                                        generic names
                                        1. DURVALUMAB
                                        id
                                        ind-span-65b3d86c757543f18db8
                                        label id
                                        5826517b-d2d2-4636-ad9c-0dc676abad9e
                                        positive predicate support span
                                        Source null
                                        qualifier mentions
                                        1. context exact
                                          combination with gemcitabine and cisplatin, as treatment of adult patients with locally advanced or metastatic biliary tract cancer (B
                                          kind
                                          age
                                          polarity
                                          not_inferred
                                          span
                                          end
                                          1401
                                          end exclusive
                                          true
                                          exact text
                                          adult patients
                                          label id
                                          5826517b-d2d2-4636-ad9c-0dc676abad9e
                                          offset unit
                                          unicode_code_points
                                          source array index
                                          0
                                          source field
                                          indications_and_usage_exact
                                          source text sha256
                                          f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                          start
                                          1387
                                        2. context exact
                                          in, as treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC).
                                          kind
                                          biomarker
                                          polarity
                                          not_inferred
                                          span
                                          end
                                          1464
                                          end exclusive
                                          true
                                          exact text
                                          metastatic biliary tract cancer (BTC)
                                          label id
                                          5826517b-d2d2-4636-ad9c-0dc676abad9e
                                          offset unit
                                          unicode_code_points
                                          source array index
                                          0
                                          source field
                                          indications_and_usage_exact
                                          source text sha256
                                          f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                          start
                                          1427
                                        3. context exact
                                          citabine and cisplatin, as treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC).
                                          kind
                                          stage_or_setting
                                          polarity
                                          not_inferred
                                          span
                                          end
                                          1458
                                          end exclusive
                                          true
                                          exact text
                                          locally advanced or metastatic biliary tract cancer
                                          label id
                                          5826517b-d2d2-4636-ad9c-0dc676abad9e
                                          offset unit
                                          unicode_code_points
                                          source array index
                                          0
                                          source field
                                          indications_and_usage_exact
                                          source text sha256
                                          f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                          start
                                          1407
                                        4. context exact
                                          • in combination with gemcitabine and cisplatin, as treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC).
                                          kind
                                          regimen
                                          polarity
                                          not_inferred
                                          span
                                          end
                                          1464
                                          end exclusive
                                          true
                                          exact text
                                          in combination with gemcitabine and cisplatin, as treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC)
                                          label id
                                          5826517b-d2d2-4636-ad9c-0dc676abad9e
                                          offset unit
                                          unicode_code_points
                                          source array index
                                          0
                                          source field
                                          indications_and_usage_exact
                                          source text sha256
                                          f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                          start
                                          1324
                                        regulatory links
                                          schema version
                                          0.1.0
                                          source batch sha256
                                          bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
                                          source defined aliases
                                          1. abbreviation
                                            NSCLC
                                            definition exact
                                            non-small cell lung cancer
                                            definition span
                                            end
                                            389
                                            end exclusive
                                            true
                                            exact text
                                            non-small cell lung cancer (NSCLC)
                                            label id
                                            5826517b-d2d2-4636-ad9c-0dc676abad9e
                                            offset unit
                                            unicode_code_points
                                            source array index
                                            0
                                            source field
                                            indications_and_usage_exact
                                            source text sha256
                                            f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                            start
                                            355
                                          source span
                                          end
                                          1465
                                          end exclusive
                                          true
                                          exact text
                                          • in combination with gemcitabine and cisplatin, as treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC).
                                          label id
                                          5826517b-d2d2-4636-ad9c-0dc676abad9e
                                          offset unit
                                          unicode_code_points
                                          source array index
                                          0
                                          source field
                                          indications_and_usage_exact
                                          source text sha256
                                          f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                          start
                                          1322
                                          source url
                                          https://api.fda.gov/drug/label.json?search=id%3A%225826517b-d2d2-4636-ad9c-0dc676abad9e%22
                                          spl effective date
                                          2026-08-31
                                          spl set id
                                          8baba4ea-2855-42fa-9bd9-5a7548d4cec3
                                          spl version
                                          34
                                          structured fields status
                                          not_extracted_no_values_inferred_from_mentions
                                          structured indication
                                          age
                                          Source null
                                          approval pathway
                                          Source null
                                          biomarker and test
                                          Source null
                                          disease stage
                                          Source null
                                          limitations
                                          Source null
                                          line
                                          Source null
                                          prior therapy
                                          Source null
                                          regimen
                                          Source null
                                          tumor histology
                                          Source null
                                          use intent
                                          unclear
                                          Passage 13 · unclassified context
                                          application numbers
                                          1. BLA761069
                                          brand names
                                          1. IMFINZI
                                          classification reasons
                                          1. no_unambiguous_positive_indication_predicate
                                          clinical review status
                                          pending
                                          content role
                                          unclassified_context
                                          context span
                                          end
                                          1673
                                          end exclusive
                                          true
                                          exact text
                                          tensive-stage small cell lung cancer (ES-SCLC). ( 1.2 ) • in combination with gemcitabine and cisplatin, as treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC). ( 1.3 ) • in combination with tremelimumab-actl, for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC). ( 1.4 ) • in combination with carboplatin and paclitaxel followed by IM
                                          label id
                                          5826517b-d2d2-4636-ad9c-0dc676abad9e
                                          offset unit
                                          unicode_code_points
                                          source array index
                                          0
                                          source field
                                          indications_and_usage_exact
                                          source text sha256
                                          f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                          start
                                          1266
                                          current approval status
                                          not_reconciled
                                          duplicate text group
                                          dup-a8930f95601dbc9d9b95
                                          extraction review status
                                          automated_candidate_pending_source_review
                                          generic names
                                          1. DURVALUMAB
                                          id
                                          ind-span-1e9c86a4d8552bc8c1d9
                                          label id
                                          5826517b-d2d2-4636-ad9c-0dc676abad9e
                                          positive predicate support span
                                          Source null
                                          qualifier mentions
                                            regulatory links
                                              schema version
                                              0.1.0
                                              source batch sha256
                                              bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
                                              source defined aliases
                                              1. abbreviation
                                                NSCLC
                                                definition exact
                                                non-small cell lung cancer
                                                definition span
                                                end
                                                389
                                                end exclusive
                                                true
                                                exact text
                                                non-small cell lung cancer (NSCLC)
                                                label id
                                                5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                offset unit
                                                unicode_code_points
                                                source array index
                                                0
                                                source field
                                                indications_and_usage_exact
                                                source text sha256
                                                f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                start
                                                355
                                              source span
                                              end
                                              1473
                                              end exclusive
                                              true
                                              exact text
                                              ( 1.3 )
                                              label id
                                              5826517b-d2d2-4636-ad9c-0dc676abad9e
                                              offset unit
                                              unicode_code_points
                                              source array index
                                              0
                                              source field
                                              indications_and_usage_exact
                                              source text sha256
                                              f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                              start
                                              1466
                                              source url
                                              https://api.fda.gov/drug/label.json?search=id%3A%225826517b-d2d2-4636-ad9c-0dc676abad9e%22
                                              spl effective date
                                              2026-08-31
                                              spl set id
                                              8baba4ea-2855-42fa-9bd9-5a7548d4cec3
                                              spl version
                                              34
                                              structured fields status
                                              not_extracted_no_values_inferred_from_mentions
                                              structured indication
                                              age
                                              Source null
                                              approval pathway
                                              Source null
                                              biomarker and test
                                              Source null
                                              disease stage
                                              Source null
                                              limitations
                                              Source null
                                              line
                                              Source null
                                              prior therapy
                                              Source null
                                              regimen
                                              Source null
                                              tumor histology
                                              Source null
                                              use intent
                                              unclear
                                              Passage 14 · unclassified context
                                              application numbers
                                              1. BLA761069
                                              brand names
                                              1. IMFINZI
                                              classification reasons
                                              1. no_unambiguous_positive_indication_predicate
                                              clinical review status
                                              pending
                                              content role
                                              unclassified_context
                                              context span
                                              end
                                              1801
                                              end exclusive
                                              true
                                              exact text
                                              stage small cell lung cancer (ES-SCLC). ( 1.2 ) • in combination with gemcitabine and cisplatin, as treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC). ( 1.3 ) • in combination with tremelimumab-actl, for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC). ( 1.4 ) • in combination with carboplatin and paclitaxel followed by IMFINZI as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is misma
                                              label id
                                              5826517b-d2d2-4636-ad9c-0dc676abad9e
                                              offset unit
                                              unicode_code_points
                                              source array index
                                              0
                                              source field
                                              indications_and_usage_exact
                                              source text sha256
                                              f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                              start
                                              1274
                                              current approval status
                                              not_reconciled
                                              duplicate text group
                                              dup-e38ee77eb3835a888ea4
                                              extraction review status
                                              automated_candidate_pending_source_review
                                              generic names
                                              1. DURVALUMAB
                                              id
                                              ind-span-6c85a551ef3dffb5415d
                                              label id
                                              5826517b-d2d2-4636-ad9c-0dc676abad9e
                                              positive predicate support span
                                              Source null
                                              qualifier mentions
                                              1. context exact
                                                in combination with tremelimumab-actl, for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC).
                                                kind
                                                age
                                                polarity
                                                not_inferred
                                                span
                                                end
                                                1550
                                                end exclusive
                                                true
                                                exact text
                                                adult patients
                                                label id
                                                5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                offset unit
                                                unicode_code_points
                                                source array index
                                                0
                                                source field
                                                indications_and_usage_exact
                                                source text sha256
                                                f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                start
                                                1536
                                              2. context exact
                                                tremelimumab-actl, for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC).
                                                kind
                                                stage_or_setting
                                                polarity
                                                not_inferred
                                                span
                                                end
                                                1600
                                                end exclusive
                                                true
                                                exact text
                                                unresectable hepatocellular carcinoma (uHCC)
                                                label id
                                                5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                offset unit
                                                unicode_code_points
                                                source array index
                                                0
                                                source field
                                                indications_and_usage_exact
                                                source text sha256
                                                f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                start
                                                1556
                                              3. context exact
                                                • in combination with tremelimumab-actl, for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC).
                                                kind
                                                regimen
                                                polarity
                                                not_inferred
                                                span
                                                end
                                                1600
                                                end exclusive
                                                true
                                                exact text
                                                in combination with tremelimumab-actl, for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC)
                                                label id
                                                5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                offset unit
                                                unicode_code_points
                                                source array index
                                                0
                                                source field
                                                indications_and_usage_exact
                                                source text sha256
                                                f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                start
                                                1476
                                              regulatory links
                                                schema version
                                                0.1.0
                                                source batch sha256
                                                bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
                                                source defined aliases
                                                1. abbreviation
                                                  NSCLC
                                                  definition exact
                                                  non-small cell lung cancer
                                                  definition span
                                                  end
                                                  389
                                                  end exclusive
                                                  true
                                                  exact text
                                                  non-small cell lung cancer (NSCLC)
                                                  label id
                                                  5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                  offset unit
                                                  unicode_code_points
                                                  source array index
                                                  0
                                                  source field
                                                  indications_and_usage_exact
                                                  source text sha256
                                                  f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                  start
                                                  355
                                                source span
                                                end
                                                1601
                                                end exclusive
                                                true
                                                exact text
                                                • in combination with tremelimumab-actl, for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC).
                                                label id
                                                5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                offset unit
                                                unicode_code_points
                                                source array index
                                                0
                                                source field
                                                indications_and_usage_exact
                                                source text sha256
                                                f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                start
                                                1474
                                                source url
                                                https://api.fda.gov/drug/label.json?search=id%3A%225826517b-d2d2-4636-ad9c-0dc676abad9e%22
                                                spl effective date
                                                2026-08-31
                                                spl set id
                                                8baba4ea-2855-42fa-9bd9-5a7548d4cec3
                                                spl version
                                                34
                                                structured fields status
                                                not_extracted_no_values_inferred_from_mentions
                                                structured indication
                                                age
                                                Source null
                                                approval pathway
                                                Source null
                                                biomarker and test
                                                Source null
                                                disease stage
                                                Source null
                                                limitations
                                                Source null
                                                line
                                                Source null
                                                prior therapy
                                                Source null
                                                regimen
                                                Source null
                                                tumor histology
                                                Source null
                                                use intent
                                                unclear
                                                Passage 15 · unclassified context
                                                application numbers
                                                1. BLA761069
                                                brand names
                                                1. IMFINZI
                                                classification reasons
                                                1. no_unambiguous_positive_indication_predicate
                                                clinical review status
                                                pending
                                                content role
                                                unclassified_context
                                                context span
                                                end
                                                1809
                                                end exclusive
                                                true
                                                exact text
                                                with locally advanced or metastatic biliary tract cancer (BTC). ( 1.3 ) • in combination with tremelimumab-actl, for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC). ( 1.4 ) • in combination with carboplatin and paclitaxel followed by IMFINZI as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repa
                                                label id
                                                5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                offset unit
                                                unicode_code_points
                                                source array index
                                                0
                                                source field
                                                indications_and_usage_exact
                                                source text sha256
                                                f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                start
                                                1402
                                                current approval status
                                                not_reconciled
                                                duplicate text group
                                                dup-4ac533f935eb6707d7b4
                                                extraction review status
                                                automated_candidate_pending_source_review
                                                generic names
                                                1. DURVALUMAB
                                                id
                                                ind-span-26f7a3d02d07fdbd6e2e
                                                label id
                                                5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                positive predicate support span
                                                Source null
                                                qualifier mentions
                                                  regulatory links
                                                    schema version
                                                    0.1.0
                                                    source batch sha256
                                                    bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
                                                    source defined aliases
                                                    1. abbreviation
                                                      NSCLC
                                                      definition exact
                                                      non-small cell lung cancer
                                                      definition span
                                                      end
                                                      389
                                                      end exclusive
                                                      true
                                                      exact text
                                                      non-small cell lung cancer (NSCLC)
                                                      label id
                                                      5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                      offset unit
                                                      unicode_code_points
                                                      source array index
                                                      0
                                                      source field
                                                      indications_and_usage_exact
                                                      source text sha256
                                                      f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                      start
                                                      355
                                                    source span
                                                    end
                                                    1609
                                                    end exclusive
                                                    true
                                                    exact text
                                                    ( 1.4 )
                                                    label id
                                                    5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                    offset unit
                                                    unicode_code_points
                                                    source array index
                                                    0
                                                    source field
                                                    indications_and_usage_exact
                                                    source text sha256
                                                    f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                    start
                                                    1602
                                                    source url
                                                    https://api.fda.gov/drug/label.json?search=id%3A%225826517b-d2d2-4636-ad9c-0dc676abad9e%22
                                                    spl effective date
                                                    2026-08-31
                                                    spl set id
                                                    8baba4ea-2855-42fa-9bd9-5a7548d4cec3
                                                    spl version
                                                    34
                                                    structured fields status
                                                    not_extracted_no_values_inferred_from_mentions
                                                    structured indication
                                                    age
                                                    Source null
                                                    approval pathway
                                                    Source null
                                                    biomarker and test
                                                    Source null
                                                    disease stage
                                                    Source null
                                                    limitations
                                                    Source null
                                                    line
                                                    Source null
                                                    prior therapy
                                                    Source null
                                                    regimen
                                                    Source null
                                                    tumor histology
                                                    Source null
                                                    use intent
                                                    unclear
                                                    Passage 16 · unclassified context
                                                    application numbers
                                                    1. BLA761069
                                                    brand names
                                                    1. IMFINZI
                                                    classification reasons
                                                    1. no_unambiguous_positive_indication_predicate
                                                    clinical review status
                                                    pending
                                                    content role
                                                    unclassified_context
                                                    context span
                                                    end
                                                    2069
                                                    end exclusive
                                                    true
                                                    exact text
                                                    ally advanced or metastatic biliary tract cancer (BTC). ( 1.3 ) • in combination with tremelimumab-actl, for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC). ( 1.4 ) • in combination with carboplatin and paclitaxel followed by IMFINZI as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR) as determined by an FDA-authorized test. ( 1.5 , 2.1 ) • in combination with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-naive, high-risk non-muscle-invasive bladder cancer (NMIBC). ( 1.6 ) • in combination w
                                                    label id
                                                    5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                    offset unit
                                                    unicode_code_points
                                                    source array index
                                                    0
                                                    source field
                                                    indications_and_usage_exact
                                                    source text sha256
                                                    f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                    start
                                                    1410
                                                    current approval status
                                                    not_reconciled
                                                    duplicate text group
                                                    dup-321ac57bb6759821f029
                                                    extraction review status
                                                    automated_candidate_pending_source_review
                                                    generic names
                                                    1. DURVALUMAB
                                                    id
                                                    ind-span-607bb0045d2f3f0ef652
                                                    label id
                                                    5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                    positive predicate support span
                                                    Source null
                                                    qualifier mentions
                                                    1. context exact
                                                      followed by IMFINZI as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial cancer that
                                                      kind
                                                      age
                                                      polarity
                                                      not_inferred
                                                      span
                                                      end
                                                      1733
                                                      end exclusive
                                                      true
                                                      exact text
                                                      adult patients
                                                      label id
                                                      5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                      offset unit
                                                      unicode_code_points
                                                      source array index
                                                      0
                                                      source field
                                                      indications_and_usage_exact
                                                      source text sha256
                                                      f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                      start
                                                      1719
                                                    2. context exact
                                                      rrent endometrial cancer that is mismatch repair deficient (dMMR) as determined by an FDA-authorized test.
                                                      kind
                                                      biomarker
                                                      polarity
                                                      not_inferred
                                                      span
                                                      end
                                                      1867
                                                      end exclusive
                                                      true
                                                      exact text
                                                      dMMR) as determined by an FDA-authorized tes
                                                      label id
                                                      5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                      offset unit
                                                      unicode_code_points
                                                      source array index
                                                      0
                                                      source field
                                                      indications_and_usage_exact
                                                      source text sha256
                                                      f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                      start
                                                      1823
                                                    3. context exact
                                                      gle agent, for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR) as determined by an F
                                                      kind
                                                      stage_or_setting
                                                      polarity
                                                      not_inferred
                                                      span
                                                      end
                                                      1790
                                                      end exclusive
                                                      true
                                                      exact text
                                                      advanced or recurrent endometrial cancer th
                                                      label id
                                                      5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                      offset unit
                                                      unicode_code_points
                                                      source array index
                                                      0
                                                      source field
                                                      indications_and_usage_exact
                                                      source text sha256
                                                      f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                      start
                                                      1747
                                                    4. context exact
                                                      • in combination with carboplatin and paclitaxel followed by IMFINZI as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR) as determined by an FD
                                                      kind
                                                      regimen
                                                      polarity
                                                      not_inferred
                                                      span
                                                      end
                                                      1791
                                                      end exclusive
                                                      true
                                                      exact text
                                                      in combination with carboplatin and paclitaxel followed by IMFINZI as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial cancer tha
                                                      label id
                                                      5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                      offset unit
                                                      unicode_code_points
                                                      source array index
                                                      0
                                                      source field
                                                      indications_and_usage_exact
                                                      source text sha256
                                                      f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                      start
                                                      1612
                                                    regulatory links
                                                      schema version
                                                      0.1.0
                                                      source batch sha256
                                                      bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
                                                      source defined aliases
                                                      1. abbreviation
                                                        NSCLC
                                                        definition exact
                                                        non-small cell lung cancer
                                                        definition span
                                                        end
                                                        389
                                                        end exclusive
                                                        true
                                                        exact text
                                                        non-small cell lung cancer (NSCLC)
                                                        label id
                                                        5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                        offset unit
                                                        unicode_code_points
                                                        source array index
                                                        0
                                                        source field
                                                        indications_and_usage_exact
                                                        source text sha256
                                                        f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                        start
                                                        355
                                                      source span
                                                      end
                                                      1869
                                                      end exclusive
                                                      true
                                                      exact text
                                                      • in combination with carboplatin and paclitaxel followed by IMFINZI as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR) as determined by an FDA-authorized test.
                                                      label id
                                                      5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                      offset unit
                                                      unicode_code_points
                                                      source array index
                                                      0
                                                      source field
                                                      indications_and_usage_exact
                                                      source text sha256
                                                      f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                      start
                                                      1610
                                                      source url
                                                      https://api.fda.gov/drug/label.json?search=id%3A%225826517b-d2d2-4636-ad9c-0dc676abad9e%22
                                                      spl effective date
                                                      2026-08-31
                                                      spl set id
                                                      8baba4ea-2855-42fa-9bd9-5a7548d4cec3
                                                      spl version
                                                      34
                                                      structured fields status
                                                      not_extracted_no_values_inferred_from_mentions
                                                      structured indication
                                                      age
                                                      Source null
                                                      approval pathway
                                                      Source null
                                                      biomarker and test
                                                      Source null
                                                      disease stage
                                                      Source null
                                                      limitations
                                                      Source null
                                                      line
                                                      Source null
                                                      prior therapy
                                                      Source null
                                                      regimen
                                                      Source null
                                                      tumor histology
                                                      Source null
                                                      use intent
                                                      unclear
                                                      Passage 17 · unclassified context
                                                      application numbers
                                                      1. BLA761069
                                                      brand names
                                                      1. IMFINZI
                                                      classification reasons
                                                      1. no_unambiguous_positive_indication_predicate
                                                      clinical review status
                                                      pending
                                                      content role
                                                      unclassified_context
                                                      context span
                                                      end
                                                      2083
                                                      end exclusive
                                                      true
                                                      exact text
                                                      IMFINZI as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR) as determined by an FDA-authorized test. ( 1.5 , 2.1 ) • in combination with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-naive, high-risk non-muscle-invasive bladder cancer (NMIBC). ( 1.6 ) • in combination with gemcitabin
                                                      label id
                                                      5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                      offset unit
                                                      unicode_code_points
                                                      source array index
                                                      0
                                                      source field
                                                      indications_and_usage_exact
                                                      source text sha256
                                                      f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                      start
                                                      1670
                                                      current approval status
                                                      not_reconciled
                                                      duplicate text group
                                                      dup-3f6f22da7c84d6505f8b
                                                      extraction review status
                                                      automated_candidate_pending_source_review
                                                      generic names
                                                      1. DURVALUMAB
                                                      id
                                                      ind-span-4f5f24978955e78b1a04
                                                      label id
                                                      5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                      positive predicate support span
                                                      Source null
                                                      qualifier mentions
                                                        regulatory links
                                                          schema version
                                                          0.1.0
                                                          source batch sha256
                                                          bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
                                                          source defined aliases
                                                          1. abbreviation
                                                            NSCLC
                                                            definition exact
                                                            non-small cell lung cancer
                                                            definition span
                                                            end
                                                            389
                                                            end exclusive
                                                            true
                                                            exact text
                                                            non-small cell lung cancer (NSCLC)
                                                            label id
                                                            5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                            offset unit
                                                            unicode_code_points
                                                            source array index
                                                            0
                                                            source field
                                                            indications_and_usage_exact
                                                            source text sha256
                                                            f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                            start
                                                            355
                                                          source span
                                                          end
                                                          1883
                                                          end exclusive
                                                          true
                                                          exact text
                                                          ( 1.5 , 2.1 )
                                                          label id
                                                          5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                          offset unit
                                                          unicode_code_points
                                                          source array index
                                                          0
                                                          source field
                                                          indications_and_usage_exact
                                                          source text sha256
                                                          f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                          start
                                                          1870
                                                          source url
                                                          https://api.fda.gov/drug/label.json?search=id%3A%225826517b-d2d2-4636-ad9c-0dc676abad9e%22
                                                          spl effective date
                                                          2026-08-31
                                                          spl set id
                                                          8baba4ea-2855-42fa-9bd9-5a7548d4cec3
                                                          spl version
                                                          34
                                                          structured fields status
                                                          not_extracted_no_values_inferred_from_mentions
                                                          structured indication
                                                          age
                                                          Source null
                                                          approval pathway
                                                          Source null
                                                          biomarker and test
                                                          Source null
                                                          disease stage
                                                          Source null
                                                          limitations
                                                          Source null
                                                          line
                                                          Source null
                                                          prior therapy
                                                          Source null
                                                          regimen
                                                          Source null
                                                          tumor histology
                                                          Source null
                                                          use intent
                                                          unclear
                                                          Passage 18 · unclassified context
                                                          application numbers
                                                          1. BLA761069
                                                          brand names
                                                          1. IMFINZI
                                                          classification reasons
                                                          1. no_unambiguous_positive_indication_predicate
                                                          clinical review status
                                                          pending
                                                          content role
                                                          unclassified_context
                                                          context span
                                                          end
                                                          2242
                                                          end exclusive
                                                          true
                                                          exact text
                                                          single agent, for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR) as determined by an FDA-authorized test. ( 1.5 , 2.1 ) • in combination with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-naive, high-risk non-muscle-invasive bladder cancer (NMIBC). ( 1.6 ) • in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent IMFINZI as adjuvant treatment following radical cystectomy, for the treatment of adult patie
                                                          label id
                                                          5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                          offset unit
                                                          unicode_code_points
                                                          source array index
                                                          0
                                                          source field
                                                          indications_and_usage_exact
                                                          source text sha256
                                                          f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                          start
                                                          1684
                                                          current approval status
                                                          not_reconciled
                                                          duplicate text group
                                                          dup-38154539eb29bca7ec0c
                                                          extraction review status
                                                          automated_candidate_pending_source_review
                                                          generic names
                                                          1. DURVALUMAB
                                                          id
                                                          ind-span-94c9eaa7f5309adb6a2a
                                                          label id
                                                          5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                          positive predicate support span
                                                          Source null
                                                          qualifier mentions
                                                          1. context exact
                                                            on with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-naive, high-risk non-muscle-invasive bladder cance
                                                            kind
                                                            age
                                                            polarity
                                                            not_inferred
                                                            span
                                                            end
                                                            1972
                                                            end exclusive
                                                            true
                                                            exact text
                                                            adult patients
                                                            label id
                                                            5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                            offset unit
                                                            unicode_code_points
                                                            source array index
                                                            0
                                                            source field
                                                            indications_and_usage_exact
                                                            source text sha256
                                                            f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                            start
                                                            1958
                                                          2. context exact
                                                            • in combination with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-naive, high-risk non-muscle-invasive bladder cancer (NMIBC).
                                                            kind
                                                            regimen
                                                            polarity
                                                            not_inferred
                                                            span
                                                            end
                                                            2041
                                                            end exclusive
                                                            true
                                                            exact text
                                                            in combination with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-naive, high-risk non-muscle-invasive bladder cancer (NMIBC)
                                                            label id
                                                            5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                            offset unit
                                                            unicode_code_points
                                                            source array index
                                                            0
                                                            source field
                                                            indications_and_usage_exact
                                                            source text sha256
                                                            f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                            start
                                                            1886
                                                          regulatory links
                                                            schema version
                                                            0.1.0
                                                            source batch sha256
                                                            bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
                                                            source defined aliases
                                                            1. abbreviation
                                                              NSCLC
                                                              definition exact
                                                              non-small cell lung cancer
                                                              definition span
                                                              end
                                                              389
                                                              end exclusive
                                                              true
                                                              exact text
                                                              non-small cell lung cancer (NSCLC)
                                                              label id
                                                              5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                              offset unit
                                                              unicode_code_points
                                                              source array index
                                                              0
                                                              source field
                                                              indications_and_usage_exact
                                                              source text sha256
                                                              f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                              start
                                                              355
                                                            source span
                                                            end
                                                            2042
                                                            end exclusive
                                                            true
                                                            exact text
                                                            • in combination with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-naive, high-risk non-muscle-invasive bladder cancer (NMIBC).
                                                            label id
                                                            5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                            offset unit
                                                            unicode_code_points
                                                            source array index
                                                            0
                                                            source field
                                                            indications_and_usage_exact
                                                            source text sha256
                                                            f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                            start
                                                            1884
                                                            source url
                                                            https://api.fda.gov/drug/label.json?search=id%3A%225826517b-d2d2-4636-ad9c-0dc676abad9e%22
                                                            spl effective date
                                                            2026-08-31
                                                            spl set id
                                                            8baba4ea-2855-42fa-9bd9-5a7548d4cec3
                                                            spl version
                                                            34
                                                            structured fields status
                                                            not_extracted_no_values_inferred_from_mentions
                                                            structured indication
                                                            age
                                                            Source null
                                                            approval pathway
                                                            Source null
                                                            biomarker and test
                                                            Source null
                                                            disease stage
                                                            Source null
                                                            limitations
                                                            Source null
                                                            line
                                                            Source null
                                                            prior therapy
                                                            Source null
                                                            regimen
                                                            Source null
                                                            tumor histology
                                                            Source null
                                                            use intent
                                                            unclear
                                                            Passage 19 · unclassified context
                                                            application numbers
                                                            1. BLA761069
                                                            brand names
                                                            1. IMFINZI
                                                            classification reasons
                                                            1. no_unambiguous_positive_indication_predicate
                                                            clinical review status
                                                            pending
                                                            content role
                                                            unclassified_context
                                                            context span
                                                            end
                                                            2250
                                                            end exclusive
                                                            true
                                                            exact text
                                                            by an FDA-authorized test. ( 1.5 , 2.1 ) • in combination with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-naive, high-risk non-muscle-invasive bladder cancer (NMIBC). ( 1.6 ) • in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent IMFINZI as adjuvant treatment following radical cystectomy, for the treatment of adult patients with
                                                            label id
                                                            5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                            offset unit
                                                            unicode_code_points
                                                            source array index
                                                            0
                                                            source field
                                                            indications_and_usage_exact
                                                            source text sha256
                                                            f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                            start
                                                            1843
                                                            current approval status
                                                            not_reconciled
                                                            duplicate text group
                                                            dup-96d63ce422d261a1efb8
                                                            extraction review status
                                                            automated_candidate_pending_source_review
                                                            generic names
                                                            1. DURVALUMAB
                                                            id
                                                            ind-span-b5fbe013dce850cb2c8b
                                                            label id
                                                            5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                            positive predicate support span
                                                            Source null
                                                            qualifier mentions
                                                              regulatory links
                                                                schema version
                                                                0.1.0
                                                                source batch sha256
                                                                bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
                                                                source defined aliases
                                                                1. abbreviation
                                                                  NSCLC
                                                                  definition exact
                                                                  non-small cell lung cancer
                                                                  definition span
                                                                  end
                                                                  389
                                                                  end exclusive
                                                                  true
                                                                  exact text
                                                                  non-small cell lung cancer (NSCLC)
                                                                  label id
                                                                  5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                  offset unit
                                                                  unicode_code_points
                                                                  source array index
                                                                  0
                                                                  source field
                                                                  indications_and_usage_exact
                                                                  source text sha256
                                                                  f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                  start
                                                                  355
                                                                source span
                                                                end
                                                                2050
                                                                end exclusive
                                                                true
                                                                exact text
                                                                ( 1.6 )
                                                                label id
                                                                5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                offset unit
                                                                unicode_code_points
                                                                source array index
                                                                0
                                                                source field
                                                                indications_and_usage_exact
                                                                source text sha256
                                                                f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                start
                                                                2043
                                                                source url
                                                                https://api.fda.gov/drug/label.json?search=id%3A%225826517b-d2d2-4636-ad9c-0dc676abad9e%22
                                                                spl effective date
                                                                2026-08-31
                                                                spl set id
                                                                8baba4ea-2855-42fa-9bd9-5a7548d4cec3
                                                                spl version
                                                                34
                                                                structured fields status
                                                                not_extracted_no_values_inferred_from_mentions
                                                                structured indication
                                                                age
                                                                Source null
                                                                approval pathway
                                                                Source null
                                                                biomarker and test
                                                                Source null
                                                                disease stage
                                                                Source null
                                                                limitations
                                                                Source null
                                                                line
                                                                Source null
                                                                prior therapy
                                                                Source null
                                                                regimen
                                                                Source null
                                                                tumor histology
                                                                Source null
                                                                use intent
                                                                unclear
                                                                Passage 20 · unclassified context
                                                                application numbers
                                                                1. BLA761069
                                                                brand names
                                                                1. IMFINZI
                                                                classification reasons
                                                                1. no_unambiguous_positive_indication_predicate
                                                                clinical review status
                                                                pending
                                                                content role
                                                                unclassified_context
                                                                context span
                                                                end
                                                                2489
                                                                end exclusive
                                                                true
                                                                exact text
                                                                A-authorized test. ( 1.5 , 2.1 ) • in combination with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-naive, high-risk non-muscle-invasive bladder cancer (NMIBC). ( 1.6 ) • in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent IMFINZI as adjuvant treatment following radical cystectomy, for the treatment of adult patients with muscle invasive bladder cancer (MIBC). ( 1.6 ) • in combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy as neoadjuvant and adjuvant treatment, followed by single agent IMFINZI, for the treatment of ad
                                                                label id
                                                                5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                offset unit
                                                                unicode_code_points
                                                                source array index
                                                                0
                                                                source field
                                                                indications_and_usage_exact
                                                                source text sha256
                                                                f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                start
                                                                1851
                                                                current approval status
                                                                not_reconciled
                                                                duplicate text group
                                                                dup-1ca543aeb2f1e6c49103
                                                                extraction review status
                                                                automated_candidate_pending_source_review
                                                                generic names
                                                                1. DURVALUMAB
                                                                id
                                                                ind-span-3890489dd080aeef2369
                                                                label id
                                                                5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                positive predicate support span
                                                                Source null
                                                                qualifier mentions
                                                                1. context exact
                                                                  reatment following radical cystectomy, for the treatment of adult patients with muscle invasive bladder cancer (MIBC).
                                                                  kind
                                                                  age
                                                                  polarity
                                                                  not_inferred
                                                                  span
                                                                  end
                                                                  2245
                                                                  end exclusive
                                                                  true
                                                                  exact text
                                                                  adult patients
                                                                  label id
                                                                  5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                  offset unit
                                                                  unicode_code_points
                                                                  source array index
                                                                  0
                                                                  source field
                                                                  indications_and_usage_exact
                                                                  source text sha256
                                                                  f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                  start
                                                                  2231
                                                                2. context exact
                                                                  • in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent IMFINZI as adjuvant treatment fol
                                                                  kind
                                                                  stage_or_setting
                                                                  polarity
                                                                  not_inferred
                                                                  span
                                                                  end
                                                                  2123
                                                                  end exclusive
                                                                  true
                                                                  exact text
                                                                  neoadjuvant treatment
                                                                  label id
                                                                  5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                  offset unit
                                                                  unicode_code_points
                                                                  source array index
                                                                  0
                                                                  source field
                                                                  indications_and_usage_exact
                                                                  source text sha256
                                                                  f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                  start
                                                                  2102
                                                                3. context exact
                                                                  neoadjuvant treatment, followed by single agent IMFINZI as adjuvant treatment following radical cystectomy, for the treatment of adult patients with muscle invasi
                                                                  kind
                                                                  stage_or_setting
                                                                  polarity
                                                                  not_inferred
                                                                  span
                                                                  end
                                                                  2204
                                                                  end exclusive
                                                                  true
                                                                  exact text
                                                                  adjuvant treatment following radical cystec
                                                                  label id
                                                                  5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                  offset unit
                                                                  unicode_code_points
                                                                  source array index
                                                                  0
                                                                  source field
                                                                  indications_and_usage_exact
                                                                  source text sha256
                                                                  f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                  start
                                                                  2161
                                                                4. context exact
                                                                  • in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent IMFINZI as adjuvant treatment following radical cystectomy, for the treatment of adult patients with muscle invasive bladder cancer (MIBC).
                                                                  kind
                                                                  regimen
                                                                  polarity
                                                                  not_inferred
                                                                  span
                                                                  end
                                                                  2232
                                                                  end exclusive
                                                                  true
                                                                  exact text
                                                                  in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent IMFINZI as adjuvant treatment following radical cystectomy, for the treatment of a
                                                                  label id
                                                                  5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                  offset unit
                                                                  unicode_code_points
                                                                  source array index
                                                                  0
                                                                  source field
                                                                  indications_and_usage_exact
                                                                  source text sha256
                                                                  f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                  start
                                                                  2053
                                                                regulatory links
                                                                  schema version
                                                                  0.1.0
                                                                  source batch sha256
                                                                  bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
                                                                  source defined aliases
                                                                  1. abbreviation
                                                                    NSCLC
                                                                    definition exact
                                                                    non-small cell lung cancer
                                                                    definition span
                                                                    end
                                                                    389
                                                                    end exclusive
                                                                    true
                                                                    exact text
                                                                    non-small cell lung cancer (NSCLC)
                                                                    label id
                                                                    5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                    offset unit
                                                                    unicode_code_points
                                                                    source array index
                                                                    0
                                                                    source field
                                                                    indications_and_usage_exact
                                                                    source text sha256
                                                                    f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                    start
                                                                    355
                                                                  source span
                                                                  end
                                                                  2289
                                                                  end exclusive
                                                                  true
                                                                  exact text
                                                                  • in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent IMFINZI as adjuvant treatment following radical cystectomy, for the treatment of adult patients with muscle invasive bladder cancer (MIBC).
                                                                  label id
                                                                  5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                  offset unit
                                                                  unicode_code_points
                                                                  source array index
                                                                  0
                                                                  source field
                                                                  indications_and_usage_exact
                                                                  source text sha256
                                                                  f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                  start
                                                                  2051
                                                                  source url
                                                                  https://api.fda.gov/drug/label.json?search=id%3A%225826517b-d2d2-4636-ad9c-0dc676abad9e%22
                                                                  spl effective date
                                                                  2026-08-31
                                                                  spl set id
                                                                  8baba4ea-2855-42fa-9bd9-5a7548d4cec3
                                                                  spl version
                                                                  34
                                                                  structured fields status
                                                                  not_extracted_no_values_inferred_from_mentions
                                                                  structured indication
                                                                  age
                                                                  Source null
                                                                  approval pathway
                                                                  Source null
                                                                  biomarker and test
                                                                  Source null
                                                                  disease stage
                                                                  Source null
                                                                  limitations
                                                                  Source null
                                                                  line
                                                                  Source null
                                                                  prior therapy
                                                                  Source null
                                                                  regimen
                                                                  Source null
                                                                  tumor histology
                                                                  Source null
                                                                  use intent
                                                                  unclear
                                                                  Passage 21 · unclassified context
                                                                  application numbers
                                                                  1. BLA761069
                                                                  brand names
                                                                  1. IMFINZI
                                                                  classification reasons
                                                                  1. no_unambiguous_positive_indication_predicate
                                                                  clinical review status
                                                                  pending
                                                                  content role
                                                                  unclassified_context
                                                                  context span
                                                                  end
                                                                  2497
                                                                  end exclusive
                                                                  true
                                                                  exact text
                                                                  isplatin as neoadjuvant treatment, followed by single agent IMFINZI as adjuvant treatment following radical cystectomy, for the treatment of adult patients with muscle invasive bladder cancer (MIBC). ( 1.6 ) • in combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy as neoadjuvant and adjuvant treatment, followed by single agent IMFINZI, for the treatment of adult pati
                                                                  label id
                                                                  5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                  offset unit
                                                                  unicode_code_points
                                                                  source array index
                                                                  0
                                                                  source field
                                                                  indications_and_usage_exact
                                                                  source text sha256
                                                                  f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                  start
                                                                  2090
                                                                  current approval status
                                                                  not_reconciled
                                                                  duplicate text group
                                                                  dup-96d63ce422d261a1efb8
                                                                  extraction review status
                                                                  automated_candidate_pending_source_review
                                                                  generic names
                                                                  1. DURVALUMAB
                                                                  id
                                                                  ind-span-54f0216233ce2805a4fd
                                                                  label id
                                                                  5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                  positive predicate support span
                                                                  Source null
                                                                  qualifier mentions
                                                                    regulatory links
                                                                      schema version
                                                                      0.1.0
                                                                      source batch sha256
                                                                      bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
                                                                      source defined aliases
                                                                      1. abbreviation
                                                                        NSCLC
                                                                        definition exact
                                                                        non-small cell lung cancer
                                                                        definition span
                                                                        end
                                                                        389
                                                                        end exclusive
                                                                        true
                                                                        exact text
                                                                        non-small cell lung cancer (NSCLC)
                                                                        label id
                                                                        5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                        offset unit
                                                                        unicode_code_points
                                                                        source array index
                                                                        0
                                                                        source field
                                                                        indications_and_usage_exact
                                                                        source text sha256
                                                                        f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                        start
                                                                        355
                                                                      source span
                                                                      end
                                                                      2297
                                                                      end exclusive
                                                                      true
                                                                      exact text
                                                                      ( 1.6 )
                                                                      label id
                                                                      5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                      offset unit
                                                                      unicode_code_points
                                                                      source array index
                                                                      0
                                                                      source field
                                                                      indications_and_usage_exact
                                                                      source text sha256
                                                                      f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                      start
                                                                      2290
                                                                      source url
                                                                      https://api.fda.gov/drug/label.json?search=id%3A%225826517b-d2d2-4636-ad9c-0dc676abad9e%22
                                                                      spl effective date
                                                                      2026-08-31
                                                                      spl set id
                                                                      8baba4ea-2855-42fa-9bd9-5a7548d4cec3
                                                                      spl version
                                                                      34
                                                                      structured fields status
                                                                      not_extracted_no_values_inferred_from_mentions
                                                                      structured indication
                                                                      age
                                                                      Source null
                                                                      approval pathway
                                                                      Source null
                                                                      biomarker and test
                                                                      Source null
                                                                      disease stage
                                                                      Source null
                                                                      limitations
                                                                      Source null
                                                                      line
                                                                      Source null
                                                                      prior therapy
                                                                      Source null
                                                                      regimen
                                                                      Source null
                                                                      tumor histology
                                                                      Source null
                                                                      use intent
                                                                      unclear
                                                                      Passage 22 · unclassified context
                                                                      application numbers
                                                                      1. BLA761069
                                                                      brand names
                                                                      1. IMFINZI
                                                                      classification reasons
                                                                      1. no_unambiguous_positive_indication_predicate
                                                                      clinical review status
                                                                      pending
                                                                      content role
                                                                      unclassified_context
                                                                      context span
                                                                      end
                                                                      2780
                                                                      end exclusive
                                                                      true
                                                                      exact text
                                                                      as neoadjuvant treatment, followed by single agent IMFINZI as adjuvant treatment following radical cystectomy, for the treatment of adult patients with muscle invasive bladder cancer (MIBC). ( 1.6 ) • in combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy as neoadjuvant and adjuvant treatment, followed by single agent IMFINZI, for the treatment of adult patients with resectable gastric or gastroesophageal junction adenocarcinoma (GC/GEJC). ( 1.7 ) 1.1 Non-Small Cell Lung Cancer • IMFINZI in combination with platinum-containing chemotherapy as neoadjuvant treatment, followed by IMFINZI continued as a single agent as adjuvant treatment a
                                                                      label id
                                                                      5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                      offset unit
                                                                      unicode_code_points
                                                                      source array index
                                                                      0
                                                                      source field
                                                                      indications_and_usage_exact
                                                                      source text sha256
                                                                      f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                      start
                                                                      2098
                                                                      current approval status
                                                                      not_reconciled
                                                                      duplicate text group
                                                                      dup-e00b574808ba1e6fc8a6
                                                                      extraction review status
                                                                      automated_candidate_pending_source_review
                                                                      generic names
                                                                      1. DURVALUMAB
                                                                      id
                                                                      ind-span-354c3de723b1caab6991
                                                                      label id
                                                                      5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                      positive predicate support span
                                                                      Source null
                                                                      qualifier mentions
                                                                      1. context exact
                                                                        ent, followed by single agent IMFINZI, for the treatment of adult patients with resectable gastric or gastroesophageal junction adenoc
                                                                        kind
                                                                        age
                                                                        polarity
                                                                        not_inferred
                                                                        span
                                                                        end
                                                                        2501
                                                                        end exclusive
                                                                        true
                                                                        exact text
                                                                        adult patients
                                                                        label id
                                                                        5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                        offset unit
                                                                        unicode_code_points
                                                                        source array index
                                                                        0
                                                                        source field
                                                                        indications_and_usage_exact
                                                                        source text sha256
                                                                        f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                        start
                                                                        2487
                                                                      2. context exact
                                                                        ucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy as neoadjuvant and adjuvant treatment, followed by single agent IMFINZI, for the treatment of adu
                                                                        kind
                                                                        stage_or_setting
                                                                        polarity
                                                                        not_inferred
                                                                        span
                                                                        end
                                                                        2430
                                                                        end exclusive
                                                                        true
                                                                        exact text
                                                                        neoadjuvant and adjuvant treatment
                                                                        label id
                                                                        5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                        offset unit
                                                                        unicode_code_points
                                                                        source array index
                                                                        0
                                                                        source field
                                                                        indications_and_usage_exact
                                                                        source text sha256
                                                                        f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                        start
                                                                        2396
                                                                      3. context exact
                                                                        gle agent IMFINZI, for the treatment of adult patients with resectable gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).
                                                                        kind
                                                                        stage_or_setting
                                                                        polarity
                                                                        not_inferred
                                                                        span
                                                                        end
                                                                        2552
                                                                        end exclusive
                                                                        true
                                                                        exact text
                                                                        resectable gastric or gastroesophageal juncti
                                                                        label id
                                                                        5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                        offset unit
                                                                        unicode_code_points
                                                                        source array index
                                                                        0
                                                                        source field
                                                                        indications_and_usage_exact
                                                                        source text sha256
                                                                        f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                        start
                                                                        2507
                                                                      4. context exact
                                                                        • in combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy as neoadjuvant and adjuvant treatment, followed by single agent IMFINZI, for the treatment of adult patients with resectable gastric or gastroesop
                                                                        kind
                                                                        regimen
                                                                        polarity
                                                                        not_inferred
                                                                        span
                                                                        end
                                                                        2479
                                                                        end exclusive
                                                                        true
                                                                        exact text
                                                                        in combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy as neoadjuvant and adjuvant treatment, followed by single agent IMFINZI, for the treat
                                                                        label id
                                                                        5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                        offset unit
                                                                        unicode_code_points
                                                                        source array index
                                                                        0
                                                                        source field
                                                                        indications_and_usage_exact
                                                                        source text sha256
                                                                        f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                        start
                                                                        2300
                                                                      regulatory links
                                                                        schema version
                                                                        0.1.0
                                                                        source batch sha256
                                                                        bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
                                                                        source defined aliases
                                                                        1. abbreviation
                                                                          NSCLC
                                                                          definition exact
                                                                          non-small cell lung cancer
                                                                          definition span
                                                                          end
                                                                          389
                                                                          end exclusive
                                                                          true
                                                                          exact text
                                                                          non-small cell lung cancer (NSCLC)
                                                                          label id
                                                                          5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                          offset unit
                                                                          unicode_code_points
                                                                          source array index
                                                                          0
                                                                          source field
                                                                          indications_and_usage_exact
                                                                          source text sha256
                                                                          f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                          start
                                                                          355
                                                                        source span
                                                                        end
                                                                        2580
                                                                        end exclusive
                                                                        true
                                                                        exact text
                                                                        • in combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy as neoadjuvant and adjuvant treatment, followed by single agent IMFINZI, for the treatment of adult patients with resectable gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).
                                                                        label id
                                                                        5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                        offset unit
                                                                        unicode_code_points
                                                                        source array index
                                                                        0
                                                                        source field
                                                                        indications_and_usage_exact
                                                                        source text sha256
                                                                        f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                        start
                                                                        2298
                                                                        source url
                                                                        https://api.fda.gov/drug/label.json?search=id%3A%225826517b-d2d2-4636-ad9c-0dc676abad9e%22
                                                                        spl effective date
                                                                        2026-08-31
                                                                        spl set id
                                                                        8baba4ea-2855-42fa-9bd9-5a7548d4cec3
                                                                        spl version
                                                                        34
                                                                        structured fields status
                                                                        not_extracted_no_values_inferred_from_mentions
                                                                        structured indication
                                                                        age
                                                                        Source null
                                                                        approval pathway
                                                                        Source null
                                                                        biomarker and test
                                                                        Source null
                                                                        disease stage
                                                                        Source null
                                                                        limitations
                                                                        Source null
                                                                        line
                                                                        Source null
                                                                        prior therapy
                                                                        Source null
                                                                        regimen
                                                                        Source null
                                                                        tumor histology
                                                                        Source null
                                                                        use intent
                                                                        unclear
                                                                        Passage 23 · unclassified context
                                                                        application numbers
                                                                        1. BLA761069
                                                                        brand names
                                                                        1. IMFINZI
                                                                        classification reasons
                                                                        1. no_unambiguous_positive_indication_predicate
                                                                        clinical review status
                                                                        pending
                                                                        content role
                                                                        unclassified_context
                                                                        context span
                                                                        end
                                                                        2788
                                                                        end exclusive
                                                                        true
                                                                        exact text
                                                                        hemotherapy as neoadjuvant and adjuvant treatment, followed by single agent IMFINZI, for the treatment of adult patients with resectable gastric or gastroesophageal junction adenocarcinoma (GC/GEJC). ( 1.7 ) 1.1 Non-Small Cell Lung Cancer • IMFINZI in combination with platinum-containing chemotherapy as neoadjuvant treatment, followed by IMFINZI continued as a single agent as adjuvant treatment after sur
                                                                        label id
                                                                        5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                        offset unit
                                                                        unicode_code_points
                                                                        source array index
                                                                        0
                                                                        source field
                                                                        indications_and_usage_exact
                                                                        source text sha256
                                                                        f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                        start
                                                                        2381
                                                                        current approval status
                                                                        not_reconciled
                                                                        duplicate text group
                                                                        dup-4c5fd9155d8a72580cb1
                                                                        extraction review status
                                                                        automated_candidate_pending_source_review
                                                                        generic names
                                                                        1. DURVALUMAB
                                                                        id
                                                                        ind-span-823963bcbf55a3e57c36
                                                                        label id
                                                                        5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                        positive predicate support span
                                                                        Source null
                                                                        qualifier mentions
                                                                          regulatory links
                                                                            schema version
                                                                            0.1.0
                                                                            source batch sha256
                                                                            bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
                                                                            source defined aliases
                                                                            1. abbreviation
                                                                              NSCLC
                                                                              definition exact
                                                                              non-small cell lung cancer
                                                                              definition span
                                                                              end
                                                                              389
                                                                              end exclusive
                                                                              true
                                                                              exact text
                                                                              non-small cell lung cancer (NSCLC)
                                                                              label id
                                                                              5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                              offset unit
                                                                              unicode_code_points
                                                                              source array index
                                                                              0
                                                                              source field
                                                                              indications_and_usage_exact
                                                                              source text sha256
                                                                              f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                              start
                                                                              355
                                                                            source span
                                                                            end
                                                                            2588
                                                                            end exclusive
                                                                            true
                                                                            exact text
                                                                            ( 1.7 )
                                                                            label id
                                                                            5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                            offset unit
                                                                            unicode_code_points
                                                                            source array index
                                                                            0
                                                                            source field
                                                                            indications_and_usage_exact
                                                                            source text sha256
                                                                            f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                            start
                                                                            2581
                                                                            source url
                                                                            https://api.fda.gov/drug/label.json?search=id%3A%225826517b-d2d2-4636-ad9c-0dc676abad9e%22
                                                                            spl effective date
                                                                            2026-08-31
                                                                            spl set id
                                                                            8baba4ea-2855-42fa-9bd9-5a7548d4cec3
                                                                            spl version
                                                                            34
                                                                            structured fields status
                                                                            not_extracted_no_values_inferred_from_mentions
                                                                            structured indication
                                                                            age
                                                                            Source null
                                                                            approval pathway
                                                                            Source null
                                                                            biomarker and test
                                                                            Source null
                                                                            disease stage
                                                                            Source null
                                                                            limitations
                                                                            Source null
                                                                            line
                                                                            Source null
                                                                            prior therapy
                                                                            Source null
                                                                            regimen
                                                                            Source null
                                                                            tumor histology
                                                                            Source null
                                                                            use intent
                                                                            unclear
                                                                            Passage 24 · unclassified context
                                                                            application numbers
                                                                            1. BLA761069
                                                                            brand names
                                                                            1. IMFINZI
                                                                            classification reasons
                                                                            1. no_unambiguous_positive_indication_predicate
                                                                            clinical review status
                                                                            pending
                                                                            content role
                                                                            unclassified_context
                                                                            context span
                                                                            end
                                                                            2819
                                                                            end exclusive
                                                                            true
                                                                            exact text
                                                                            apy as neoadjuvant and adjuvant treatment, followed by single agent IMFINZI, for the treatment of adult patients with resectable gastric or gastroesophageal junction adenocarcinoma (GC/GEJC). ( 1.7 ) 1.1 Non-Small Cell Lung Cancer • IMFINZI in combination with platinum-containing chemotherapy as neoadjuvant treatment, followed by IMFINZI continued as a single agent as adjuvant treatment after surgery, is indicated for the trea
                                                                            label id
                                                                            5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                            offset unit
                                                                            unicode_code_points
                                                                            source array index
                                                                            0
                                                                            source field
                                                                            indications_and_usage_exact
                                                                            source text sha256
                                                                            f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                            start
                                                                            2389
                                                                            current approval status
                                                                            not_reconciled
                                                                            duplicate text group
                                                                            dup-a70eb9caf7da42d2b390
                                                                            extraction review status
                                                                            automated_candidate_pending_source_review
                                                                            generic names
                                                                            1. DURVALUMAB
                                                                            id
                                                                            ind-span-3d91b4a3a4504b42599b
                                                                            label id
                                                                            5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                            positive predicate support span
                                                                            Source null
                                                                            qualifier mentions
                                                                              regulatory links
                                                                                schema version
                                                                                0.1.0
                                                                                source batch sha256
                                                                                bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
                                                                                source defined aliases
                                                                                1. abbreviation
                                                                                  NSCLC
                                                                                  definition exact
                                                                                  non-small cell lung cancer
                                                                                  definition span
                                                                                  end
                                                                                  389
                                                                                  end exclusive
                                                                                  true
                                                                                  exact text
                                                                                  non-small cell lung cancer (NSCLC)
                                                                                  label id
                                                                                  5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                  offset unit
                                                                                  unicode_code_points
                                                                                  source array index
                                                                                  0
                                                                                  source field
                                                                                  indications_and_usage_exact
                                                                                  source text sha256
                                                                                  f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                  start
                                                                                  355
                                                                                source span
                                                                                end
                                                                                2619
                                                                                end exclusive
                                                                                true
                                                                                exact text
                                                                                1.1 Non-Small Cell Lung Cancer
                                                                                label id
                                                                                5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                offset unit
                                                                                unicode_code_points
                                                                                source array index
                                                                                0
                                                                                source field
                                                                                indications_and_usage_exact
                                                                                source text sha256
                                                                                f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                start
                                                                                2589
                                                                                source url
                                                                                https://api.fda.gov/drug/label.json?search=id%3A%225826517b-d2d2-4636-ad9c-0dc676abad9e%22
                                                                                spl effective date
                                                                                2026-08-31
                                                                                spl set id
                                                                                8baba4ea-2855-42fa-9bd9-5a7548d4cec3
                                                                                spl version
                                                                                34
                                                                                structured fields status
                                                                                not_extracted_no_values_inferred_from_mentions
                                                                                structured indication
                                                                                age
                                                                                Source null
                                                                                approval pathway
                                                                                Source null
                                                                                biomarker and test
                                                                                Source null
                                                                                disease stage
                                                                                Source null
                                                                                limitations
                                                                                Source null
                                                                                line
                                                                                Source null
                                                                                prior therapy
                                                                                Source null
                                                                                regimen
                                                                                Source null
                                                                                tumor histology
                                                                                Source null
                                                                                use intent
                                                                                unclear
                                                                                Passage 25 · positive indication candidate
                                                                                application numbers
                                                                                1. BLA761069
                                                                                brand names
                                                                                1. IMFINZI
                                                                                classification reasons
                                                                                1. explicit_positive_indication_predicate
                                                                                2. tumor_or_malignant_hematology_words_in_positive_statement
                                                                                clinical review status
                                                                                pending
                                                                                content role
                                                                                positive_indication_candidate
                                                                                context span
                                                                                end
                                                                                3245
                                                                                end exclusive
                                                                                true
                                                                                exact text
                                                                                treatment, followed by single agent IMFINZI, for the treatment of adult patients with resectable gastric or gastroesophageal junction adenocarcinoma (GC/GEJC). ( 1.7 ) 1.1 Non-Small Cell Lung Cancer • IMFINZI in combination with platinum-containing chemotherapy as neoadjuvant treatment, followed by IMFINZI continued as a single agent as adjuvant treatment after surgery, is indicated for the treatment of adult patients with resectable (tumors ≥ 4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. • IMFINZI, as a single agent, is indicated for the treatment of adult patients with unresectable Stage III NSCLC whose disease has not progressed following concurrent platinum-based chemotherapy and
                                                                                label id
                                                                                5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                offset unit
                                                                                unicode_code_points
                                                                                source array index
                                                                                0
                                                                                source field
                                                                                indications_and_usage_exact
                                                                                source text sha256
                                                                                f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                start
                                                                                2420
                                                                                current approval status
                                                                                not_reconciled
                                                                                duplicate text group
                                                                                dup-5a11fb370bb06fd817de
                                                                                extraction review status
                                                                                automated_candidate_pending_source_review
                                                                                generic names
                                                                                1. DURVALUMAB
                                                                                id
                                                                                ind-span-2707dc496ab207c685ec
                                                                                label id
                                                                                5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                positive predicate support span
                                                                                end
                                                                                2806
                                                                                end exclusive
                                                                                true
                                                                                exact text
                                                                                is indicated
                                                                                label id
                                                                                5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                offset unit
                                                                                unicode_code_points
                                                                                source array index
                                                                                0
                                                                                source field
                                                                                indications_and_usage_exact
                                                                                source text sha256
                                                                                f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                start
                                                                                2794
                                                                                qualifier mentions
                                                                                1. context exact
                                                                                  treatment after surgery, is indicated for the treatment of adult patients with resectable (tumors ≥ 4 cm and/or node positive) non-sm
                                                                                  kind
                                                                                  age
                                                                                  polarity
                                                                                  not_inferred
                                                                                  span
                                                                                  end
                                                                                  2842
                                                                                  end exclusive
                                                                                  true
                                                                                  exact text
                                                                                  adult patients
                                                                                  label id
                                                                                  5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                  offset unit
                                                                                  unicode_code_points
                                                                                  source array index
                                                                                  0
                                                                                  source field
                                                                                  indications_and_usage_exact
                                                                                  source text sha256
                                                                                  f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                  start
                                                                                  2828
                                                                                2. context exact
                                                                                  ncer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements.
                                                                                  kind
                                                                                  biomarker
                                                                                  polarity
                                                                                  not_inferred
                                                                                  span
                                                                                  end
                                                                                  3022
                                                                                  end exclusive
                                                                                  true
                                                                                  exact text
                                                                                  EGFR) mutations or anaplastic lymphoma kinas
                                                                                  label id
                                                                                  5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                  offset unit
                                                                                  unicode_code_points
                                                                                  source array index
                                                                                  0
                                                                                  source field
                                                                                  indications_and_usage_exact
                                                                                  source text sha256
                                                                                  f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                  start
                                                                                  2978
                                                                                3. context exact
                                                                                  or receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements.
                                                                                  kind
                                                                                  biomarker
                                                                                  polarity
                                                                                  not_inferred
                                                                                  span
                                                                                  end
                                                                                  3044
                                                                                  end exclusive
                                                                                  true
                                                                                  exact text
                                                                                  ALK) rearrangements
                                                                                  label id
                                                                                  5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                  offset unit
                                                                                  unicode_code_points
                                                                                  source array index
                                                                                  0
                                                                                  source field
                                                                                  indications_and_usage_exact
                                                                                  source text sha256
                                                                                  f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                  start
                                                                                  3025
                                                                                4. context exact
                                                                                  NZI in combination with platinum-containing chemotherapy as neoadjuvant treatment, followed by IMFINZI continued as a single agent as adjuvan
                                                                                  kind
                                                                                  stage_or_setting
                                                                                  polarity
                                                                                  not_inferred
                                                                                  span
                                                                                  end
                                                                                  2707
                                                                                  end exclusive
                                                                                  true
                                                                                  exact text
                                                                                  neoadjuvant treatment
                                                                                  label id
                                                                                  5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                  offset unit
                                                                                  unicode_code_points
                                                                                  source array index
                                                                                  0
                                                                                  source field
                                                                                  indications_and_usage_exact
                                                                                  source text sha256
                                                                                  f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                  start
                                                                                  2686
                                                                                5. context exact
                                                                                  eatment, followed by IMFINZI continued as a single agent as adjuvant treatment after surgery, is indicated for the treatment of adult patients with rese
                                                                                  kind
                                                                                  stage_or_setting
                                                                                  polarity
                                                                                  not_inferred
                                                                                  span
                                                                                  end
                                                                                  2792
                                                                                  end exclusive
                                                                                  true
                                                                                  exact text
                                                                                  adjuvant treatment after surgery
                                                                                  label id
                                                                                  5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                  offset unit
                                                                                  unicode_code_points
                                                                                  source array index
                                                                                  0
                                                                                  source field
                                                                                  indications_and_usage_exact
                                                                                  source text sha256
                                                                                  f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                  start
                                                                                  2760
                                                                                6. context exact
                                                                                  gery, is indicated for the treatment of adult patients with resectable (tumors ≥ 4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal
                                                                                  kind
                                                                                  stage_or_setting
                                                                                  polarity
                                                                                  not_inferred
                                                                                  span
                                                                                  end
                                                                                  2893
                                                                                  end exclusive
                                                                                  true
                                                                                  exact text
                                                                                  resectable (tumors ≥ 4 cm and/or node positiv
                                                                                  label id
                                                                                  5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                  offset unit
                                                                                  unicode_code_points
                                                                                  source array index
                                                                                  0
                                                                                  source field
                                                                                  indications_and_usage_exact
                                                                                  source text sha256
                                                                                  f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                  start
                                                                                  2848
                                                                                7. context exact
                                                                                  • IMFINZI in combination with platinum-containing chemotherapy as neoadjuvant treatment, followed by IMFINZI continued as a single agent as adjuvant treatment after surgery, is indicated for the treatment of adult patients with resectable (tumors ≥
                                                                                  kind
                                                                                  regimen
                                                                                  polarity
                                                                                  not_inferred
                                                                                  span
                                                                                  end
                                                                                  2809
                                                                                  end exclusive
                                                                                  true
                                                                                  exact text
                                                                                  in combination with platinum-containing chemotherapy as neoadjuvant treatment, followed by IMFINZI continued as a single agent as adjuvant treatment after surgery, is indicated fo
                                                                                  label id
                                                                                  5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                  offset unit
                                                                                  unicode_code_points
                                                                                  source array index
                                                                                  0
                                                                                  source field
                                                                                  indications_and_usage_exact
                                                                                  source text sha256
                                                                                  f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                  start
                                                                                  2630
                                                                                regulatory links
                                                                                  schema version
                                                                                  0.1.0
                                                                                  source batch sha256
                                                                                  bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
                                                                                  source defined aliases
                                                                                  1. abbreviation
                                                                                    NSCLC
                                                                                    definition exact
                                                                                    non-small cell lung cancer
                                                                                    definition span
                                                                                    end
                                                                                    389
                                                                                    end exclusive
                                                                                    true
                                                                                    exact text
                                                                                    non-small cell lung cancer (NSCLC)
                                                                                    label id
                                                                                    5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                    offset unit
                                                                                    unicode_code_points
                                                                                    source array index
                                                                                    0
                                                                                    source field
                                                                                    indications_and_usage_exact
                                                                                    source text sha256
                                                                                    f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                    start
                                                                                    355
                                                                                  source span
                                                                                  end
                                                                                  3045
                                                                                  end exclusive
                                                                                  true
                                                                                  exact text
                                                                                  • IMFINZI in combination with platinum-containing chemotherapy as neoadjuvant treatment, followed by IMFINZI continued as a single agent as adjuvant treatment after surgery, is indicated for the treatment of adult patients with resectable (tumors ≥ 4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements.
                                                                                  label id
                                                                                  5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                  offset unit
                                                                                  unicode_code_points
                                                                                  source array index
                                                                                  0
                                                                                  source field
                                                                                  indications_and_usage_exact
                                                                                  source text sha256
                                                                                  f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                  start
                                                                                  2620
                                                                                  source url
                                                                                  https://api.fda.gov/drug/label.json?search=id%3A%225826517b-d2d2-4636-ad9c-0dc676abad9e%22
                                                                                  spl effective date
                                                                                  2026-08-31
                                                                                  spl set id
                                                                                  8baba4ea-2855-42fa-9bd9-5a7548d4cec3
                                                                                  spl version
                                                                                  34
                                                                                  structured fields status
                                                                                  not_extracted_no_values_inferred_from_mentions
                                                                                  structured indication
                                                                                  age
                                                                                  Source null
                                                                                  approval pathway
                                                                                  Source null
                                                                                  biomarker and test
                                                                                  Source null
                                                                                  disease stage
                                                                                  Source null
                                                                                  limitations
                                                                                  Source null
                                                                                  line
                                                                                  Source null
                                                                                  prior therapy
                                                                                  Source null
                                                                                  regimen
                                                                                  Source null
                                                                                  tumor histology
                                                                                  Source null
                                                                                  use intent
                                                                                  tumor_directed_candidate
                                                                                  Passage 26 · positive indication candidate
                                                                                  application numbers
                                                                                  1. BLA761069
                                                                                  brand names
                                                                                  1. IMFINZI
                                                                                  classification reasons
                                                                                  1. explicit_positive_indication_predicate
                                                                                  2. tumor_or_malignant_hematology_words_in_positive_statement
                                                                                  clinical review status
                                                                                  pending
                                                                                  content role
                                                                                  positive_indication_candidate
                                                                                  context span
                                                                                  end
                                                                                  3470
                                                                                  end exclusive
                                                                                  true
                                                                                  exact text
                                                                                  h resectable (tumors ≥ 4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. • IMFINZI, as a single agent, is indicated for the treatment of adult patients with unresectable Stage III NSCLC whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy (cCRT). • IMFINZI, in combination with tremelimumab-actl and platinum-based chemotherapy, is indicated for the treatment of adult patients with metastatic NSCLC with no sensitizing EGFR mutations or ALK geno
                                                                                  label id
                                                                                  5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                  offset unit
                                                                                  unicode_code_points
                                                                                  source array index
                                                                                  0
                                                                                  source field
                                                                                  indications_and_usage_exact
                                                                                  source text sha256
                                                                                  f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                  start
                                                                                  2846
                                                                                  current approval status
                                                                                  not_reconciled
                                                                                  duplicate text group
                                                                                  dup-a738cfce113a60c2a3b3
                                                                                  extraction review status
                                                                                  automated_candidate_pending_source_review
                                                                                  generic names
                                                                                  1. DURVALUMAB
                                                                                  id
                                                                                  ind-span-8fe360f0118dc5d71bea
                                                                                  label id
                                                                                  5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                  positive predicate support span
                                                                                  end
                                                                                  3088
                                                                                  end exclusive
                                                                                  true
                                                                                  exact text
                                                                                  is indicated
                                                                                  label id
                                                                                  5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                  offset unit
                                                                                  unicode_code_points
                                                                                  source array index
                                                                                  0
                                                                                  source field
                                                                                  indications_and_usage_exact
                                                                                  source text sha256
                                                                                  f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                  start
                                                                                  3076
                                                                                  qualifier mentions
                                                                                  1. context exact
                                                                                    FINZI, as a single agent, is indicated for the treatment of adult patients with unresectable Stage III NSCLC whose disease has not pro
                                                                                    kind
                                                                                    age
                                                                                    polarity
                                                                                    not_inferred
                                                                                    span
                                                                                    end
                                                                                    3124
                                                                                    end exclusive
                                                                                    true
                                                                                    exact text
                                                                                    adult patients
                                                                                    label id
                                                                                    5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                    offset unit
                                                                                    unicode_code_points
                                                                                    source array index
                                                                                    0
                                                                                    source field
                                                                                    indications_and_usage_exact
                                                                                    source text sha256
                                                                                    f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                    start
                                                                                    3110
                                                                                  2. context exact
                                                                                    gent, is indicated for the treatment of adult patients with unresectable Stage III NSCLC whose disease has not progressed following concurrent platinum-based chemother
                                                                                    kind
                                                                                    stage_or_setting
                                                                                    polarity
                                                                                    not_inferred
                                                                                    span
                                                                                    end
                                                                                    3177
                                                                                    end exclusive
                                                                                    true
                                                                                    exact text
                                                                                    unresectable Stage III NSCLC whose disease has
                                                                                    label id
                                                                                    5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                    offset unit
                                                                                    unicode_code_points
                                                                                    source array index
                                                                                    0
                                                                                    source field
                                                                                    indications_and_usage_exact
                                                                                    source text sha256
                                                                                    f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                    start
                                                                                    3130
                                                                                  3. context exact
                                                                                    • IMFINZI, as a single agent, is indicated for the treatment of adult patients with unresectable Stage III NSCLC whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy (cCRT).
                                                                                    kind
                                                                                    regimen
                                                                                    polarity
                                                                                    not_inferred
                                                                                    span
                                                                                    end
                                                                                    3234
                                                                                    end exclusive
                                                                                    true
                                                                                    exact text
                                                                                    as a single agent, is indicated for the treatment of adult patients with unresectable Stage III NSCLC whose disease has not progressed following concurrent platinum-based chemot
                                                                                    label id
                                                                                    5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                    offset unit
                                                                                    unicode_code_points
                                                                                    source array index
                                                                                    0
                                                                                    source field
                                                                                    indications_and_usage_exact
                                                                                    source text sha256
                                                                                    f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                    start
                                                                                    3057
                                                                                  regulatory links
                                                                                    schema version
                                                                                    0.1.0
                                                                                    source batch sha256
                                                                                    bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
                                                                                    source defined aliases
                                                                                    1. abbreviation
                                                                                      NSCLC
                                                                                      definition exact
                                                                                      non-small cell lung cancer
                                                                                      definition span
                                                                                      end
                                                                                      389
                                                                                      end exclusive
                                                                                      true
                                                                                      exact text
                                                                                      non-small cell lung cancer (NSCLC)
                                                                                      label id
                                                                                      5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                      offset unit
                                                                                      unicode_code_points
                                                                                      source array index
                                                                                      0
                                                                                      source field
                                                                                      indications_and_usage_exact
                                                                                      source text sha256
                                                                                      f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                      start
                                                                                      355
                                                                                    source span
                                                                                    end
                                                                                    3270
                                                                                    end exclusive
                                                                                    true
                                                                                    exact text
                                                                                    • IMFINZI, as a single agent, is indicated for the treatment of adult patients with unresectable Stage III NSCLC whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy (cCRT).
                                                                                    label id
                                                                                    5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                    offset unit
                                                                                    unicode_code_points
                                                                                    source array index
                                                                                    0
                                                                                    source field
                                                                                    indications_and_usage_exact
                                                                                    source text sha256
                                                                                    f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                    start
                                                                                    3046
                                                                                    source url
                                                                                    https://api.fda.gov/drug/label.json?search=id%3A%225826517b-d2d2-4636-ad9c-0dc676abad9e%22
                                                                                    spl effective date
                                                                                    2026-08-31
                                                                                    spl set id
                                                                                    8baba4ea-2855-42fa-9bd9-5a7548d4cec3
                                                                                    spl version
                                                                                    34
                                                                                    structured fields status
                                                                                    not_extracted_no_values_inferred_from_mentions
                                                                                    structured indication
                                                                                    age
                                                                                    Source null
                                                                                    approval pathway
                                                                                    Source null
                                                                                    biomarker and test
                                                                                    Source null
                                                                                    disease stage
                                                                                    Source null
                                                                                    limitations
                                                                                    Source null
                                                                                    line
                                                                                    Source null
                                                                                    prior therapy
                                                                                    Source null
                                                                                    regimen
                                                                                    Source null
                                                                                    tumor histology
                                                                                    Source null
                                                                                    use intent
                                                                                    tumor_directed_candidate
                                                                                    Passage 27 · positive indication candidate
                                                                                    application numbers
                                                                                    1. BLA761069
                                                                                    brand names
                                                                                    1. IMFINZI
                                                                                    classification reasons
                                                                                    1. explicit_positive_indication_predicate
                                                                                    2. tumor_or_malignant_hematology_words_in_positive_statement
                                                                                    clinical review status
                                                                                    pending
                                                                                    content role
                                                                                    positive_indication_candidate
                                                                                    context span
                                                                                    end
                                                                                    3692
                                                                                    end exclusive
                                                                                    true
                                                                                    exact text
                                                                                    ent, is indicated for the treatment of adult patients with unresectable Stage III NSCLC whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy (cCRT). • IMFINZI, in combination with tremelimumab-actl and platinum-based chemotherapy, is indicated for the treatment of adult patients with metastatic NSCLC with no sensitizing EGFR mutations or ALK genomic tumor aberrations. 1.2 Small Cell Lung Cancer • IMFINZI, as a single agent, is indicated for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed followin
                                                                                    label id
                                                                                    5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                    offset unit
                                                                                    unicode_code_points
                                                                                    source array index
                                                                                    0
                                                                                    source field
                                                                                    indications_and_usage_exact
                                                                                    source text sha256
                                                                                    f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                    start
                                                                                    3071
                                                                                    current approval status
                                                                                    not_reconciled
                                                                                    duplicate text group
                                                                                    dup-d7776740ac62ef275c2f
                                                                                    extraction review status
                                                                                    automated_candidate_pending_source_review
                                                                                    generic names
                                                                                    1. DURVALUMAB
                                                                                    id
                                                                                    ind-span-cdf32e18099d08fee63b
                                                                                    label id
                                                                                    5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                    positive predicate support span
                                                                                    end
                                                                                    3365
                                                                                    end exclusive
                                                                                    true
                                                                                    exact text
                                                                                    is indicated
                                                                                    label id
                                                                                    5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                    offset unit
                                                                                    unicode_code_points
                                                                                    source array index
                                                                                    0
                                                                                    source field
                                                                                    indications_and_usage_exact
                                                                                    source text sha256
                                                                                    f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                    start
                                                                                    3353
                                                                                    qualifier mentions
                                                                                    1. context exact
                                                                                      tinum-based chemotherapy, is indicated for the treatment of adult patients with metastatic NSCLC with no sensitizing EGFR mutations or
                                                                                      kind
                                                                                      age
                                                                                      polarity
                                                                                      not_inferred
                                                                                      span
                                                                                      end
                                                                                      3401
                                                                                      end exclusive
                                                                                      true
                                                                                      exact text
                                                                                      adult patients
                                                                                      label id
                                                                                      5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                      offset unit
                                                                                      unicode_code_points
                                                                                      source array index
                                                                                      0
                                                                                      source field
                                                                                      indications_and_usage_exact
                                                                                      source text sha256
                                                                                      f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                      start
                                                                                      3387
                                                                                    2. context exact
                                                                                      rapy, is indicated for the treatment of adult patients with metastatic NSCLC with no sensitizing EGFR mutations or ALK genomic tumor aberrations.
                                                                                      kind
                                                                                      biomarker
                                                                                      polarity
                                                                                      not_inferred
                                                                                      span
                                                                                      end
                                                                                      3450
                                                                                      end exclusive
                                                                                      true
                                                                                      exact text
                                                                                      metastatic NSCLC with no sensitizing EGFR m
                                                                                      label id
                                                                                      5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                      offset unit
                                                                                      unicode_code_points
                                                                                      source array index
                                                                                      0
                                                                                      source field
                                                                                      indications_and_usage_exact
                                                                                      source text sha256
                                                                                      f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                      start
                                                                                      3407
                                                                                    3. context exact
                                                                                      with metastatic NSCLC with no sensitizing EGFR mutations or ALK genomic tumor aberrations.
                                                                                      kind
                                                                                      biomarker
                                                                                      polarity
                                                                                      not_inferred
                                                                                      span
                                                                                      end
                                                                                      3491
                                                                                      end exclusive
                                                                                      true
                                                                                      exact text
                                                                                      ALK genomic tumor aberrations
                                                                                      label id
                                                                                      5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                      offset unit
                                                                                      unicode_code_points
                                                                                      source array index
                                                                                      0
                                                                                      source field
                                                                                      indications_and_usage_exact
                                                                                      source text sha256
                                                                                      f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                      start
                                                                                      3462
                                                                                    4. context exact
                                                                                      rapy, is indicated for the treatment of adult patients with metastatic NSCLC with no sensitizing EGFR mutations or ALK genomic tumor aberrations.
                                                                                      kind
                                                                                      stage_or_setting
                                                                                      polarity
                                                                                      not_inferred
                                                                                      span
                                                                                      end
                                                                                      3452
                                                                                      end exclusive
                                                                                      true
                                                                                      exact text
                                                                                      metastatic NSCLC with no sensitizing EGFR mut
                                                                                      label id
                                                                                      5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                      offset unit
                                                                                      unicode_code_points
                                                                                      source array index
                                                                                      0
                                                                                      source field
                                                                                      indications_and_usage_exact
                                                                                      source text sha256
                                                                                      f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                      start
                                                                                      3407
                                                                                    5. context exact
                                                                                      • IMFINZI, in combination with tremelimumab-actl and platinum-based chemotherapy, is indicated for the treatment of adult patients with metastatic NSCLC with no sensitizing EGFR mutations or ALK genomic tumor aberrations.
                                                                                      kind
                                                                                      regimen
                                                                                      polarity
                                                                                      not_inferred
                                                                                      span
                                                                                      end
                                                                                      3461
                                                                                      end exclusive
                                                                                      true
                                                                                      exact text
                                                                                      in combination with tremelimumab-actl and platinum-based chemotherapy, is indicated for the treatment of adult patients with metastatic NSCLC with no sensitizing EGFR mutations or
                                                                                      label id
                                                                                      5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                      offset unit
                                                                                      unicode_code_points
                                                                                      source array index
                                                                                      0
                                                                                      source field
                                                                                      indications_and_usage_exact
                                                                                      source text sha256
                                                                                      f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                      start
                                                                                      3282
                                                                                    regulatory links
                                                                                      schema version
                                                                                      0.1.0
                                                                                      source batch sha256
                                                                                      bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
                                                                                      source defined aliases
                                                                                      1. abbreviation
                                                                                        NSCLC
                                                                                        definition exact
                                                                                        non-small cell lung cancer
                                                                                        definition span
                                                                                        end
                                                                                        389
                                                                                        end exclusive
                                                                                        true
                                                                                        exact text
                                                                                        non-small cell lung cancer (NSCLC)
                                                                                        label id
                                                                                        5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                        offset unit
                                                                                        unicode_code_points
                                                                                        source array index
                                                                                        0
                                                                                        source field
                                                                                        indications_and_usage_exact
                                                                                        source text sha256
                                                                                        f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                        start
                                                                                        355
                                                                                      source span
                                                                                      end
                                                                                      3492
                                                                                      end exclusive
                                                                                      true
                                                                                      exact text
                                                                                      • IMFINZI, in combination with tremelimumab-actl and platinum-based chemotherapy, is indicated for the treatment of adult patients with metastatic NSCLC with no sensitizing EGFR mutations or ALK genomic tumor aberrations.
                                                                                      label id
                                                                                      5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                      offset unit
                                                                                      unicode_code_points
                                                                                      source array index
                                                                                      0
                                                                                      source field
                                                                                      indications_and_usage_exact
                                                                                      source text sha256
                                                                                      f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                      start
                                                                                      3271
                                                                                      source url
                                                                                      https://api.fda.gov/drug/label.json?search=id%3A%225826517b-d2d2-4636-ad9c-0dc676abad9e%22
                                                                                      spl effective date
                                                                                      2026-08-31
                                                                                      spl set id
                                                                                      8baba4ea-2855-42fa-9bd9-5a7548d4cec3
                                                                                      spl version
                                                                                      34
                                                                                      structured fields status
                                                                                      not_extracted_no_values_inferred_from_mentions
                                                                                      structured indication
                                                                                      age
                                                                                      Source null
                                                                                      approval pathway
                                                                                      Source null
                                                                                      biomarker and test
                                                                                      Source null
                                                                                      disease stage
                                                                                      Source null
                                                                                      limitations
                                                                                      Source null
                                                                                      line
                                                                                      Source null
                                                                                      prior therapy
                                                                                      Source null
                                                                                      regimen
                                                                                      Source null
                                                                                      tumor histology
                                                                                      Source null
                                                                                      use intent
                                                                                      tumor_directed_candidate
                                                                                      Passage 28 · unclassified context
                                                                                      application numbers
                                                                                      1. BLA761069
                                                                                      brand names
                                                                                      1. IMFINZI
                                                                                      classification reasons
                                                                                      1. no_unambiguous_positive_indication_predicate
                                                                                      clinical review status
                                                                                      pending
                                                                                      content role
                                                                                      unclassified_context
                                                                                      context span
                                                                                      end
                                                                                      3719
                                                                                      end exclusive
                                                                                      true
                                                                                      exact text
                                                                                      ion with tremelimumab-actl and platinum-based chemotherapy, is indicated for the treatment of adult patients with metastatic NSCLC with no sensitizing EGFR mutations or ALK genomic tumor aberrations. 1.2 Small Cell Lung Cancer • IMFINZI, as a single agent, is indicated for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based
                                                                                      label id
                                                                                      5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                      offset unit
                                                                                      unicode_code_points
                                                                                      source array index
                                                                                      0
                                                                                      source field
                                                                                      indications_and_usage_exact
                                                                                      source text sha256
                                                                                      f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                      start
                                                                                      3293
                                                                                      current approval status
                                                                                      not_reconciled
                                                                                      duplicate text group
                                                                                      dup-bc6e225a3f5ee80843c4
                                                                                      extraction review status
                                                                                      automated_candidate_pending_source_review
                                                                                      generic names
                                                                                      1. DURVALUMAB
                                                                                      id
                                                                                      ind-span-c03dbc122330daa9b499
                                                                                      label id
                                                                                      5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                      positive predicate support span
                                                                                      Source null
                                                                                      qualifier mentions
                                                                                        regulatory links
                                                                                          schema version
                                                                                          0.1.0
                                                                                          source batch sha256
                                                                                          bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
                                                                                          source defined aliases
                                                                                          1. abbreviation
                                                                                            NSCLC
                                                                                            definition exact
                                                                                            non-small cell lung cancer
                                                                                            definition span
                                                                                            end
                                                                                            389
                                                                                            end exclusive
                                                                                            true
                                                                                            exact text
                                                                                            non-small cell lung cancer (NSCLC)
                                                                                            label id
                                                                                            5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                            offset unit
                                                                                            unicode_code_points
                                                                                            source array index
                                                                                            0
                                                                                            source field
                                                                                            indications_and_usage_exact
                                                                                            source text sha256
                                                                                            f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                            start
                                                                                            355
                                                                                          source span
                                                                                          end
                                                                                          3519
                                                                                          end exclusive
                                                                                          true
                                                                                          exact text
                                                                                          1.2 Small Cell Lung Cancer
                                                                                          label id
                                                                                          5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                          offset unit
                                                                                          unicode_code_points
                                                                                          source array index
                                                                                          0
                                                                                          source field
                                                                                          indications_and_usage_exact
                                                                                          source text sha256
                                                                                          f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                          start
                                                                                          3493
                                                                                          source url
                                                                                          https://api.fda.gov/drug/label.json?search=id%3A%225826517b-d2d2-4636-ad9c-0dc676abad9e%22
                                                                                          spl effective date
                                                                                          2026-08-31
                                                                                          spl set id
                                                                                          8baba4ea-2855-42fa-9bd9-5a7548d4cec3
                                                                                          spl version
                                                                                          34
                                                                                          structured fields status
                                                                                          not_extracted_no_values_inferred_from_mentions
                                                                                          structured indication
                                                                                          age
                                                                                          Source null
                                                                                          approval pathway
                                                                                          Source null
                                                                                          biomarker and test
                                                                                          Source null
                                                                                          disease stage
                                                                                          Source null
                                                                                          limitations
                                                                                          Source null
                                                                                          line
                                                                                          Source null
                                                                                          prior therapy
                                                                                          Source null
                                                                                          regimen
                                                                                          Source null
                                                                                          tumor histology
                                                                                          Source null
                                                                                          use intent
                                                                                          unclear
                                                                                          Passage 29 · positive indication candidate
                                                                                          application numbers
                                                                                          1. BLA761069
                                                                                          brand names
                                                                                          1. IMFINZI
                                                                                          classification reasons
                                                                                          1. explicit_positive_indication_predicate
                                                                                          2. tumor_or_malignant_hematology_words_in_positive_statement
                                                                                          clinical review status
                                                                                          pending
                                                                                          content role
                                                                                          positive_indication_candidate
                                                                                          context span
                                                                                          end
                                                                                          3962
                                                                                          end exclusive
                                                                                          true
                                                                                          exact text
                                                                                          and platinum-based chemotherapy, is indicated for the treatment of adult patients with metastatic NSCLC with no sensitizing EGFR mutations or ALK genomic tumor aberrations. 1.2 Small Cell Lung Cancer • IMFINZI, as a single agent, is indicated for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy (cCRT). • IMFINZI, in combination with etoposide and either carboplatin or cisplatin, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). 1.3 Bi
                                                                                          label id
                                                                                          5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                          offset unit
                                                                                          unicode_code_points
                                                                                          source array index
                                                                                          0
                                                                                          source field
                                                                                          indications_and_usage_exact
                                                                                          source text sha256
                                                                                          f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                          start
                                                                                          3320
                                                                                          current approval status
                                                                                          not_reconciled
                                                                                          duplicate text group
                                                                                          dup-db1eaed9648ced40a8bb
                                                                                          extraction review status
                                                                                          automated_candidate_pending_source_review
                                                                                          generic names
                                                                                          1. DURVALUMAB
                                                                                          id
                                                                                          ind-span-3e0f1ae40314b99820db
                                                                                          label id
                                                                                          5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                          positive predicate support span
                                                                                          end
                                                                                          3562
                                                                                          end exclusive
                                                                                          true
                                                                                          exact text
                                                                                          is indicated
                                                                                          label id
                                                                                          5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                          offset unit
                                                                                          unicode_code_points
                                                                                          source array index
                                                                                          0
                                                                                          source field
                                                                                          indications_and_usage_exact
                                                                                          source text sha256
                                                                                          f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                          start
                                                                                          3550
                                                                                          qualifier mentions
                                                                                          1. context exact
                                                                                            FINZI, as a single agent, is indicated for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose d
                                                                                            kind
                                                                                            age
                                                                                            polarity
                                                                                            not_inferred
                                                                                            span
                                                                                            end
                                                                                            3598
                                                                                            end exclusive
                                                                                            true
                                                                                            exact text
                                                                                            adult patients
                                                                                            label id
                                                                                            5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                            offset unit
                                                                                            unicode_code_points
                                                                                            source array index
                                                                                            0
                                                                                            source field
                                                                                            indications_and_usage_exact
                                                                                            source text sha256
                                                                                            f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                            start
                                                                                            3584
                                                                                          2. context exact
                                                                                            • IMFINZI, as a single agent, is indicated for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy (cCRT).
                                                                                            kind
                                                                                            regimen
                                                                                            polarity
                                                                                            not_inferred
                                                                                            span
                                                                                            end
                                                                                            3708
                                                                                            end exclusive
                                                                                            true
                                                                                            exact text
                                                                                            as a single agent, is indicated for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent pla
                                                                                            label id
                                                                                            5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                            offset unit
                                                                                            unicode_code_points
                                                                                            source array index
                                                                                            0
                                                                                            source field
                                                                                            indications_and_usage_exact
                                                                                            source text sha256
                                                                                            f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                            start
                                                                                            3531
                                                                                          regulatory links
                                                                                            schema version
                                                                                            0.1.0
                                                                                            source batch sha256
                                                                                            bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
                                                                                            source defined aliases
                                                                                            1. abbreviation
                                                                                              NSCLC
                                                                                              definition exact
                                                                                              non-small cell lung cancer
                                                                                              definition span
                                                                                              end
                                                                                              389
                                                                                              end exclusive
                                                                                              true
                                                                                              exact text
                                                                                              non-small cell lung cancer (NSCLC)
                                                                                              label id
                                                                                              5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                              offset unit
                                                                                              unicode_code_points
                                                                                              source array index
                                                                                              0
                                                                                              source field
                                                                                              indications_and_usage_exact
                                                                                              source text sha256
                                                                                              f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                              start
                                                                                              355
                                                                                            source span
                                                                                            end
                                                                                            3762
                                                                                            end exclusive
                                                                                            true
                                                                                            exact text
                                                                                            • IMFINZI, as a single agent, is indicated for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy (cCRT).
                                                                                            label id
                                                                                            5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                            offset unit
                                                                                            unicode_code_points
                                                                                            source array index
                                                                                            0
                                                                                            source field
                                                                                            indications_and_usage_exact
                                                                                            source text sha256
                                                                                            f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                            start
                                                                                            3520
                                                                                            source url
                                                                                            https://api.fda.gov/drug/label.json?search=id%3A%225826517b-d2d2-4636-ad9c-0dc676abad9e%22
                                                                                            spl effective date
                                                                                            2026-08-31
                                                                                            spl set id
                                                                                            8baba4ea-2855-42fa-9bd9-5a7548d4cec3
                                                                                            spl version
                                                                                            34
                                                                                            structured fields status
                                                                                            not_extracted_no_values_inferred_from_mentions
                                                                                            structured indication
                                                                                            age
                                                                                            Source null
                                                                                            approval pathway
                                                                                            Source null
                                                                                            biomarker and test
                                                                                            Source null
                                                                                            disease stage
                                                                                            Source null
                                                                                            limitations
                                                                                            Source null
                                                                                            line
                                                                                            Source null
                                                                                            prior therapy
                                                                                            Source null
                                                                                            regimen
                                                                                            Source null
                                                                                            tumor histology
                                                                                            Source null
                                                                                            use intent
                                                                                            tumor_directed_candidate
                                                                                            Passage 30 · positive indication candidate
                                                                                            application numbers
                                                                                            1. BLA761069
                                                                                            brand names
                                                                                            1. IMFINZI
                                                                                            classification reasons
                                                                                            1. explicit_positive_indication_predicate
                                                                                            2. tumor_or_malignant_hematology_words_in_positive_statement
                                                                                            clinical review status
                                                                                            pending
                                                                                            content role
                                                                                            positive_indication_candidate
                                                                                            context span
                                                                                            end
                                                                                            4155
                                                                                            end exclusive
                                                                                            true
                                                                                            exact text
                                                                                            for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy (cCRT). • IMFINZI, in combination with etoposide and either carboplatin or cisplatin, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). 1.3 Biliary Tract Cancers IMFINZI, in combination with gemcitabine and cisplatin, is indicated for the treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC). 1.4
                                                                                            label id
                                                                                            5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                            offset unit
                                                                                            unicode_code_points
                                                                                            source array index
                                                                                            0
                                                                                            source field
                                                                                            indications_and_usage_exact
                                                                                            source text sha256
                                                                                            f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                            start
                                                                                            3563
                                                                                            current approval status
                                                                                            not_reconciled
                                                                                            duplicate text group
                                                                                            dup-859f02e8c25d15c4dc2f
                                                                                            extraction review status
                                                                                            automated_candidate_pending_source_review
                                                                                            generic names
                                                                                            1. DURVALUMAB
                                                                                            id
                                                                                            ind-span-7fe2fe1b3edba61cb2e1
                                                                                            label id
                                                                                            5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                            positive predicate support span
                                                                                            end
                                                                                            3853
                                                                                            end exclusive
                                                                                            true
                                                                                            exact text
                                                                                            is indicated
                                                                                            label id
                                                                                            5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                            offset unit
                                                                                            unicode_code_points
                                                                                            source array index
                                                                                            0
                                                                                            source field
                                                                                            indications_and_usage_exact
                                                                                            source text sha256
                                                                                            f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                            start
                                                                                            3841
                                                                                            qualifier mentions
                                                                                            1. context exact
                                                                                              or cisplatin, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).
                                                                                              kind
                                                                                              age
                                                                                              polarity
                                                                                              not_inferred
                                                                                              span
                                                                                              end
                                                                                              3900
                                                                                              end exclusive
                                                                                              true
                                                                                              exact text
                                                                                              adult patients
                                                                                              label id
                                                                                              5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                              offset unit
                                                                                              unicode_code_points
                                                                                              source array index
                                                                                              0
                                                                                              source field
                                                                                              indications_and_usage_exact
                                                                                              source text sha256
                                                                                              f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                              start
                                                                                              3886
                                                                                            2. context exact
                                                                                              e and either carboplatin or cisplatin, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).
                                                                                              kind
                                                                                              prior_therapy_or_line
                                                                                              polarity
                                                                                              not_inferred
                                                                                              span
                                                                                              end
                                                                                              3954
                                                                                              end exclusive
                                                                                              true
                                                                                              exact text
                                                                                              first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC)
                                                                                              label id
                                                                                              5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                              offset unit
                                                                                              unicode_code_points
                                                                                              source array index
                                                                                              0
                                                                                              source field
                                                                                              indications_and_usage_exact
                                                                                              source text sha256
                                                                                              f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                              start
                                                                                              3862
                                                                                            3. context exact
                                                                                              • IMFINZI, in combination with etoposide and either carboplatin or cisplatin, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).
                                                                                              kind
                                                                                              regimen
                                                                                              polarity
                                                                                              not_inferred
                                                                                              span
                                                                                              end
                                                                                              3953
                                                                                              end exclusive
                                                                                              true
                                                                                              exact text
                                                                                              in combination with etoposide and either carboplatin or cisplatin, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC
                                                                                              label id
                                                                                              5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                              offset unit
                                                                                              unicode_code_points
                                                                                              source array index
                                                                                              0
                                                                                              source field
                                                                                              indications_and_usage_exact
                                                                                              source text sha256
                                                                                              f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                              start
                                                                                              3774
                                                                                            regulatory links
                                                                                              schema version
                                                                                              0.1.0
                                                                                              source batch sha256
                                                                                              bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
                                                                                              source defined aliases
                                                                                              1. abbreviation
                                                                                                NSCLC
                                                                                                definition exact
                                                                                                non-small cell lung cancer
                                                                                                definition span
                                                                                                end
                                                                                                389
                                                                                                end exclusive
                                                                                                true
                                                                                                exact text
                                                                                                non-small cell lung cancer (NSCLC)
                                                                                                label id
                                                                                                5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                                offset unit
                                                                                                unicode_code_points
                                                                                                source array index
                                                                                                0
                                                                                                source field
                                                                                                indications_and_usage_exact
                                                                                                source text sha256
                                                                                                f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                                start
                                                                                                355
                                                                                              source span
                                                                                              end
                                                                                              3955
                                                                                              end exclusive
                                                                                              true
                                                                                              exact text
                                                                                              • IMFINZI, in combination with etoposide and either carboplatin or cisplatin, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).
                                                                                              label id
                                                                                              5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                              offset unit
                                                                                              unicode_code_points
                                                                                              source array index
                                                                                              0
                                                                                              source field
                                                                                              indications_and_usage_exact
                                                                                              source text sha256
                                                                                              f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                              start
                                                                                              3763
                                                                                              source url
                                                                                              https://api.fda.gov/drug/label.json?search=id%3A%225826517b-d2d2-4636-ad9c-0dc676abad9e%22
                                                                                              spl effective date
                                                                                              2026-08-31
                                                                                              spl set id
                                                                                              8baba4ea-2855-42fa-9bd9-5a7548d4cec3
                                                                                              spl version
                                                                                              34
                                                                                              structured fields status
                                                                                              not_extracted_no_values_inferred_from_mentions
                                                                                              structured indication
                                                                                              age
                                                                                              Source null
                                                                                              approval pathway
                                                                                              Source null
                                                                                              biomarker and test
                                                                                              Source null
                                                                                              disease stage
                                                                                              Source null
                                                                                              limitations
                                                                                              Source null
                                                                                              line
                                                                                              Source null
                                                                                              prior therapy
                                                                                              Source null
                                                                                              regimen
                                                                                              Source null
                                                                                              tumor histology
                                                                                              Source null
                                                                                              use intent
                                                                                              tumor_directed_candidate
                                                                                              Passage 31 · positive indication candidate
                                                                                              application numbers
                                                                                              1. BLA761069
                                                                                              brand names
                                                                                              1. IMFINZI
                                                                                              classification reasons
                                                                                              1. explicit_positive_indication_predicate
                                                                                              2. tumor_or_malignant_hematology_words_in_positive_statement
                                                                                              clinical review status
                                                                                              pending
                                                                                              content role
                                                                                              positive_indication_candidate
                                                                                              context span
                                                                                              end
                                                                                              4350
                                                                                              end exclusive
                                                                                              true
                                                                                              exact text
                                                                                              cCRT). • IMFINZI, in combination with etoposide and either carboplatin or cisplatin, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). 1.3 Biliary Tract Cancers IMFINZI, in combination with gemcitabine and cisplatin, is indicated for the treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC). 1.4 Hepatocellular Carcinoma IMFINZI, in combination with tremelimumab-actl, is indicated for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC). 1.5 Endometrial Cancer
                                                                                              label id
                                                                                              5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                              offset unit
                                                                                              unicode_code_points
                                                                                              source array index
                                                                                              0
                                                                                              source field
                                                                                              indications_and_usage_exact
                                                                                              source text sha256
                                                                                              f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                              start
                                                                                              3756
                                                                                              current approval status
                                                                                              not_reconciled
                                                                                              duplicate text group
                                                                                              dup-8a3d2a377ef82ceee81d
                                                                                              extraction review status
                                                                                              automated_candidate_pending_source_review
                                                                                              generic names
                                                                                              1. DURVALUMAB
                                                                                              id
                                                                                              ind-span-d1de113b8a6ebcfe6ace
                                                                                              label id
                                                                                              5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                              positive predicate support span
                                                                                              end
                                                                                              4050
                                                                                              end exclusive
                                                                                              true
                                                                                              exact text
                                                                                              is indicated
                                                                                              label id
                                                                                              5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                              offset unit
                                                                                              unicode_code_points
                                                                                              source array index
                                                                                              0
                                                                                              source field
                                                                                              indications_and_usage_exact
                                                                                              source text sha256
                                                                                              f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                              start
                                                                                              4038
                                                                                              qualifier mentions
                                                                                              1. context exact
                                                                                                emcitabine and cisplatin, is indicated for the treatment of adult patients with locally advanced or metastatic biliary tract cancer (B
                                                                                                kind
                                                                                                age
                                                                                                polarity
                                                                                                not_inferred
                                                                                                span
                                                                                                end
                                                                                                4086
                                                                                                end exclusive
                                                                                                true
                                                                                                exact text
                                                                                                adult patients
                                                                                                label id
                                                                                                5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                                offset unit
                                                                                                unicode_code_points
                                                                                                source array index
                                                                                                0
                                                                                                source field
                                                                                                indications_and_usage_exact
                                                                                                source text sha256
                                                                                                f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                                start
                                                                                                4072
                                                                                              2. context exact
                                                                                                or the treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC).
                                                                                                kind
                                                                                                biomarker
                                                                                                polarity
                                                                                                not_inferred
                                                                                                span
                                                                                                end
                                                                                                4149
                                                                                                end exclusive
                                                                                                true
                                                                                                exact text
                                                                                                metastatic biliary tract cancer (BTC)
                                                                                                label id
                                                                                                5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                                offset unit
                                                                                                unicode_code_points
                                                                                                source array index
                                                                                                0
                                                                                                source field
                                                                                                indications_and_usage_exact
                                                                                                source text sha256
                                                                                                f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                                start
                                                                                                4112
                                                                                              3. context exact
                                                                                                atin, is indicated for the treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC).
                                                                                                kind
                                                                                                stage_or_setting
                                                                                                polarity
                                                                                                not_inferred
                                                                                                span
                                                                                                end
                                                                                                4143
                                                                                                end exclusive
                                                                                                true
                                                                                                exact text
                                                                                                locally advanced or metastatic biliary tract cancer
                                                                                                label id
                                                                                                5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                                offset unit
                                                                                                unicode_code_points
                                                                                                source array index
                                                                                                0
                                                                                                source field
                                                                                                indications_and_usage_exact
                                                                                                source text sha256
                                                                                                f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                                start
                                                                                                4092
                                                                                              4. context exact
                                                                                                1.3 Biliary Tract Cancers IMFINZI, in combination with gemcitabine and cisplatin, is indicated for the treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC).
                                                                                                kind
                                                                                                regimen
                                                                                                polarity
                                                                                                not_inferred
                                                                                                span
                                                                                                end
                                                                                                4149
                                                                                                end exclusive
                                                                                                true
                                                                                                exact text
                                                                                                in combination with gemcitabine and cisplatin, is indicated for the treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC)
                                                                                                label id
                                                                                                5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                                offset unit
                                                                                                unicode_code_points
                                                                                                source array index
                                                                                                0
                                                                                                source field
                                                                                                indications_and_usage_exact
                                                                                                source text sha256
                                                                                                f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                                start
                                                                                                3991
                                                                                              regulatory links
                                                                                                schema version
                                                                                                0.1.0
                                                                                                source batch sha256
                                                                                                bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
                                                                                                source defined aliases
                                                                                                1. abbreviation
                                                                                                  NSCLC
                                                                                                  definition exact
                                                                                                  non-small cell lung cancer
                                                                                                  definition span
                                                                                                  end
                                                                                                  389
                                                                                                  end exclusive
                                                                                                  true
                                                                                                  exact text
                                                                                                  non-small cell lung cancer (NSCLC)
                                                                                                  label id
                                                                                                  5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                                  offset unit
                                                                                                  unicode_code_points
                                                                                                  source array index
                                                                                                  0
                                                                                                  source field
                                                                                                  indications_and_usage_exact
                                                                                                  source text sha256
                                                                                                  f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                                  start
                                                                                                  355
                                                                                                source span
                                                                                                end
                                                                                                4150
                                                                                                end exclusive
                                                                                                true
                                                                                                exact text
                                                                                                1.3 Biliary Tract Cancers IMFINZI, in combination with gemcitabine and cisplatin, is indicated for the treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC).
                                                                                                label id
                                                                                                5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                                offset unit
                                                                                                unicode_code_points
                                                                                                source array index
                                                                                                0
                                                                                                source field
                                                                                                indications_and_usage_exact
                                                                                                source text sha256
                                                                                                f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                                start
                                                                                                3956
                                                                                                source url
                                                                                                https://api.fda.gov/drug/label.json?search=id%3A%225826517b-d2d2-4636-ad9c-0dc676abad9e%22
                                                                                                spl effective date
                                                                                                2026-08-31
                                                                                                spl set id
                                                                                                8baba4ea-2855-42fa-9bd9-5a7548d4cec3
                                                                                                spl version
                                                                                                34
                                                                                                structured fields status
                                                                                                not_extracted_no_values_inferred_from_mentions
                                                                                                structured indication
                                                                                                age
                                                                                                Source null
                                                                                                approval pathway
                                                                                                Source null
                                                                                                biomarker and test
                                                                                                Source null
                                                                                                disease stage
                                                                                                Source null
                                                                                                limitations
                                                                                                Source null
                                                                                                line
                                                                                                Source null
                                                                                                prior therapy
                                                                                                Source null
                                                                                                regimen
                                                                                                Source null
                                                                                                tumor histology
                                                                                                Source null
                                                                                                use intent
                                                                                                tumor_directed_candidate
                                                                                                Passage 32 · positive indication candidate
                                                                                                application numbers
                                                                                                1. BLA761069
                                                                                                brand names
                                                                                                1. IMFINZI
                                                                                                classification reasons
                                                                                                1. explicit_positive_indication_predicate
                                                                                                2. tumor_or_malignant_hematology_words_in_positive_statement
                                                                                                clinical review status
                                                                                                pending
                                                                                                content role
                                                                                                positive_indication_candidate
                                                                                                context span
                                                                                                end
                                                                                                4527
                                                                                                end exclusive
                                                                                                true
                                                                                                exact text
                                                                                                LC). 1.3 Biliary Tract Cancers IMFINZI, in combination with gemcitabine and cisplatin, is indicated for the treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC). 1.4 Hepatocellular Carcinoma IMFINZI, in combination with tremelimumab-actl, is indicated for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC). 1.5 Endometrial Cancer IMFINZI, in combination with carboplatin and paclitaxel followed by IMFINZI as a single agent, is indicated for the treatment of adult patients with primary advanced or recurre
                                                                                                label id
                                                                                                5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                                offset unit
                                                                                                unicode_code_points
                                                                                                source array index
                                                                                                0
                                                                                                source field
                                                                                                indications_and_usage_exact
                                                                                                source text sha256
                                                                                                f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                                start
                                                                                                3951
                                                                                                current approval status
                                                                                                not_reconciled
                                                                                                duplicate text group
                                                                                                dup-d50d29f0b5faf462cc00
                                                                                                extraction review status
                                                                                                automated_candidate_pending_source_review
                                                                                                generic names
                                                                                                1. DURVALUMAB
                                                                                                id
                                                                                                ind-span-6b65a0a9b5a8a8eb1029
                                                                                                label id
                                                                                                5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                                positive predicate support span
                                                                                                end
                                                                                                4240
                                                                                                end exclusive
                                                                                                true
                                                                                                exact text
                                                                                                is indicated
                                                                                                label id
                                                                                                5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                                offset unit
                                                                                                unicode_code_points
                                                                                                source array index
                                                                                                0
                                                                                                source field
                                                                                                indications_and_usage_exact
                                                                                                source text sha256
                                                                                                f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                                start
                                                                                                4228
                                                                                                qualifier mentions
                                                                                                1. context exact
                                                                                                  n with tremelimumab-actl, is indicated for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC).
                                                                                                  kind
                                                                                                  age
                                                                                                  polarity
                                                                                                  not_inferred
                                                                                                  span
                                                                                                  end
                                                                                                  4276
                                                                                                  end exclusive
                                                                                                  true
                                                                                                  exact text
                                                                                                  adult patients
                                                                                                  label id
                                                                                                  5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                                  offset unit
                                                                                                  unicode_code_points
                                                                                                  source array index
                                                                                                  0
                                                                                                  source field
                                                                                                  indications_and_usage_exact
                                                                                                  source text sha256
                                                                                                  f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                                  start
                                                                                                  4262
                                                                                                2. context exact
                                                                                                  actl, is indicated for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC).
                                                                                                  kind
                                                                                                  stage_or_setting
                                                                                                  polarity
                                                                                                  not_inferred
                                                                                                  span
                                                                                                  end
                                                                                                  4326
                                                                                                  end exclusive
                                                                                                  true
                                                                                                  exact text
                                                                                                  unresectable hepatocellular carcinoma (uHCC)
                                                                                                  label id
                                                                                                  5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                                  offset unit
                                                                                                  unicode_code_points
                                                                                                  source array index
                                                                                                  0
                                                                                                  source field
                                                                                                  indications_and_usage_exact
                                                                                                  source text sha256
                                                                                                  f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                                  start
                                                                                                  4282
                                                                                                3. context exact
                                                                                                  1.4 Hepatocellular Carcinoma IMFINZI, in combination with tremelimumab-actl, is indicated for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC).
                                                                                                  kind
                                                                                                  regimen
                                                                                                  polarity
                                                                                                  not_inferred
                                                                                                  span
                                                                                                  end
                                                                                                  4326
                                                                                                  end exclusive
                                                                                                  true
                                                                                                  exact text
                                                                                                  in combination with tremelimumab-actl, is indicated for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC)
                                                                                                  label id
                                                                                                  5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                                  offset unit
                                                                                                  unicode_code_points
                                                                                                  source array index
                                                                                                  0
                                                                                                  source field
                                                                                                  indications_and_usage_exact
                                                                                                  source text sha256
                                                                                                  f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                                  start
                                                                                                  4189
                                                                                                regulatory links
                                                                                                  schema version
                                                                                                  0.1.0
                                                                                                  source batch sha256
                                                                                                  bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
                                                                                                  source defined aliases
                                                                                                  1. abbreviation
                                                                                                    NSCLC
                                                                                                    definition exact
                                                                                                    non-small cell lung cancer
                                                                                                    definition span
                                                                                                    end
                                                                                                    389
                                                                                                    end exclusive
                                                                                                    true
                                                                                                    exact text
                                                                                                    non-small cell lung cancer (NSCLC)
                                                                                                    label id
                                                                                                    5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                                    offset unit
                                                                                                    unicode_code_points
                                                                                                    source array index
                                                                                                    0
                                                                                                    source field
                                                                                                    indications_and_usage_exact
                                                                                                    source text sha256
                                                                                                    f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                                    start
                                                                                                    355
                                                                                                  source span
                                                                                                  end
                                                                                                  4327
                                                                                                  end exclusive
                                                                                                  true
                                                                                                  exact text
                                                                                                  1.4 Hepatocellular Carcinoma IMFINZI, in combination with tremelimumab-actl, is indicated for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC).
                                                                                                  label id
                                                                                                  5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                                  offset unit
                                                                                                  unicode_code_points
                                                                                                  source array index
                                                                                                  0
                                                                                                  source field
                                                                                                  indications_and_usage_exact
                                                                                                  source text sha256
                                                                                                  f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                                  start
                                                                                                  4151
                                                                                                  source url
                                                                                                  https://api.fda.gov/drug/label.json?search=id%3A%225826517b-d2d2-4636-ad9c-0dc676abad9e%22
                                                                                                  spl effective date
                                                                                                  2026-08-31
                                                                                                  spl set id
                                                                                                  8baba4ea-2855-42fa-9bd9-5a7548d4cec3
                                                                                                  spl version
                                                                                                  34
                                                                                                  structured fields status
                                                                                                  not_extracted_no_values_inferred_from_mentions
                                                                                                  structured indication
                                                                                                  age
                                                                                                  Source null
                                                                                                  approval pathway
                                                                                                  Source null
                                                                                                  biomarker and test
                                                                                                  Source null
                                                                                                  disease stage
                                                                                                  Source null
                                                                                                  limitations
                                                                                                  Source null
                                                                                                  line
                                                                                                  Source null
                                                                                                  prior therapy
                                                                                                  Source null
                                                                                                  regimen
                                                                                                  Source null
                                                                                                  tumor histology
                                                                                                  Source null
                                                                                                  use intent
                                                                                                  tumor_directed_candidate
                                                                                                  Passage 33 · positive indication candidate
                                                                                                  application numbers
                                                                                                  1. BLA761069
                                                                                                  brand names
                                                                                                  1. IMFINZI
                                                                                                  classification reasons
                                                                                                  1. explicit_positive_indication_predicate
                                                                                                  2. tumor_or_malignant_hematology_words_in_positive_statement
                                                                                                  clinical review status
                                                                                                  pending
                                                                                                  content role
                                                                                                  positive_indication_candidate
                                                                                                  context span
                                                                                                  end
                                                                                                  4870
                                                                                                  end exclusive
                                                                                                  true
                                                                                                  exact text
                                                                                                  ry tract cancer (BTC). 1.4 Hepatocellular Carcinoma IMFINZI, in combination with tremelimumab-actl, is indicated for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC). 1.5 Endometrial Cancer IMFINZI, in combination with carboplatin and paclitaxel followed by IMFINZI as a single agent, is indicated for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] . 1.6 Bladder Cancer • IMFINZI in combination with Bacillus Calmette-Guérin (BCG) is indicated for the treatment of adult patients with BCG-naive, high-risk non-muscle-invasive bladder cancer (NMIBC).
                                                                                                  label id
                                                                                                  5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                                  offset unit
                                                                                                  unicode_code_points
                                                                                                  source array index
                                                                                                  0
                                                                                                  source field
                                                                                                  indications_and_usage_exact
                                                                                                  source text sha256
                                                                                                  f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                                  start
                                                                                                  4128
                                                                                                  current approval status
                                                                                                  not_reconciled
                                                                                                  duplicate text group
                                                                                                  dup-e113575b23b63f8d93fc
                                                                                                  extraction review status
                                                                                                  automated_candidate_pending_source_review
                                                                                                  generic names
                                                                                                  1. DURVALUMAB
                                                                                                  id
                                                                                                  ind-span-5f120f90713a9d89c9d4
                                                                                                  label id
                                                                                                  5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                                  positive predicate support span
                                                                                                  end
                                                                                                  4458
                                                                                                  end exclusive
                                                                                                  true
                                                                                                  exact text
                                                                                                  is indicated
                                                                                                  label id
                                                                                                  5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                                  offset unit
                                                                                                  unicode_code_points
                                                                                                  source array index
                                                                                                  0
                                                                                                  source field
                                                                                                  indications_and_usage_exact
                                                                                                  source text sha256
                                                                                                  f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                                  start
                                                                                                  4446
                                                                                                  qualifier mentions
                                                                                                  1. context exact
                                                                                                    MFINZI as a single agent, is indicated for the treatment of adult patients with primary advanced or recurrent endometrial cancer that
                                                                                                    kind
                                                                                                    age
                                                                                                    polarity
                                                                                                    not_inferred
                                                                                                    span
                                                                                                    end
                                                                                                    4494
                                                                                                    end exclusive
                                                                                                    true
                                                                                                    exact text
                                                                                                    adult patients
                                                                                                    label id
                                                                                                    5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                                    offset unit
                                                                                                    unicode_code_points
                                                                                                    source array index
                                                                                                    0
                                                                                                    source field
                                                                                                    indications_and_usage_exact
                                                                                                    source text sha256
                                                                                                    f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                                    start
                                                                                                    4480
                                                                                                  2. context exact
                                                                                                    rrent endometrial cancer that is mismatch repair deficient (dMMR) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] .
                                                                                                    kind
                                                                                                    biomarker
                                                                                                    polarity
                                                                                                    not_inferred
                                                                                                    span
                                                                                                    end
                                                                                                    4628
                                                                                                    end exclusive
                                                                                                    true
                                                                                                    exact text
                                                                                                    dMMR) as determined by an FDA-authorized tes
                                                                                                    label id
                                                                                                    5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                                    offset unit
                                                                                                    unicode_code_points
                                                                                                    source array index
                                                                                                    0
                                                                                                    source field
                                                                                                    indications_and_usage_exact
                                                                                                    source text sha256
                                                                                                    f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                                    start
                                                                                                    4584
                                                                                                  3. context exact
                                                                                                    indicated for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR) as determined by an F
                                                                                                    kind
                                                                                                    stage_or_setting
                                                                                                    polarity
                                                                                                    not_inferred
                                                                                                    span
                                                                                                    end
                                                                                                    4551
                                                                                                    end exclusive
                                                                                                    true
                                                                                                    exact text
                                                                                                    advanced or recurrent endometrial cancer th
                                                                                                    label id
                                                                                                    5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                                    offset unit
                                                                                                    unicode_code_points
                                                                                                    source array index
                                                                                                    0
                                                                                                    source field
                                                                                                    indications_and_usage_exact
                                                                                                    source text sha256
                                                                                                    f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                                    start
                                                                                                    4508
                                                                                                  4. context exact
                                                                                                    1.5 Endometrial Cancer IMFINZI, in combination with carboplatin and paclitaxel followed by IMFINZI as a single agent, is indicated for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR) as determ
                                                                                                    kind
                                                                                                    regimen
                                                                                                    polarity
                                                                                                    not_inferred
                                                                                                    span
                                                                                                    end
                                                                                                    4539
                                                                                                    end exclusive
                                                                                                    true
                                                                                                    exact text
                                                                                                    in combination with carboplatin and paclitaxel followed by IMFINZI as a single agent, is indicated for the treatment of adult patients with primary advanced or recurrent endometri
                                                                                                    label id
                                                                                                    5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                                    offset unit
                                                                                                    unicode_code_points
                                                                                                    source array index
                                                                                                    0
                                                                                                    source field
                                                                                                    indications_and_usage_exact
                                                                                                    source text sha256
                                                                                                    f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                                    start
                                                                                                    4360
                                                                                                  regulatory links
                                                                                                    schema version
                                                                                                    0.1.0
                                                                                                    source batch sha256
                                                                                                    bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
                                                                                                    source defined aliases
                                                                                                    1. abbreviation
                                                                                                      NSCLC
                                                                                                      definition exact
                                                                                                      non-small cell lung cancer
                                                                                                      definition span
                                                                                                      end
                                                                                                      389
                                                                                                      end exclusive
                                                                                                      true
                                                                                                      exact text
                                                                                                      non-small cell lung cancer (NSCLC)
                                                                                                      label id
                                                                                                      5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                                      offset unit
                                                                                                      unicode_code_points
                                                                                                      source array index
                                                                                                      0
                                                                                                      source field
                                                                                                      indications_and_usage_exact
                                                                                                      source text sha256
                                                                                                      f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                                      start
                                                                                                      355
                                                                                                    source span
                                                                                                    end
                                                                                                    4670
                                                                                                    end exclusive
                                                                                                    true
                                                                                                    exact text
                                                                                                    1.5 Endometrial Cancer IMFINZI, in combination with carboplatin and paclitaxel followed by IMFINZI as a single agent, is indicated for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] .
                                                                                                    label id
                                                                                                    5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                                    offset unit
                                                                                                    unicode_code_points
                                                                                                    source array index
                                                                                                    0
                                                                                                    source field
                                                                                                    indications_and_usage_exact
                                                                                                    source text sha256
                                                                                                    f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                                    start
                                                                                                    4328
                                                                                                    source url
                                                                                                    https://api.fda.gov/drug/label.json?search=id%3A%225826517b-d2d2-4636-ad9c-0dc676abad9e%22
                                                                                                    spl effective date
                                                                                                    2026-08-31
                                                                                                    spl set id
                                                                                                    8baba4ea-2855-42fa-9bd9-5a7548d4cec3
                                                                                                    spl version
                                                                                                    34
                                                                                                    structured fields status
                                                                                                    not_extracted_no_values_inferred_from_mentions
                                                                                                    structured indication
                                                                                                    age
                                                                                                    Source null
                                                                                                    approval pathway
                                                                                                    Source null
                                                                                                    biomarker and test
                                                                                                    Source null
                                                                                                    disease stage
                                                                                                    Source null
                                                                                                    limitations
                                                                                                    Source null
                                                                                                    line
                                                                                                    Source null
                                                                                                    prior therapy
                                                                                                    Source null
                                                                                                    regimen
                                                                                                    Source null
                                                                                                    tumor histology
                                                                                                    Source null
                                                                                                    use intent
                                                                                                    tumor_directed_candidate
                                                                                                    Passage 34 · unclassified context
                                                                                                    application numbers
                                                                                                    1. BLA761069
                                                                                                    brand names
                                                                                                    1. IMFINZI
                                                                                                    classification reasons
                                                                                                    1. no_unambiguous_positive_indication_predicate
                                                                                                    clinical review status
                                                                                                    pending
                                                                                                    content role
                                                                                                    unclassified_context
                                                                                                    context span
                                                                                                    end
                                                                                                    4889
                                                                                                    end exclusive
                                                                                                    true
                                                                                                    exact text
                                                                                                    tment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] . 1.6 Bladder Cancer • IMFINZI in combination with Bacillus Calmette-Guérin (BCG) is indicated for the treatment of adult patients with BCG-naive, high-risk non-muscle-invasive bladder cancer (NMIBC). • IMFINZI in combin
                                                                                                    label id
                                                                                                    5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                                    offset unit
                                                                                                    unicode_code_points
                                                                                                    source array index
                                                                                                    0
                                                                                                    source field
                                                                                                    indications_and_usage_exact
                                                                                                    source text sha256
                                                                                                    f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                                    start
                                                                                                    4471
                                                                                                    current approval status
                                                                                                    not_reconciled
                                                                                                    duplicate text group
                                                                                                    dup-da34520b1e38d3acca8a
                                                                                                    extraction review status
                                                                                                    automated_candidate_pending_source_review
                                                                                                    generic names
                                                                                                    1. DURVALUMAB
                                                                                                    id
                                                                                                    ind-span-aafd8879cdbb8f9e4f6c
                                                                                                    label id
                                                                                                    5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                                    positive predicate support span
                                                                                                    Source null
                                                                                                    qualifier mentions
                                                                                                      regulatory links
                                                                                                        schema version
                                                                                                        0.1.0
                                                                                                        source batch sha256
                                                                                                        bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
                                                                                                        source defined aliases
                                                                                                        1. abbreviation
                                                                                                          NSCLC
                                                                                                          definition exact
                                                                                                          non-small cell lung cancer
                                                                                                          definition span
                                                                                                          end
                                                                                                          389
                                                                                                          end exclusive
                                                                                                          true
                                                                                                          exact text
                                                                                                          non-small cell lung cancer (NSCLC)
                                                                                                          label id
                                                                                                          5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                                          offset unit
                                                                                                          unicode_code_points
                                                                                                          source array index
                                                                                                          0
                                                                                                          source field
                                                                                                          indications_and_usage_exact
                                                                                                          source text sha256
                                                                                                          f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                                          start
                                                                                                          355
                                                                                                        source span
                                                                                                        end
                                                                                                        4689
                                                                                                        end exclusive
                                                                                                        true
                                                                                                        exact text
                                                                                                        1.6 Bladder Cancer
                                                                                                        label id
                                                                                                        5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                                        offset unit
                                                                                                        unicode_code_points
                                                                                                        source array index
                                                                                                        0
                                                                                                        source field
                                                                                                        indications_and_usage_exact
                                                                                                        source text sha256
                                                                                                        f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                                        start
                                                                                                        4671
                                                                                                        source url
                                                                                                        https://api.fda.gov/drug/label.json?search=id%3A%225826517b-d2d2-4636-ad9c-0dc676abad9e%22
                                                                                                        spl effective date
                                                                                                        2026-08-31
                                                                                                        spl set id
                                                                                                        8baba4ea-2855-42fa-9bd9-5a7548d4cec3
                                                                                                        spl version
                                                                                                        34
                                                                                                        structured fields status
                                                                                                        not_extracted_no_values_inferred_from_mentions
                                                                                                        structured indication
                                                                                                        age
                                                                                                        Source null
                                                                                                        approval pathway
                                                                                                        Source null
                                                                                                        biomarker and test
                                                                                                        Source null
                                                                                                        disease stage
                                                                                                        Source null
                                                                                                        limitations
                                                                                                        Source null
                                                                                                        line
                                                                                                        Source null
                                                                                                        prior therapy
                                                                                                        Source null
                                                                                                        regimen
                                                                                                        Source null
                                                                                                        tumor histology
                                                                                                        Source null
                                                                                                        use intent
                                                                                                        unclear
                                                                                                        Passage 35 · positive indication candidate
                                                                                                        application numbers
                                                                                                        1. BLA761069
                                                                                                        brand names
                                                                                                        1. IMFINZI
                                                                                                        classification reasons
                                                                                                        1. explicit_positive_indication_predicate
                                                                                                        2. tumor_or_malignant_hematology_words_in_positive_statement
                                                                                                        clinical review status
                                                                                                        pending
                                                                                                        content role
                                                                                                        positive_indication_candidate
                                                                                                        context span
                                                                                                        end
                                                                                                        5069
                                                                                                        end exclusive
                                                                                                        true
                                                                                                        exact text
                                                                                                        ents with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] . 1.6 Bladder Cancer • IMFINZI in combination with Bacillus Calmette-Guérin (BCG) is indicated for the treatment of adult patients with BCG-naive, high-risk non-muscle-invasive bladder cancer (NMIBC). • IMFINZI in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent IMFINZI as adjuvant treatment following radical cystectomy, is indicated for the treatment o
                                                                                                        label id
                                                                                                        5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                                        offset unit
                                                                                                        unicode_code_points
                                                                                                        source array index
                                                                                                        0
                                                                                                        source field
                                                                                                        indications_and_usage_exact
                                                                                                        source text sha256
                                                                                                        f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                                        start
                                                                                                        4490
                                                                                                        current approval status
                                                                                                        not_reconciled
                                                                                                        duplicate text group
                                                                                                        dup-56c63d5c940d610dfbd8
                                                                                                        extraction review status
                                                                                                        automated_candidate_pending_source_review
                                                                                                        generic names
                                                                                                        1. DURVALUMAB
                                                                                                        id
                                                                                                        ind-span-272aecd2a134e3f2cccd
                                                                                                        label id
                                                                                                        5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                                        positive predicate support span
                                                                                                        end
                                                                                                        4763
                                                                                                        end exclusive
                                                                                                        true
                                                                                                        exact text
                                                                                                        is indicated
                                                                                                        label id
                                                                                                        5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                                        offset unit
                                                                                                        unicode_code_points
                                                                                                        source array index
                                                                                                        0
                                                                                                        source field
                                                                                                        indications_and_usage_exact
                                                                                                        source text sha256
                                                                                                        f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                                        start
                                                                                                        4751
                                                                                                        qualifier mentions
                                                                                                        1. context exact
                                                                                                          lus Calmette-Guérin (BCG) is indicated for the treatment of adult patients with BCG-naive, high-risk non-muscle-invasive bladder cance
                                                                                                          kind
                                                                                                          age
                                                                                                          polarity
                                                                                                          not_inferred
                                                                                                          span
                                                                                                          end
                                                                                                          4799
                                                                                                          end exclusive
                                                                                                          true
                                                                                                          exact text
                                                                                                          adult patients
                                                                                                          label id
                                                                                                          5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                                          offset unit
                                                                                                          unicode_code_points
                                                                                                          source array index
                                                                                                          0
                                                                                                          source field
                                                                                                          indications_and_usage_exact
                                                                                                          source text sha256
                                                                                                          f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                                          start
                                                                                                          4785
                                                                                                        2. context exact
                                                                                                          • IMFINZI in combination with Bacillus Calmette-Guérin (BCG) is indicated for the treatment of adult patients with BCG-naive, high-risk non-muscle-invasive bladder cancer (NMIBC).
                                                                                                          kind
                                                                                                          regimen
                                                                                                          polarity
                                                                                                          not_inferred
                                                                                                          span
                                                                                                          end
                                                                                                          4868
                                                                                                          end exclusive
                                                                                                          true
                                                                                                          exact text
                                                                                                          in combination with Bacillus Calmette-Guérin (BCG) is indicated for the treatment of adult patients with BCG-naive, high-risk non-muscle-invasive bladder cancer (NMIBC)
                                                                                                          label id
                                                                                                          5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                                          offset unit
                                                                                                          unicode_code_points
                                                                                                          source array index
                                                                                                          0
                                                                                                          source field
                                                                                                          indications_and_usage_exact
                                                                                                          source text sha256
                                                                                                          f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                                          start
                                                                                                          4700
                                                                                                        regulatory links
                                                                                                          schema version
                                                                                                          0.1.0
                                                                                                          source batch sha256
                                                                                                          bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
                                                                                                          source defined aliases
                                                                                                          1. abbreviation
                                                                                                            NSCLC
                                                                                                            definition exact
                                                                                                            non-small cell lung cancer
                                                                                                            definition span
                                                                                                            end
                                                                                                            389
                                                                                                            end exclusive
                                                                                                            true
                                                                                                            exact text
                                                                                                            non-small cell lung cancer (NSCLC)
                                                                                                            label id
                                                                                                            5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                                            offset unit
                                                                                                            unicode_code_points
                                                                                                            source array index
                                                                                                            0
                                                                                                            source field
                                                                                                            indications_and_usage_exact
                                                                                                            source text sha256
                                                                                                            f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                                            start
                                                                                                            355
                                                                                                          source span
                                                                                                          end
                                                                                                          4869
                                                                                                          end exclusive
                                                                                                          true
                                                                                                          exact text
                                                                                                          • IMFINZI in combination with Bacillus Calmette-Guérin (BCG) is indicated for the treatment of adult patients with BCG-naive, high-risk non-muscle-invasive bladder cancer (NMIBC).
                                                                                                          label id
                                                                                                          5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                                          offset unit
                                                                                                          unicode_code_points
                                                                                                          source array index
                                                                                                          0
                                                                                                          source field
                                                                                                          indications_and_usage_exact
                                                                                                          source text sha256
                                                                                                          f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                                          start
                                                                                                          4690
                                                                                                          source url
                                                                                                          https://api.fda.gov/drug/label.json?search=id%3A%225826517b-d2d2-4636-ad9c-0dc676abad9e%22
                                                                                                          spl effective date
                                                                                                          2026-08-31
                                                                                                          spl set id
                                                                                                          8baba4ea-2855-42fa-9bd9-5a7548d4cec3
                                                                                                          spl version
                                                                                                          34
                                                                                                          structured fields status
                                                                                                          not_extracted_no_values_inferred_from_mentions
                                                                                                          structured indication
                                                                                                          age
                                                                                                          Source null
                                                                                                          approval pathway
                                                                                                          Source null
                                                                                                          biomarker and test
                                                                                                          Source null
                                                                                                          disease stage
                                                                                                          Source null
                                                                                                          limitations
                                                                                                          Source null
                                                                                                          line
                                                                                                          Source null
                                                                                                          prior therapy
                                                                                                          Source null
                                                                                                          regimen
                                                                                                          Source null
                                                                                                          tumor histology
                                                                                                          Source null
                                                                                                          use intent
                                                                                                          tumor_directed_candidate
                                                                                                          Passage 36 · positive indication candidate
                                                                                                          application numbers
                                                                                                          1. BLA761069
                                                                                                          brand names
                                                                                                          1. IMFINZI
                                                                                                          classification reasons
                                                                                                          1. explicit_positive_indication_predicate
                                                                                                          2. tumor_or_malignant_hematology_words_in_positive_statement
                                                                                                          clinical review status
                                                                                                          pending
                                                                                                          content role
                                                                                                          positive_indication_candidate
                                                                                                          context span
                                                                                                          end
                                                                                                          5475
                                                                                                          end exclusive
                                                                                                          true
                                                                                                          exact text
                                                                                                          1.6 Bladder Cancer • IMFINZI in combination with Bacillus Calmette-Guérin (BCG) is indicated for the treatment of adult patients with BCG-naive, high-risk non-muscle-invasive bladder cancer (NMIBC). • IMFINZI in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent IMFINZI as adjuvant treatment following radical cystectomy, is indicated for the treatment of adult patients with muscle invasive bladder cancer (MIBC). 1. 7 Gastric or gastroesophageal junction adeno carcinoma IMFINZI in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) as neoadjuvant and adjuvant treatment, followed by single-agent IMFINZI, is indicated for the treatment of adult patients with resectable gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).
                                                                                                          label id
                                                                                                          5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                                          offset unit
                                                                                                          unicode_code_points
                                                                                                          source array index
                                                                                                          0
                                                                                                          source field
                                                                                                          indications_and_usage_exact
                                                                                                          source text sha256
                                                                                                          f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                                          start
                                                                                                          4670
                                                                                                          current approval status
                                                                                                          not_reconciled
                                                                                                          duplicate text group
                                                                                                          dup-cc9b5c7923ed377a2c7d
                                                                                                          extraction review status
                                                                                                          automated_candidate_pending_source_review
                                                                                                          generic names
                                                                                                          1. DURVALUMAB
                                                                                                          id
                                                                                                          ind-span-f92bca25987712659e7d
                                                                                                          label id
                                                                                                          5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                                          positive predicate support span
                                                                                                          end
                                                                                                          5049
                                                                                                          end exclusive
                                                                                                          true
                                                                                                          exact text
                                                                                                          is indicated
                                                                                                          label id
                                                                                                          5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                                          offset unit
                                                                                                          unicode_code_points
                                                                                                          source array index
                                                                                                          0
                                                                                                          source field
                                                                                                          indications_and_usage_exact
                                                                                                          source text sha256
                                                                                                          f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                                          start
                                                                                                          5037
                                                                                                          qualifier mentions
                                                                                                          1. context exact
                                                                                                            owing radical cystectomy, is indicated for the treatment of adult patients with muscle invasive bladder cancer (MIBC). 1. 7 Gastric or
                                                                                                            kind
                                                                                                            age
                                                                                                            polarity
                                                                                                            not_inferred
                                                                                                            span
                                                                                                            end
                                                                                                            5085
                                                                                                            end exclusive
                                                                                                            true
                                                                                                            exact text
                                                                                                            adult patients
                                                                                                            label id
                                                                                                            5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                                            offset unit
                                                                                                            unicode_code_points
                                                                                                            source array index
                                                                                                            0
                                                                                                            source field
                                                                                                            indications_and_usage_exact
                                                                                                            source text sha256
                                                                                                            f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                                            start
                                                                                                            5071
                                                                                                          2. context exact
                                                                                                            by single-agent IMFINZI, is indicated for the treatment of adult patients with resectable gastric or gastroesophageal junction adenoc
                                                                                                            kind
                                                                                                            age
                                                                                                            polarity
                                                                                                            not_inferred
                                                                                                            span
                                                                                                            end
                                                                                                            5396
                                                                                                            end exclusive
                                                                                                            true
                                                                                                            exact text
                                                                                                            adult patients
                                                                                                            label id
                                                                                                            5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                                            offset unit
                                                                                                            unicode_code_points
                                                                                                            source array index
                                                                                                            0
                                                                                                            source field
                                                                                                            indications_and_usage_exact
                                                                                                            source text sha256
                                                                                                            f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                                            start
                                                                                                            5382
                                                                                                          3. context exact
                                                                                                            • IMFINZI in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent IMFINZI as adjuvant treatment fol
                                                                                                            kind
                                                                                                            stage_or_setting
                                                                                                            polarity
                                                                                                            not_inferred
                                                                                                            span
                                                                                                            end
                                                                                                            4950
                                                                                                            end exclusive
                                                                                                            true
                                                                                                            exact text
                                                                                                            neoadjuvant treatment
                                                                                                            label id
                                                                                                            5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                                            offset unit
                                                                                                            unicode_code_points
                                                                                                            source array index
                                                                                                            0
                                                                                                            source field
                                                                                                            indications_and_usage_exact
                                                                                                            source text sha256
                                                                                                            f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                                            start
                                                                                                            4929
                                                                                                          4. context exact
                                                                                                            neoadjuvant treatment, followed by single agent IMFINZI as adjuvant treatment following radical cystectomy, is indicated for the treatment of adult patients with
                                                                                                            kind
                                                                                                            stage_or_setting
                                                                                                            polarity
                                                                                                            not_inferred
                                                                                                            span
                                                                                                            end
                                                                                                            5031
                                                                                                            end exclusive
                                                                                                            true
                                                                                                            exact text
                                                                                                            adjuvant treatment following radical cystec
                                                                                                            label id
                                                                                                            5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                                            offset unit
                                                                                                            unicode_code_points
                                                                                                            source array index
                                                                                                            0
                                                                                                            source field
                                                                                                            indications_and_usage_exact
                                                                                                            source text sha256
                                                                                                            f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                                            start
                                                                                                            4988
                                                                                                          5. context exact
                                                                                                            uorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) as neoadjuvant and adjuvant treatment, followed by single-agent IMFINZI, is indicated for the tre
                                                                                                            kind
                                                                                                            stage_or_setting
                                                                                                            polarity
                                                                                                            not_inferred
                                                                                                            span
                                                                                                            end
                                                                                                            5312
                                                                                                            end exclusive
                                                                                                            true
                                                                                                            exact text
                                                                                                            neoadjuvant and adjuvant treatment
                                                                                                            label id
                                                                                                            5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                                            offset unit
                                                                                                            unicode_code_points
                                                                                                            source array index
                                                                                                            0
                                                                                                            source field
                                                                                                            indications_and_usage_exact
                                                                                                            source text sha256
                                                                                                            f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                                            start
                                                                                                            5278
                                                                                                          6. context exact
                                                                                                            INZI, is indicated for the treatment of adult patients with resectable gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).
                                                                                                            kind
                                                                                                            stage_or_setting
                                                                                                            polarity
                                                                                                            not_inferred
                                                                                                            span
                                                                                                            end
                                                                                                            5447
                                                                                                            end exclusive
                                                                                                            true
                                                                                                            exact text
                                                                                                            resectable gastric or gastroesophageal juncti
                                                                                                            label id
                                                                                                            5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                                            offset unit
                                                                                                            unicode_code_points
                                                                                                            source array index
                                                                                                            0
                                                                                                            source field
                                                                                                            indications_and_usage_exact
                                                                                                            source text sha256
                                                                                                            f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                                            start
                                                                                                            5402
                                                                                                          7. context exact
                                                                                                            • IMFINZI in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent IMFINZI as adjuvant treatment following radical cystectomy, is indicated for the treatment of adult patients with muscle invasive bladder canc
                                                                                                            kind
                                                                                                            regimen
                                                                                                            polarity
                                                                                                            not_inferred
                                                                                                            span
                                                                                                            end
                                                                                                            5059
                                                                                                            end exclusive
                                                                                                            true
                                                                                                            exact text
                                                                                                            in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent IMFINZI as adjuvant treatment following radical cystectomy, is indicated for the t
                                                                                                            label id
                                                                                                            5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                                            offset unit
                                                                                                            unicode_code_points
                                                                                                            source array index
                                                                                                            0
                                                                                                            source field
                                                                                                            indications_and_usage_exact
                                                                                                            source text sha256
                                                                                                            f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                                            start
                                                                                                            4880
                                                                                                          8. context exact
                                                                                                            astric or gastroesophageal junction adeno carcinoma IMFINZI in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) as neoadjuvant and adjuvant treatment, followed by single-agent IMFINZI, is indicated for the treatment of adult patients with resectable gastric or gastroesoph
                                                                                                            kind
                                                                                                            regimen
                                                                                                            polarity
                                                                                                            not_inferred
                                                                                                            span
                                                                                                            end
                                                                                                            5375
                                                                                                            end exclusive
                                                                                                            true
                                                                                                            exact text
                                                                                                            in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) as neoadjuvant and adjuvant treatment, followed by single-agent IMFINZI, is indicated for the treatm
                                                                                                            label id
                                                                                                            5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                                            offset unit
                                                                                                            unicode_code_points
                                                                                                            source array index
                                                                                                            0
                                                                                                            source field
                                                                                                            indications_and_usage_exact
                                                                                                            source text sha256
                                                                                                            f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                                            start
                                                                                                            5196
                                                                                                          regulatory links
                                                                                                            schema version
                                                                                                            0.1.0
                                                                                                            source batch sha256
                                                                                                            bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
                                                                                                            source defined aliases
                                                                                                            1. abbreviation
                                                                                                              NSCLC
                                                                                                              definition exact
                                                                                                              non-small cell lung cancer
                                                                                                              definition span
                                                                                                              end
                                                                                                              389
                                                                                                              end exclusive
                                                                                                              true
                                                                                                              exact text
                                                                                                              non-small cell lung cancer (NSCLC)
                                                                                                              label id
                                                                                                              5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                                              offset unit
                                                                                                              unicode_code_points
                                                                                                              source array index
                                                                                                              0
                                                                                                              source field
                                                                                                              indications_and_usage_exact
                                                                                                              source text sha256
                                                                                                              f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                                              start
                                                                                                              355
                                                                                                            source span
                                                                                                            end
                                                                                                            5475
                                                                                                            end exclusive
                                                                                                            true
                                                                                                            exact text
                                                                                                            • IMFINZI in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent IMFINZI as adjuvant treatment following radical cystectomy, is indicated for the treatment of adult patients with muscle invasive bladder cancer (MIBC). 1. 7 Gastric or gastroesophageal junction adeno carcinoma IMFINZI in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) as neoadjuvant and adjuvant treatment, followed by single-agent IMFINZI, is indicated for the treatment of adult patients with resectable gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).
                                                                                                            label id
                                                                                                            5826517b-d2d2-4636-ad9c-0dc676abad9e
                                                                                                            offset unit
                                                                                                            unicode_code_points
                                                                                                            source array index
                                                                                                            0
                                                                                                            source field
                                                                                                            indications_and_usage_exact
                                                                                                            source text sha256
                                                                                                            f2bd8c528227efe180cbb5f723ca221c9514a6e80eeb932d791f3450ed616873
                                                                                                            start
                                                                                                            4870
                                                                                                            source url
                                                                                                            https://api.fda.gov/drug/label.json?search=id%3A%225826517b-d2d2-4636-ad9c-0dc676abad9e%22
                                                                                                            spl effective date
                                                                                                            2026-08-31
                                                                                                            spl set id
                                                                                                            8baba4ea-2855-42fa-9bd9-5a7548d4cec3
                                                                                                            spl version
                                                                                                            34
                                                                                                            structured fields status
                                                                                                            not_extracted_no_values_inferred_from_mentions
                                                                                                            structured indication
                                                                                                            age
                                                                                                            Source null
                                                                                                            approval pathway
                                                                                                            Source null
                                                                                                            biomarker and test
                                                                                                            Source null
                                                                                                            disease stage
                                                                                                            Source null
                                                                                                            limitations
                                                                                                            Source null
                                                                                                            line
                                                                                                            Source null
                                                                                                            prior therapy
                                                                                                            Source null
                                                                                                            regimen
                                                                                                            Source null
                                                                                                            tumor histology
                                                                                                            Source null
                                                                                                            use intent
                                                                                                            tumor_directed_candidate

                                                                                                            Preserved source evidence · Not medical advice